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3. Introduction  
 
Complex chronic inflammatory diseases, including atherosclerosis, are major 
global health issues. However, treatment options are limited. Modern systems 
biology postulates that the precise and comprehensive identification and 
characterization of structural and functional protein networks yields targets for 
effective and specific pharmacological intervention. Chemokines constitute a 
family of approximately 50 inflammatory cytokines that regulate leukocyte 
migration which represents a ubiquitous feature of all inflammatory processes. It 
has been shown that several chemokines form functionally active heterodimers. 
However, a comprehensive interactome of all currently known chemokines has not 
been developed. We have therefore performed an extensive study of 
chemokine/chemokine interactions and expanded the concept to another 
molecular entity to demonstrate a broader scale of the chemokine interactome. In 
project 1, we generated a chart of all heterodimeric chemokine interactions by 
means of biochemical and biophysical assays and validated their functional 
relevance by cellular and animal experiments. In project 2, we extended the 
concept of chemokine interactions to the family of galectins. An extensive 
understanding of chemokine interactions may help to specifically interfere with 
inflammatory processes, such as the progression of atherosclerotic plaques, while 
preserving host defense. 
 
3.1 Protein/protein interactions in health and disease 
 
Medical molecular biology was traditionally based on a focused and reductionist 
one gene-one disease model which implied that a single genetic mutation directly 
generates a clinical phenotype. Hence, scientific problems were approached 




to interfere with an assumed chain of action. This approach was well suited to test 
focused scientific hypotheses, but lacked efficiency in generating experimental 
data, sensitivity in identifying preclinical disease and specificity in classifying 
clinical disease (1). 
Consequently, diseases were increasingly defined as changes in large datasets 
(2). In a more global, horizontal, strategy multiple molecules were identified and 
characterized using high-throughput tools under different experimental conditions 
(3). For example, genomics and proteomics (the suffix -ome designates an entirety 
of some sort) attempt to describe the entire human genome and proteome and 
catalogue their variants. However, it became clear that the pathophysiological role 
of a gene depends on the position of the protein in a complex structural and 
functional network with other genetic and environmental factors (4). Therefore, 
even with detailed and comprehensive information on genes and proteins at hand, 
the assignment of context and function to proteins in clinical disorders remained 
challenging (3, 4). 
 
Modern systems biology attempts to combine the traditional vertical hypothesis-
driven science with the more recent horizontal discovery science in an integrative 
manner. It seeks to entirely characterize all the components of a particular system 
by multiple high-throughput methods, to experimentally perturb and monitor the 
components in a systematic manner, to reconcile the experimental outcome with 
model hypotheses on their structural and functional relations, and eventually to 
interfere with the system based on the generated hypotheses (5). 
 
The protein/protein interactome (and also the protein/glycan interactome that will 
be referred to and the protein/nucleic acid interactome that will not be discussed) 
plays an important role in the precise molecular characterization of human 




perturb protein interactions than nondisease variants (7). And difference and extent 
of the perturbation account for a disease phenotype (7). This applies to simple 
diseases characterized by a single failure of the system (e.g. primary 
immunodeficiency disorders) and particularly to the more common complex 
systemic diseases (e.g. chronic inflammatory diseases such as atherosclerosis) 
(4). The identification and characterization of structure and function of 
protein/protein pairs remains methodologically challenging. However, the 
disruption or imitation of protein/protein interactions is a promising concept for the 
design of effective single-target, multi-target low-dose and multi-stage therapies 
with limited toxicity (2, 4). 
 
3.2 Chemokine/chemokine interactions 
 
Chemokines are extracellular proteins with a molecular weight ranging between 8 
and 12 kDa. Whereas their amino acid sequence may differ widely, their secondary 
and tertiary structure is highly conserved. All chemokines exhibit a flexible N-
terminal segment, followed by a three-stranded antiparallel β-sheet and a C-
terminal α-helix folded onto the β-sheet (8). In almost all cases, their structure is 
stabilized by two disulfide bridges. With approximately 50 members, the group of 
chemokines constitutes the largest entity of cytokines. Chemokines are classified 
in four groups, the two most common types being a CC-type with the first two 
cysteine residues being adjacent and a CXC-type with the cysteines being 
separated by a non-conserved amino acid (Table1). Their nomenclature is derived 
from the chemokine type, followed by the letter “L” for “ligand” and a number which 
specifies their order of discovery. Each chemokine binds to and activates one or 
several of 18 G protein-coupled chemokine receptors (GPCRs) with its core 
domain and N-terminus. The receptors are named after the chemokine type they 




order of discovery. Each receptor may bind to several chemokines (Table 2). 
Chemokines must be immobilized on cell surface glycosaminoglycans (GAGs) to 
elicit their function in vivo (9). 
 
The primary role of chemokines is the mediation of leukocyte trafficking into 
lymphoid organs and peripheral tissue in homeostasis and during innate and 
adaptive immune responses in acute and chronic inflammation (10, 11). However, 
they may also be involved in other immunoregulatory processes such as immune 
cell activation, differentiation and proliferation and nonleukocytic cell activation and 
migration in angiogenesis or thrombosis (12, 13). Virtually all diseases involve 
chemokines. Disease models in which chemokines are particularly relevant include 
atherosclerosis leading to myocardial infarction and stroke (14-16), rheumatoid 
arthritis (17), allergic asthma (18), HIV (19) and cancer (20). Due to their central 
functional role, chemokine expression and activity is tightly regulated. Mechanisms 
of adaptation include the control of their transcription and translation (e.g. by 
miRNA), splice variation, posttranslational modifications (e.g. by proteolytic 
cleavage) and chemokine degradation (21). In addition, oligomerization of 
chemokines and chemokine receptors (Table 1 and 2) (8, 22), chemokine receptor 
recycling and biased signaling, receptor antagonism (23) and scavenging by 
atypical decoy receptors (24) (Table 2), chemokine interaction with cell surface 
GAGs (9), chemokine-binding proteins (e.g. high mobility group box 1 (HMGB1)) 
and atypical chemokines (e.g. macrophage migration inhibitory factor (MIF)) (25) 
affect chemokine activity (Table 2). Given the shear number of chemokines and 
chemokine receptors, and their promiscuous interactions, a high level of 
redundancy has initially been attributed to the system. However, 
chemokine/chemokine interactions and also chemokine interactions with GAGs 
(which foster chemokine oligomerization), seem to render the chemokine system 




Chemokines homodimerize in elongated end-to-end CC-type dimers in a two-
stranded antiparallel β-sheet formed between their N-termini, and globular CXC-
type dimers with antiparallel α-helices on top of an extended β-sheet (Table 1) (8). 
Dimerization alters chemokine function (21). Since complex pathophysiological 
conditions, particularly inflammation, most often involve multiple chemokines, 
structural and functional similarities between different chemokines prompted the 
investigation of their heterodimerization. Initial reports suggested that the 
combination of chemokines may enhance or inhibit their function, with chemokines 
in subfunctional concentrations exerting a synergistic effect when combined (26-
29). Since then, several studies demonstrated that chemokine heterodimers are 
functionally implicated in disease models such as atherosclerosis and cancer and 
may be targeted by small peptide inhibitors (Fig. 1) (15, 30, 31). However, a 
comprehensive interactome of all chemokines which may provide a basis for better 
understanding the suitability of chemokine interactions as targets for systems-
based therapeutic approaches has not been determined. 
 
3.3 Chemokine-binding proteins 
 
When functional chemokine heterodimers were first described, it had already been 
discovered that other species express many chemokine-binding proteins (CKBPs) 
and exploit their immunomodulatory potential for host evasion. For instance, it had 
been demonstrated that chemokines interact broadly with many viral proteins (32). 
Later it was shown that chemokines interact selectively with tick-specific evasins 
(33). In most instances, these CKBPs inhibit chemokine function by blocking 
GPCR binding, alter their tertiary or quaternary structure and affect their 





Considering the relatively abundant occurrence of CKBPs in other species, it is 
noteworthy that only three endogenous soluble CKBPs have been described so far 
in humans. The damage-associated molecular pattern HMGB1 interacts 
specifically with CXCL12 and potentiates CXCL12 activity by forming a complex 
with two chemokine molecules and two chemokine receptor molecules on the cell 
surface (25). The GAG-binding protein tumor necrosis factor-stimulated gene 6 
protein (TSG-6) interacts with several chemokines (34) and inhibits their activity by 
preventing the interaction of chemokines with endothelial GAGs. And the 
neutrophil-derived defensin human neutrophil peptide 1 (HNP-1) interacts with 











Table 1. Structures of the chemokine subtypes. The tertiary (monomer) and quarternary (homooligomer) 
structure of the different chemokine subtypes are shown. The CC-type was derived from the structure of CCL2 
((36), protein data bank (PDB) access codes 1DOL and 1DOK), the CXC-type from CXCL8 ((37), PDB access 
codes 5D14 and 1IL8), the XC-type shows XCL1 ((38),(39), PDB access codes 1J9O and 2N54) and the only 
CX3C-type is CX3CL1 ((40), PDB access code 1F2L). β-sheets are displayed in yellow, helices in red, cysteine 
residues and disulfide bridges in blue. In the quarternary structures monomers are presented in green and 
















































4.1 A comprehensive chemokine/chemokine interactome 
 
In project 1, we systematically evaluated the binary interaction of all human 
chemokines by solid-phase assays. In total, we found approximately 200 of 1250 
possible interactions. We then confirmed our results by surface plasmon 
resonance (SPR). Mostly inflammatory/nonhomeostatic chemokines interact (Fig. 
2, A and B). By means of nuclear magnetic resonance (NMR) spectroscopy and 
molecular dynamics simulations (MDSs), we could show that CCL5 and CCL2, 
CCL17 and CXCL4 form CC-type heterodimers whereas CCL5 and CXCL12 form 
CXC-type heterodimers. We confirmed that CC-type interactions are synergistic in 
cell signaling, transmigration with activated human T cells and endothelial arrest 
assays with T cells and monocytes. Synergistic effects may be differentially 
mediated to increase the potency of the targeted chemokines by receptor 
heteromerization or the efficacy by receptor retention (via auxiliary GAG binding). 
However, CXC-type heterodimers are inhibitory (Fig. 3). Their effect is mediated 
by conformational changes in the targeted chemokine and chemokine receptors. 
To confirm our functional results and evaluate their therapeutic potential, we 
utilized our structural findings to design specific CCL5-derived inhibitory peptides 
which disrupt or mimic chemokine interactions. Cyclic CAN and CKEY which 
constitute different parts of the interfaces with CCL17 and CXCL4 disrupt the 
interaction between CCL5 and CCL17 and CCL5 and CXCL4 respectively to 
abrogate synergisms. Linear VREY and its cyclic multiple [VREY]4 mimic parts of 
the interface with CCL5 and interact with CXCL12 to imitate the inhibitory effect of 
CCL5. Furthermore, we designed obligate CCL5/CCL17 (obligate RANTES-TARC 
heterodimer (ORATH)) and CCL5/CXCL4 (obligate PF4-RANTES heterodimer 




arrest compared to CCL5 and CCL17 combined. OPRAH exhibits increased 
potency and efficacy in T cell migration and monocyte arrest compared to CCL5 
and CXCL4 combined. To demonstrate the incidence of the uncovered chemokine 
interactions in vivo, we detected endogenous CCL5/CCL17 heterodimers in murine 
lymph nodes by a proximity ligation assay. We then validated the relevance of our 
concept in murine models of acute and chronic inflammation. In a model of LPS-
induced acute lung injury in which neutrophil recruitment is triggered by platelet 
chemokines, CKEY reduces neutrophil infiltration in the lung. In a model of diet-
induced atherosclerosis, CAN reduces aortic lesion size possibly by limiting the 
CCL17-dependent recruitment of naive T cells in which conversion to regulatory T 
(Treg) cells is suppressed. Of note, we found CCL5/CCL17 heteromers in the aortic 
root of diseased mice, in plaque of human coronary arteries but not in healthy 
coronaries. Replacing CXCL4 with an interaction-deficient CXCL4 variant reduces 
lesion size with the same efficiency than a CXCL4 knockout. This effect was 
attributed to a reduction in plaque macrophages. OPRAH restores lesion size and 
plaque macrophage count in CCL5-/-CXCL4-/- mice. Interestingly, whereas 
CCL5/CCL17 heterodimers are detected in the aortic root, the size of lesions in the 
aortic root is not affected by CXCL4 knockout/CXCL4 variant knockin. 
Furthermore, [VERY]4 inhibits CXCL12-dependent aggregation of murine and 
human platelets relevant to atherothrombosis. 
 
4.2 A chemokine/galectin interactome 
 
In project 2, we extended the chemokine interactome to another molecular entity. 
We demonstrated that chemokines interact with galectins, a family of β-
galactoside-binding proteins (nine in humans) which are structurally and 
functionally similar to chemokines. All galectins comprise a β-sandwich structure 




of this structure are termed S-face (or sugar-binding face) and F-face (46). 
Interestingly, it has been shown that galectins can form homodimers, 
homooligomers and heterodimers (47, 48). Galectins regulate immune cell 
recruitment in inflammatory conditions such as atherosclerosis (49). Using solid-
phase assays and SPR, we showed that many chemokines interact specifically 
with galectin-1 and -3 (Gal-1/-3) (Fig. 4 and 5). We then focused on CXCL12 and 
Gal-3 to investigate the mechanism of their interaction by NMR spectroscopy. To 
test the relevance of our findings in vivo, we detected CXCL12/Gal-3 heterodimers 
in murine lymph nodes by means of a proximity ligation assay. Furthermore, we 
showed that Gal-3 inhibits CXCL12-induced immune cell recruitment in 
transmigration assays with different leukocyte subsets and a murine model of 
peritoneal inflammation. Gal-3 impairs CXCL12-induced CXCR4 signaling without 
interfering with receptor internalization. Based on cell binding studies and MDSs, 
we suggested that Gal-3 inhibits CXCL12 signaling by forming a ternary complex 







Fig. 1. Chemokine interactions as documented by previous publications. Interactions are depicted as a node-edge model where nodes represent proteins and edges 
represent physical interactions (50, 51). Atherogenic chemokines are shown in orange (14, 15, 52). Homeostatic chemokines in gray (11). The figure was generated with 





Fig. 2A. The new chemokine interactome. Known interactions are shown in gray. New interactions are shown in blue (confirmed by both ligand blot and SPR, in pink found only 















Fig. 3. The functional implications of the new chemokine interactome. (A) Known or presumably synergistic CC-type interactions are shown. (B) Known or presumably inhibitory 




A                   B 
 
 
Fig. 4. Known and new interactions of chemokines with other cytokines. (A) Known interactions of chemokines with high mobility group box 1 (HMGB1), human neutrophil 
peptide 1 (HNP-1) and tumor necrosis factor-stimulated gene 6 protein (TSG-6) are shown in gray. Nonchemokine cytokines are depicted as diamonds. (B) New interactions of 













5. Discussion: Potential pharmacological implications 
 
Our findings may have therapeutic implications. Despite the recognized 
importance of chemokines for the mediation of inflammation, primarily two reasons 
preclude targeting chemokines for therapeutic interventions. First, the function of 
single chemokines may be redundant or, conversely, restricted, and therefore 
resistant to pharmacological intervention. Second, given that the chemokine 
system constitutes an important part of the immune system, long-term treatments 
may impair host defense. Hence, despite overwhelming evidence for their 
involvement in the pathophysiology of many diseases, strategies to effectively and 
specifically target the chemokine system are lagging behind. 
 
Chemokine heterodimers may pose limits to redundancy and robustness while 
increasing the specificity of the system, and may therefore lend themselves to 
pharmacological intervention. For example, two chemokines A and B may activate 
the same chemokine receptor so are presumably redundant. Targeting chemokine 
A alone would not be effective because chemokine B may take over its function. 
However, the two chemokines may interact with other chemokines which alter their 
function. Therefore targeting chemokine A by interrupting or mimicking interactions 
with these chemokines (e.g. with small peptide/molecule inhibitors) may well 
represent an effective treatment option. It may also be that chemokines A and B 
play a restricted role but regulate the system in a complex interplay. Targeting 
chemokine A or chemokine B alone would not affect the system sufficiently. Well-
designed interference with shared interactions of both chemokines may constitute 
an effective pharmacological option. Furthermore, targeting a chemokine which 
has a predominant role in a system A (e.g. with specific antibodies) may be 




process B. By contrast, interfering with specific interactions of this chemokine may 
under certain conditions represent a means to specifically target an adverse 
process A without interfering with a beneficial process B, in which the same 
chemokine is also involved. Of note, our findings suggest that mostly inflammatory 
chemokines form heterodimers which may increase the specificity of 
pharmacological interventions. Furthermore, chemokine-derived peptides, 
polyantagonistic peptide bundles or monomolecular polyantagonists are well 
suited to meet therapeutic requirements. 
 
Our results are particularly relevant to systemic chronic diseases with a strong 
inflammatory pathogenesis. Atherosclerosis is a chronic inflammatory disease of 
large and medium-size arteries defined by endothelial dysfunction and 
subendothelial deposition and modification of lipoproteins. Modified lipoproteins 
then foster the recruitment of inflammatory cells of the innate and adaptive immune 
response in a feed-forward loop. Cell migration into, out of and within 
atherosclerotic lesions constitutes a preeminent driver of the disease (Fig. 6A) (14, 
15). This inflammatory response generates atherosclerotic plaques that narrow, or 
occlude vessels after plaque rupture. Atherosclerosis constitutes the underlying 
pathology of most cardiovascular diseases, including myocardial infarction, stroke, 
peripheral artery disease and aneurisms and is involved in complications of 
hypertension or diabetes. It is estimated that the United States will spend more 
than 1 trillion dollars on direct and indirect costs related to cardiovascular diseases 
by 2030, which will constitute almost 5% of their GDP by then (53). 
 
Although the inflammatory pathogenesis of the disease has long been 
documented, traditional therapeutic approaches have been based on lipid-lowering 
agents (statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) 




patients suffer cardiovascular events despite recommended treatment. For 
example, one study evaluated the effect of moderate and intensive statin therapy 
on cardiovascular events in patients with a recent acute coronary syndrome. Even 
with intensive therapy which effectively reduced low-density lipoprotein (LDL) 
cholesterol levels, approximately 20% of the patients still suffered cardiovascular 
events or death from any cause (see e.g. the Pravastatin or Atorvastatin Evaluation 
and Infection Therapy - Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 
22) study (54)). These cardiovascular events may be mostly attributed to residual 
inflammation as measured by increased C-reactive protein (CRP) levels that 
independently predict recurrent mycocardial infarction or death of coronary cause 
more strongly than LDL cholesterol levels (55). Recent anti-inflammatory 
approaches have been successful in decreasing this inflammatory risk. The 
monoclonal interleukin-1β (IL-1β) antibody Canakinumab reduced cardiovascular 
events by approximately 15% compared to placebo in patients after myocardial 
infarction with increased high-sensitivity CRP levels on lipid-lowering therapy. This 
effect was independent of lipid-level lowering (see the Canakinumab 
Antiinflammatory Thrombosis Outcome Study (CANTOS) trial (56)). Colchicine, an 
anti-inflammatory inhibitor of microtubule formation, reduced cardiovascular 
events by approximately 70% compared to placebo in patients with stable coronary 
artery disease under statin (see the Low-Dose Colchicine (LoDoCo) trial (57)). 
However, side effects in these trials where common. For example, patients in the 
CANTOS trial exhibited an increase in fatal infections and sepsis that counteracted 
the reduction in cardiovascular events to a net equal all-cause mortality compared 
to placebo (56). Therefore, more specific interference with inflammatory pathways 
is necessary. The complexity of the immune system may allow to target specific 
immune cell types, lesion stages and regions if targets and their mechanisms of 





Chemokines may constitute targets for efficient anti-inflammatory intervention as 
shown for CCR2 agonists (58-60). In fact, a specific chemokine may have a precise 
cell type-specific function at a specific disease stage. For example, CCL5 can be 
detected in atherosclerotic lesions but not in healthy arteries particularly in the 
initial phase of the disease (61). It is involved in the recruitment of T cells and 
monocytes mediating inflammatory monocyte and T cell arrest on the endothelium 
(Fig. 6A) (15). The polymorphism G403A near the CCL5 gene has been correlated 
with an enhanced risk for coronary artery disease (62). Other chemokines such as 
CXCL12 are expressed in atherosclerotic plaques but not in healthy vessels 
particularly at later stages of the disease. Genome-wide association studies 
(GWASs) attributed a proatherogenic role to endothelial CXCL12 (63).  
Although initial studies have shown that CCL5 and CXCL12 interact with other 
chemokines (CXCL4/CXCL7 and CXCL7 respectively) and chemokine-binding 
proteins (HNP1/TSG-6 and HMGB1/TSG-6 respectively) (Fig. 1 and 4A), our 
studies extend the spectrum of their interactions to more than 20 other chemokines 
and, in addition, to the two galectins Gal-1 and Gal-3 (Fig. 2, A and B, 4B and 5). 
Of note, Gal-3 has a proatherogenic role, is a marker for macrophages (Mac-2) 
and attracts monocytes and macrophages (Fig. 6A) (49). Provided that temporal 
expression profiles of interacting chemokines and other inflammatory mediators in 
the plaque overlap, it may now be possible to characterize the disease stage or 
location of an atherosclerotic plaque based on chemokine interactions (Fig. 6B). 
For example, in project 1, we observed CCL5/CC17 heterodimer formation in 
diseased human coronaries but not in healthy vessels. Furthermore, we could 
show differences between the vascular regions of plaque progression. We 
provided evidence that functionally active CCL5/CXCL4 heterodimers form in the 
aorta and aortic arch, but not the aortic root where CCL5/CCL17 can be detected. 
These specific interactions may than be targeted without interfering with host 




has proven very successful in the past (64). This approach may integrate detailed 
knowledge on the function of specific chemokines with the comprehensive analysis 
of their interactions paving the way for effective and specific therapeutics against 









Fig. 6. Chemokines and chemokine interactions in the progression of atherosclerotic plaque. (A, from left to right) This figure is a highly simplified depiction of the 
pathophysiological processes leading to atherosclerotic plaque from its initiation, over the early lesion or fatty streak, to the advanced plaque (14, 15, 51, 61, 65-68). Risk factors 
for atherosclerosis (e.g. high blood pressure) induce endothelial injury (not shown). This injury facilitates the entry of low-density lipoproteins (LDLs) from the blood stream into the 
vascular tunica intima. LDLs are oxidized (oxLDLs) and stimulate endothelial cells to express adhesion molecules (not shown) and chemokines. Consequently, platelets and blood 
leukocytes, most importantly T cells and monocytes, adhere to the inflamed endothelium. Platelets deposit chemokines on endothelial glycosaminoglycans (GAGs) which facilitate 
their oligomerization as homooligomers or heterodimers. Leukocytes transmigrate through the endothelium to the tunica intima. The recruitment of leukocytes is mediated by 
various chemokines and their respective heptahelical G protein-coupled receptors (GPCRs). We showed in project 1 that a CCL5/CXCL4 heterodimer promotes monocyte 
adhesion to the inflamed endothelium and T cell migration synergistically by retaining the CCL5 receptor CCR5 on the cell surface. Type 2 T helper (Th2) cells and regulatory T 
(Treg) cells control the more abundant type 1 T helper (Th1) cells. In project 1, we demonstrated that a CCL5/CCL17 heterodimer inhibits the generation of Treg cells 
synergistically. Naive T cells are either activated within the plaque by oxLDL-particle presenting dendritic cells (not shown) or migrate to secondary lymphatic organs through the 
tunica media for activation (not shown). Inflammatory macrophages evolve from migrated monocytes and take up oxLDL via Toll-like receptors (TLRs). They produce chemokines 
and other inflammatory cytokines (e.g. interleukin-1β (IL-1β)) which active them in an autocrine manner (e.g. via the interleukin-1 receptor (IL1R)). Th1 cells and inflammatory 
macrophages stimulate each other via an interaction between the T-cell receptor (TCR) on the T cell and the oxLDL particle-presenting major histocompatibility complex class II 
(MHC II) on the macrophage. Monocytes also develop into anti-inflammatory foam cells that clear oxLDL via scavenger receptors. Galectin-3 (Gal-3 or macrophage-2 antigen 
(Mac-2)) is a proatherogenic macrophage marker. In project 2, we suggested that it may also exert an antiatherogenic function by interacting with several chemokines to inhibit T 
cell and monocyte migration. Apoptotic foam cells (dashed outline) constitute a necrotic core of cellular debris and cholesterol (orange). Smooth muscle cells from the tunica media 
migrate into the developing plaque. They are activated by oxLDL to express chemokines but also produce extracellular matrix in a fibrotic cap to stabilize the plaque (gray). (B) We 
demonstrate in project 1 that chemokines act in a complex network of heterodimeric interactions (gray circles). Depending on the type of interaction, chemokine heterodimers may 
be synergistic (green connecting line) or inhibitory (red connecting line, gray line if the type of interaction is unknown, dashed line if the heterodimer is functionally neutral). These 
networks may be combined with intraplaque expression data of relevant chemokines (in this figure according to the literature, see e.g. (67, 68), visualized by the different size of 
the chemokines and the different width of their connecting lines). We envision that these chemokine networks are in dynamic chemical equilibrium depending on the affinity of the 
chemokines to each other (not shown). Hence, the networks may be specific in terms of disease progression and location of a plaque within the vasculature. More importantly, they 










Chemokines play a central role in many inflammatory diseases, including 
atherosclerosis. Their function is tightly regulated. Exemplary studies had shown 
that chemokines interact with other chemokines and CKBPs. However, the validity 
of a comprehensive chemokine interactome as regulatory mechanism and 
therapeutic target had not been investigated. In project 1, we tested all human 
chemokines for heterodimeric interactions by solid-phase assays and SPR and 
structurally analyzed the interaction of example pairs by NMR spectroscopy. We 
then investigated the function of these pairs by transmigration and endothelial 
arrest assays. We confirmed that CC-chemokines form synergistic CC-type 
heterodimers, whereas CXC-chemokines form inhibitory CXC-type dimers. We 
then designed small peptide inhibitors to disrupt chemokine heterodimers and 
covalently linked obligate chemokine heterodimers to prove the validity of the 
chemokine interactome in mouse models of acute lung injury and atherosclerosis. 
In project 2, we extended the chemokine interactome to another molecular entity, 
glycan-binding galectins. We found that Gal-1 and 3 interact specifically with 
several chemokines. We established the structural model of a CXCL12/Gal-3 
heterodimer by NMR spectroscopy and showed that Gal-3 inhibits CXCL12-
induced immune cell recruitment in vitro and in vivo. Both studies support the 
concept of the chemokine interactome as a general principle in immunoregulation. 
The data may provide the basis for the design of powerful and specific therapies 











Chemokine sind entscheidend an der Entstehung entzündlicher Erkrankungen wie 
Atherosklerose beteiligt. Sie unterliegen genauen regulatorischen Mechanismen. 
Einige Studien konnten beispielhaft zeigen, dass Chemokine mit anderen 
Chemokinen und Chemokin-bindenden Proteinen interagieren. Allerdings wurde 
bisher nicht nachgewiesen, dass diese Interaktionen Teil eines regulatorischen 
Mechanismus für die Mehrzahl der Chemokine im Sinne eines Chemokin-
Interaktoms sind und damit einen Therapieansatz darstellen. In Projekt 1 
untersuchten wir alle menschlichen Chemokine mit Hilfe von Festphasen-
Immunassays und Oberflächenplasmonresonanz auf die Bildung von Chemokin-
Heterodimeren hin und analysierten einige Paare mit 
Kernspinresonanzspektroskopie strukturell. Darüber hinaus untersuchten wir die 
funktionellen Auswirkungen der Paarbildung in Transmigrationsversuchen und 
endothelialen Arrestassays. Wir bestätigten, dass CC-Chemokine funktionell 
synergistische Heterodimere vom CC-Typ, CXC-Chemokine hingegen 
inhibitorische Dimere vom CXC-Typ bilden. Wir entwickelten Inhibitoren auf 
Peptidbasis, die die Bildung von Chemokin-Heterodimeren verhindern, und 
kovalent verknüpfte obligate Chemokin-Heterodimere, um die Wirkung von 
Chemokin-Heterodimeren in vivo anhand von Mausmodellen des akuten 
Lungenversagens und der Atherosklerose zu beweisen. In Projekt 2 erweiterten 
wir das Chemokin-Interaktom um die Gruppe der glykan-bindenden Galektine. Wir 
fanden heraus, dass Gal-1 und Gal-3 spezifisch mit einer Reihe von Chemokinen 
interagieren. Wir entwarfen ein Strukturmodell der Interaktion von CXCL12 und 
Gal-3 mit Hilfe von Kernspinresonanzspektroskopie und konnten zeigen, dass Gal-
3 die CXCL12-vermittelte Chemotaxis von Leukozyten in vitro und in vivo hemmt. 
Beide Arbeiten unterstützen die Hypothese, dass das Chemokin-Interaktom  




könnten grundsätzlich zur Entwicklung von effektiven und spezifisch wirksamen 





8. Personal contributions 
 
In project 1, I planned, executed and interpreted results of solid-phase experiments, 
transmigration and endothelial arrest assays. This included the generation of a T cell model to 
test numerous chemokine interactions using only one cell type. I presented my data regularly 
in lab meetings and was involved in discussions on project progress and planning. 
 
In project 2, I planned, executed and interpreted results of solid-phase experiments, SPR 
experiments, transmigration assays and mouse experiments, signaling and cell binding 
studies, proximity ligation experiments, cell aggregation experiments and cell viability studies. 
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Chemokine interactome mapping enables tailored
intervention in acute and chronic inflammation
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Chemokines orchestrate leukocyte trafficking and function in health and disease. Heterophilic interactions between
chemokines in a given microenvironment may amplify, inhibit, or modulate their activity; however, a systematic
evaluation of the chemokine interactome has not been performed. We used immunoligand blotting and surface
plasmon resonance to obtain a comprehensive map of chemokine-chemokine interactions and to confirm their
specificity. Structure-function analyses revealed that chemokine activity can be enhanced by CC-type heterodimers
but inhibited by CXC-type heterodimers. Functional synergism was achieved through receptor heteromerization
induced by CCL5-CCL17 or receptor retention at the cell surface via auxiliary proteoglycan binding of CCL5-CXCL4.
In contrast, inhibitory activity relied on conformational changes (in CXCL12), affecting receptor signaling. Obligate
CC-type heterodimers showed high efficacy and potency and drove acute lung injury and atherosclerosis, processes
abrogated by specific CCL5-derived peptide inhibitors or knock-in of an interaction-deficient CXCL4 variant. Ather-
oprotective effects of CCL17 deficiency were phenocopied by a CCL5-derived peptide disrupting CCL5-CCL17 het-
erodimers, whereas a CCL5 a-helix peptide mimicked inhibitory effects on CXCL12-driven platelet aggregation.








Chemokines regulate leukocyte activation and coordinate their
trafficking to sites of inflammation or during immune surveillance.
The G protein–coupled receptor (GPCR) binding and function of
chemokines are governed by their interaction with cell surface pro-
teoglycans, oligomer formation, naturally occurring antagonists, and
proteolytic processing (1, 2). Recent studies unveiled that hetero-
meric interactions between chemokines modify their biological activ-
ities and provide structural insight into underlying mechanisms.
Consequently, we hypothesized that a functional chemokine interac-
tome composed of pairwise heteromeric interactions could inform
how signals conferred by individual chemokines can be integrated
to control leukocyte responses (3, 4).
Many chemokines form homodimers or oligomers based on two
modes to support interfaces: CC-type or CXC-type (5). Dimerization
in a CC-type occurs via interaction of the flexible N termini to form
a two-stranded antiparallel b-sheet, whereas in a CXC-type, chemo-
kines interact by antiparallel extension of preformed b-strands (5). In
addition, their structural similarity allows chemokines to form
unique heterodimers to shape the overall signaling response of theirreceptors, and homo- and heteromerization of some chemokines are
linked to glycosaminoglycan (GAG) binding (4–7). Molecular dy-
namics simulation (MDS) for selected chemokine homo- and het-
erodimer pairs predicts that association of free energies depend
upon the particular chemokine combination and dimer-type (CC or
CXC), some of which are energetically favored over others (8). MDS
suggests that CC chemokines preferably engage in CC-type interac-
tions and that CXC chemokines favor a CXC-type, whereas both in-
teractions can occur in mixed CC-CXC heteromers. Preferred modes
of interaction have been validated experimentally for some chemokine
pairs but have not been extensively explored or linked to differential
functions. Nuclear magnetic resonance (NMR) analyses revealed that
CC chemokine receptor 2 (CCR2) ligands form CC-type heteromers
and that CCL5 forms a mixed CC-type heteromer with the CXC che-
mokine CXCL4 (6, 7). The CXC-type heterodimer CXCL4-CXCL8 in-
hibits CXCL8-mediated endothelial cell activation and proliferation,
binding CXCR2 less strongly than CXCL8 alone (9, 10). Peptide-
mediated disruption of the CCL5-CXCL4 heteromer revealed that this
interaction enhances CCL5-mediated leukocyte recruitment, acute lung
injury, and atherosclerosis in mouse models (7, 11); however, other het-
eromers have not been evaluated in disease models.
Among the interactions between platelet-derived chemokines iden-
tified by mass spectrometry, MDS revealed that CXCL4 can undergo
conformational changes to align its a-helix with that of CXCL12 to
form a CXC-type dimer (12). Without providing clues toward the type
of interaction, screening for synergistic effects on leukocytes showed
that combinations of CCR7 agonists with some nonagonist chemo-
kines led to formation of heteromers that enhance T cell migration
and CCR2 ligand activity in monocytes (13, 14). Such evidence of
functional synergy implied that heteromers may act as amplifiers in
SC I ENCE TRANS LAT IONAL MED I C I N E | R E S EARCH ART I C L Echemokine-rich tissues; however, a systematic and in-depth ap-
proach to map interactions between chemokines and to verify their
functional specificity has not been undertaken. Here, we have
established the chemokine interactome comprising all heterophilic
chemokine-chemokine interactions. We further show that CC-type
heterodimers mediate functional synergism, whereas CXC-type
heterodimers cause inhibitory effects, both of which can be targeted












Mapping the chemokine interactome
Unbiased bidirectional immunoblot chemokine screening, in which
one partner was immobilized on a nitrocellulose membrane and
the other remained in solution (fig. S1), identified heteromeric inter-
actions between pairwise combinations of all known human chemo-
kines. Interactions were considered positive when they exceeded a
densitometry threshold of 5% (on average) relative to positive
controls in either direction (Fig. 1A and table S1). The full interac-
tome matrix revealed hotspots of heteromeric interactions (mostly for
inflammatory pairs) and large areas devoid of interactions (Fig. 1A).
Neither CC chemokines that adopt unusual polymeric or unique
monomer states (CCL3, CCL4, and CCL18) (15, 16) nor trans-
membrane chemokines (CX3CL1 and CXCL16) formed heteromers.
With the exception of CCR7 ligands, only a few nonmucosal homeo-
static chemokines or plasma chemokines activated by N-terminal
cleavage (1) engaged in interactions.
In pursuit of disease-specific therapeutic targets, we focused on
chemokines involved in atherosclerosis. CCL2 interacted with
CCL5, CXCL8, and other CCR2 ligands (Fig. 1A). The atherogenic
CCR1/3/5 agonist CCL5 was the most promiscuous chemokine,
forming heteromers with 24 partners (Fig. 1A). Various CXCR2
and CXCR3 ligands (2) interacted with each other and with CCL2,
CCL5, or CCL11. We did not consider CCR7 ligands because of their
inconclusive role in atherosclerosis models (17). The atypical chemo-
kine CXCL4 interacted with CXCL12 and many atherogenic chemo-
kines. CXCL4L1, a CXCL4 variant that differs at three C-terminal
residues (18, 19), primarily interacted with CCL19/21/25/27 and
CXCL12 but not with CCL5, thus displaying a more homeostatic
profile. An explanation as to why CXCL4L1 does not interact with
CCL5 is that the changes in the C-terminal helix lead to a larger angle
formed with the central b-sheet and exposure of residues within the
core that are usually covered by the helix (19). Because heterodimer
formation of CCL5-CXCL4 requires residues from the b-sheet of
CXCL4 (7), this alteration may critically interfere with the binding
of CCL5.
The multiple interactions observed for CCL5 and CXCL4 were val-
idated by surface plasmon resonance (SPR), which also confirmed the
interactions of atheroprotective CXCL12 with CCL5 or CXCL4 and a
more selective interaction pattern of CCL17 (Fig. 1, B to E). Thresh-
olds for SPR and densitometry were defined so as to minimize the
number of nonvalidated interactions. In addition to observing positive
signals in ligand blots and/or in previous assays, interactions were
considered bona fide when they passed these thresholds or had good
affinity [dissociation constant (Kd) < 10
−6 M] despite subthreshold
SPR responses (Fig. 1, A to E, and table S2).
To elaborate interactions of interest, we performed kinetics
analyses, for example, using native CCL5 and CCL5E66S (to obtain
equilibrium binding at higher concentrations) on CCL17-conjugatedvon Hundelshausen et al., Sci. Transl. Med. 9, eaah6650 (2017) 5 April 2017  
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E66S
had equivalent affinity for CCL17 and CXCL4 (Kd < 10
−8 M), inter-
mediate affinity for CCL2 and CXCL7 (Kd < 10
−7 M), and lower
affinity for CXCL12 (table S2). The affinities of CCL5 for CXCL4,
CXCL4K50E, and the CXCL4R>Q mutant with abolished heparin bind-
ing (20) were moderately reduced or similar, whereas CXCL4L1 did
not bind CCL5 but retained affinity for CXCL12. Conversely, CCL5
and the mutant CCL5E66S had high affinity for CXCL4, whereas mu-
tation of the basic BBXB cluster (CCL544AANA47) or E26 (CCL5E26A)
resulted in no or impaired binding, identifying residues critical for the
interaction. CCL5 and CCL5E66S showed similar affinities for CCL17
and CXCL12. Monomeric CCL5MT7 (N-methylated T7) did not bind
CXCL4 and bound CCL17 with 17-fold lower affinity, consistent with
a role of the CCL5 N terminus in CC-type interactions. CCL5E26A but
not CCL544AANA47 had high affinity for CCL17, implying a specific role
of E26 in binding to CXCL4, with the BBXB motif also involved in
binding to CCL17.
Formation of different types of chemokine heterodimers
We focused our NMR structural studies on CCL5 and partners selected
for their range of interactions and inflammatory relevance. To avoid
higher-order aggregation (21) and poor spectral characteristics of na-
tive CCL5 (22), we used CCL5E66S. The CXCL4K50E mutant was ap-
plied to attenuate CXCL4 tetramer formation and to allay concerns
about broadening of NMR spectra due to chemical exchange (23).
Heteronuclear single-quantum coherence (HSQC) with 15N-enriched
CCL5E66S is exemplified by CXCL4K50E and CCL17 (Fig. 2, A and
B; see full spectra in fig. S3). Substantial resonance broadening and
minimal chemical shift (Dd) changes indicated heteromeric interac-
tions in the intermediate exchange regime. Changes in resonance in-
tensity (Dintensity) and Dd of the CCL5E66S monomer were plotted
versus its sequence (Fig. 2, C to F). Because CCL5E66S dimer reso-
nances were much less perturbed (fig. S4, A to D), we concluded that
heteromeric interactions with CCL5E66S occur between monomers
and not dimers. This was supported by comparing Dd and Dintensity
changes for native CXCL4 interactions with monomeric and dimeric
CCL5E66S (fig. S4, E to H) and for CXCL4K50E interactions with
15N-enriched wild-type CCL5 at low concentrations (fig. S5). Relative
amounts of heterodimer depend on the presence of various homooli-
gomer states and their respective equilibrium constants. Nevertheless,
our subsequent results with the obligate CCL5MT7 monomer and the
noninteracting CXCL4L1 variant that show a lack of functional syn-
ergy make off-target effects and altered monomer activity unlikely.
Moderate changes in Dd and homodimers suggest that NMR-deduced
binding constants for the heterodimer are higher than those obtained
by SPR. Such differences in the affinity range between NMR and SPR
are to be expected, primarily because NMR studies require the use of
lower pH values and higher protein concentrations than those present
under physiological conditions that are better mimicked by SPR using
surface-immobilized binding partners.
The type of heterodimer formed (CC or CXC) was elucidated by
analyzing spectral changes (Dd and Dintensity). The most perturbed
CCL5E66S monomer resonances belong to residues (7 to 14, 30 to 33,
and 47 to 50) involved in CC-type dimers (Fig. 2, C to F, and fig. S4, E
and F). In both heteropairs, residues 7 to 11 at the primary CC-type
dimer interface displayed relatively large changes. In CCL5E66S, resi-
dues 47 to 50 (corresponding to b-strand 3) were more perturbed by
interactions with CCL17, whereas residues 30 to 33 were more affect-
ed by interactions with CXCL4K50E or CXCL4. As compared to CCL17,












smaller spectral effects for CXCL4 indicate
slightly weaker interactions with CCL5E66S,
confirming that heterodimer stability de-
pends on residue composition and subunit
orientation at the interface (8). Although
the coexistence of monomeric, homooligo-
meric, and heterodimeric conformations
and formation of both heterodimer types
may occur with varying molar ratios (fig.
S6), these two chemokine pairs prefer to
form CC-type heterodimers (Fig. 2, G
and H).
As evidenced by CCL5E66S-induced
15N-CXCL12 spectral changes that reflect
intermediate exchange, CXCL12 and
CCL5 also form heterodimers (fig. S7,
A and B). The most perturbed 15N-
CXCL12 resonances belong to residues
in b-strand 1 and the C-terminal helix,
which are involved in the CXC-type di-
mer interface. Combining 15N-CCL5E66S
and unlabeled CXCL12 was also indica-
tive of an interaction but inconclusive in
terms of heterodimer-type formed (fig.
S7, C and D). Other chemokines, for ex-
ample, CXCL10, induced relatively nonspecific and moderate spectral
changes that are likely attributable to their propensity for homoaggre-
gation, as seen for CXCL10 tetramers (24), and increased viscosity atvon Hundelshausen et al., Sci. Transl. Med. 9, eaah6650 (2017) 5 April 2017  
51higher concentrations (fig. S7E). Weighted averaging of Dintensity
changes and MDS-based in silico modeling supported the idea that










































































































































































0 25 50 400 8000 20 40 250 500
RU CXCL4
0 20 40 50 150 250Fig. 1. Mapping of the chemokine interac-
tome. (A) Chemokine-chemokine interactions
were detected by bidirectional immunoligand
blotting. Known atherogenic chemokines are
highlighted in orange, and nonmucosal homeo-
static chemokines are shaded in gray. No inter-
action for nonmucosal homeostatic chemokines
(gray square) or all other chemokines (white
square) is shown. Black squares indicate that an-
tibody binding indistinguishably detects both
immobilized and soluble (complexed) chemo-
kine. Chemokine interactions were considered
positive (blue) if the densitometric signal ex-
ceeded that of the positive control by 5% (on
average) on either side of the blot (n = 2 to 4
independent experiments). Chemokine interac-
tions previously identified and experimentally
confirmed by other techniques are indicated in
dark blue. (B to E) Binding of soluble chemo-
kines (100 nM) to immobilized CCL5 (B), CXCL4
(C), CXCL12 (D), and CCL17 (E) was assessed by
SPR. Mass equivalent response units (RU) were
compared after the association phase. SPR
thresholds (as indicated by dotted lines) opti-
mally delineating binders (black bars) and non-
binders (white bars) were based on median
values derived from all tested interactions of
CCL5, CXCL4, and CXCL12 (B to D) or were set
at 300 RU by interpolation with immunoblotting
for CCL17. Data represent means ± SEM (n = 3 to
5 independent experiments).


























































































































































































Fig. 2. Characterization of chemokine interactions by NMR spectroscopy. (A to F) 1H-15N HSQC spectra were acquired with 128 scans per transient and sweep widths
of 16 parts per million (ppm) in the 1H (2000 points) dimension and 22 ppm in the 15N (200 points) dimension. Expansions are shown for 15N-CCL5E66S, either alone (red) or
in the presence of unlabeled CXCL4 (blue) (A) or unlabeled CCL17 (blue) (B); the molar ratios of CCL17/CCL5E66S (1H; 850 MHz) and CXCL4/CCL5E66S (1H; 700 MHz) were 33:1
(20 mM CCL5E66S) and 20:1 (30 mM CCL5E66S), respectively. Labels indicate monomers (m), dimers (d), and 15N bleed-through from CCL17 (x). The changes in intensity
(Dintensity) and chemical shift (Dd) for the 15N-CCL5E66S monomer resonances upon binding to CXCL4 (C and E) and CCL17 (D and F) versus those of CCL5E66S are shown.
(G and H) Primary CCL5E66S residues binding CXCL4 (G) and CCL17 (H) heterodimer subunits are indicated on the basis of the native CCL5 homodimer structure (Protein
Data Bank 1U4L). The broadest resonances within a single subunit are in red (>2 SD above average), orange (between 1 and 2 SD), and blue (<1 SD). Full-view HSQC
spectra are displayed in fig. S3.von Hundelshausen et al., Sci. Transl. Med. 9, eaah6650 (2017) 5 April 2017  
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CXCL4, whereas CCL2, CCL17, and CXCL4 favor formation of
CC-type heterodimers with CCL5 (table S3).
To exploit our structural models for the design of peptide-based
inhibitors, we generated CCL5-derived peptides (CKEY, CAN and
VREY), which form part of the heterodimer interfaces with CXCL4,
CCL17, and CXCL12, respectively (table S4). Modeled CCL5-CCL17
(CC-type) and CCL5-CXCL12 (CXC-type) heterodimers are illus-
trated in fig. S8 (A and B). Cyclic CKEY, containing N-loop and
b-sheet 2 with residues K25 to R44 (7), reversed CXCL4-induced
changes in Dd and broadening of 15N-CCL5E66S monomer, but not
homodimer, resonances (fig. S9, A and B). Cyclic CAN comprising
CCL5 b-sheet 3 (residues K33 to N52) interacted with CCL17 (fig.
S10) and partially reversed CCL17-induced changes in Dd and broad-
ening of 15N-CCL5E66S monomer resonances (fig. S11, A and B). Per-
turbations at the binding interfaces reflect a specific disruption of both
CC-type heterodimers. Linear VREY (a-helix residues E54 to S68)
mimicked heterodimer interactions of CCL5 with 15N-CXCL12 as sim-
ilar resonances at the dimer interface were chemically shifted. To improve
solubility and conformational stability (25), we generated a four-helix
template-assembled synthetic protein (TASP) version of VREY ([VREY]4;
fig. S12A). Changes in Dd and a structural perturbation plot (fig. S12, B
to D) indicated that [VREY]4 interacts with 15N-CXCL12 and attenu-
ates its homo- or heterodimer state, as evidenced by relevant shifts at
the interface (fig. S12E).
We validated these findings using SPR, where CKEY inhibited the
interaction of CCL5 with CXCL4 but not with CCL17 or CXCL12;
this effect was abrogated in the variant CKEYRE by substitutions at
key residues R44 and E26, crucial for heterodimerization (table S5).
Conversely, CAN inhibited the interaction of CCL5 with CCL17 but
not with CXCL4 or CXCL12, whereas the N-terminal peptide CCL51−33
blocked both CC-type interactions of CCL5 with CXCL4 or CCL17 (ta-
ble S5). Finally, [VREY]4 competed with CCL5 for binding to CXCL12
but not to CCL17 or CXCL4 (table S5). These data suggest that chemo-
kine heterodimers can be specifically disrupted by peptides to target
their activity.
Differential function and disruption of heterodimers
To assess the functional effects of chemokine heterodimers, we studied
chemotaxis of activated humanT cells, which display a large chemokine-
receptor repertoire (fig. S13A) and differentially respond to various
chemokines (fig. S13, B to G). Whereas CCL5 plus CCL17 or CXCL4
(CC-type), but not interaction-deficient CXCL4L1, acted synergisti-
cally to enhance chemotaxis (Fig. 3, A toD, and fig. S14, A to C), com-
bination with CCL5, CXCL4, or CXCL4L1 (CXC-type) inhibited
CXCL12-induced chemotaxis (fig. S14, D to F). Consistent with a lack
of specific interactions, CCL5 plus CCL3 or CXCL10 resulted in func-
tionally neutral, that is, neither synergistic nor inhibitory, effects (fig.
S14, G and H). Furthermore, combinations preferentially forming CC-
type heterodimers (CCL5 plus CXCL4, CCL2, or CCL17) acted syner-
gistically to increase monocyte and/or T cell arrest (Fig. 3, E and F, and
fig. S15A). By contrast, combinations forming CXC-type heterodimers,
such as CXCL4 and CXCL8 or CCL5 and CXCL12, exerted inhibitory
or less than additive effects (fig. S15, B andC). Overall, different types of
heterodimeric interactions can have opposite functional consequences,
namely, all CC-type interactions identified and functionally tested were
synergistic, whereas all CXC-type interactions identified and function-
ally tested were inhibitory.
In the chemotactic dose-response curve, a left shift demonstrated
that CCL5 increased the potency of CCL17 (Fig. 3A), indicatingvon Hundelshausen et al., Sci. Transl. Med. 9, eaah6650 (2017) 5 April 2017  
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CCL5-CCL17 involved both the CCL17 receptor (CCR4) and CCL5
receptors (CCR1 or CCR5), as shown by inhibition with the CCR4
antagonist C021 and the CCL5 receptor antagonist Met-RANTES
(fig. S15D). By contrast, CXCL4 increased the efficacy of CCL5 over
the entire dose range (Fig. 3B). This effect was blocked by Met-
RANTES but not by an antibody to the low-affinity CXCL4 receptor
CXCR3 (fig. S15E). These data imply that different modes of synergy
(affecting potency or efficacy) occur through distinct mechanisms.
Notably, monomeric CCL5MT7 did not form strong heterodimers or
support functional synergy with CCL17 or CXCL4, whereas the N-
terminal peptide CCL51−33 blocked synergistic effects of CCL5 with
CXCL4, CCL17, or CCL2, indicating that N-terminal motifs are required
for CC-type heterodimer formation and activity (Fig. 3, C, D, G, and H).
Consistent with SPR results, CKEY but not CKEYRE specifically
inhibited CCL5-CXCL4 synergy, and CAN specifically inhibited
CCL5-CCL17 (Fig. 3, C, D, G, and H, and fig. S15, F and G). Peptide
targeting of heterodimer interfaces encompassing b-strands 2 or 3
with adjacent loops thus confers specificity for functional inhibition.
Mimicking the effects of CCL5, [VREY]4 but not the other peptides
inhibited CXCL12 activity in chemotaxis and arrest (fig. S15, C and H).
Along with our NMR data, this indicates that CCL5 and [VREY]4
induce structural changes in the CXCL12 dimer, thereby inhibiting
CXCL12 activity.
On the basis of modeling (Fig. 2G), we generated a covalently
linked CC-type CXCL4-CCL5 heterodimer termed OPRAH (obli-
gate PF4-RANTES heterodimer; Fig. 3I) by introducing an oxime
linker between N-terminal residues of CCL5 (T7) and CXCL4 (L8).
The efficacy and potency of OPRAH in triggering monocyte arrest
and T cell chemotaxis were greater than those of CCL5 alone or in
combination with CXCL4 at concentrations favoring heterodimer
formation (Fig. 3J and fig. S15I). By contrast, OPRAH with the N
termini tethered at the first residues (nOPRAH) failed to enhance
function (Fig. 3J), showing an importance of freely available N ter-
mini. CKEY did not inhibit the effects of OPRAH (Fig. 3K). An
obligate CCL5-CCL17 heterodimer, ORATH (obligate RANTES
TARC heterodimer), induced T cell arrest with higher potency
and efficacy than CCL5 and CCL17 combined (fig. S15J), establish-
ing that heterodimers are responsible for the synergistic effects.
To address underlying mechanisms for synergy, we used an in situ
proximity ligation assay (26) reporting protein interactions that detect
the presence of CCL5-CCL17 heterodimers formed on activated en-
dothelial cells after incubation with both chemokines or with Met-
RANTES (fig. S16, A and B). Endogenous heterodimers could be
detected in mouse lymph nodes (fig. S16, C and D). In dendritic cells
(DCs), which express both CCR4 and CCR5, CCL5-CCL17 heterodi-
mers assembled on the cell surface when adding both chemokines,
whereas CCR4-CCR5 complexes were constitutively present (Fig. 4A).
The increase in CCL5-CCL17 heterodimers was inhibited by CAN
(Fig. 4B), revealing that heterodimers can be disrupted by peptides
in a cellular context. Notably, the number of CCR4-CCR5 complexes
was increased by combining CCL5 and CCL17 but not by either alone
(Fig. 4C), as were ligand-receptor cross-interactions (fig. S17, A to D).
This effect was impaired by CAN, thus being mediated by CCL5-
CCL17 heterodimers, and disrupted by CCR5-derived peptides
spanning transmembrane 1 and 4 motifs (Fig. 4C), as seen for
CCR5 homodimers (27). Peptide-based disruption of CCL5-CCL17
or CCR5-CCR4 impeded synergy in T cell chemotaxis (Fig. 4D and
fig. S17E), substantiating a role of ligand-induced receptor heteromer












complexes. Binding competition assays revealed that the affinity of
CCL17 for CCR4 was higher when adding CCL5 but not CXCL1, to
promote heterodimer formation (Fig. 4E and fig. S17F). To test whether
CCL5-CCL17 can elicit receptor heteromer activity distinct from its
monomers, we used GloSensor transfectants expressing CCR4 or
CCR4 and CCR5 to assess cyclic adenosine monophosphate (cAMP)
signaling. Our data show that CCR4 and CCR5 together mediate the
synergistic effects of CCL5-CCL17 on Gi-mediated inhibition of cAMP
formation (fig. S17G). In contrast, transfectants expressing CCR1 onlyvon Hundelshausen et al., Sci. Transl. Med. 9, eaah6650 (2017) 5 April 2017  
54efficiently responded to OPRAH (fig. S18A). As for a combination of
CCL2 and CCL5 favoring CCR2-CCR5 heterodimerization to enhance
cell arrest (28), phosphatidylinositol 3-kinase signaling was also ad-
dressed by CCR4-CCR5 heteromers, in that combining CCL5 and
CCL17 induced its sustained activation (fig. S18, B and C).
To identify mechanisms underlying CXCL4-mediated synergy,
we used the GAG binding–impaired mutant CXCL4R>Q, which forms
heterodimers with CCL5 (table S2). This mutant did not enhance
CCL5-induced monocyte arrest, suggesting that GAG binding throughA
CCL17 [nM]




































































































































































































































































































Fig. 3. Differential function and specific inhibition of chemokine combinations. (A to D) Transwell filter chemotaxis assays were performed using interleukin-2
(IL-2)–activated and CD3/C28-activated human T cells. The chemotactic index was determined as the ratio of chemokine-induced versus unstimulated migration by
counting the cells in the bottom chamber. Combinations of CCL5 (1 nM) plus CCL17 at the indicated concentrations (n = 7) (A), CXCL4 (4 nM) plus CCL5 at the indicated
concentrations (B) (n = 6), CCL5 or CCL5MT7 (both 1 nM) plus CCL17 (0.1 nM; n = 9) (C), and CCL5 plus CXCL4 (both 4 nM) or obligate platelet factor 4 (PF4)–RANTES
heterodimer (OPRAH; 0.4 nM) (n = 6) (D) were added to the bottom chamber. The CCL5 peptides CCL51−33 (N-terminal), CAN (CCL5-CCL17 interface), and CKEY (CCL5-
CXCL4 interface) were added at 10-fold molar excess. (E to K) Isolated human blood monocytes were perfused over IL-1b–activated human aortic endothelial cells (HAoECs)
preincubated with chemokines, and numbers of adherent cells per high-power field (HPF) were counted. HAoECs were incubated with CCL5 and/or CXCL4 (40 nM each) (E and
G) and with CCL5 and/or CCL2 (4 nM each; n = 17) (F and H). Dashed lines indicate virtually calculated additive effects. Monocytes were preincubated with the CCL5 receptor
antagonist Met-RANTES (Met-R; 40 nM), and CCL51−33, CKEY, or CAN (40 nM each) was combined with CCL5 plus CXCL4 (G) or CCL5 plus CCL2 (H) for pretreating HAoECs (n =
3). (I) Energy-minimized structure model depicting the CC-type interaction of CCL5 (gray) and CXCL4 (blue) trapped via a covalent oxime linkage (magenta), yielding an
obligate PF4-RANTES heterodimer (OPRAH). (J) HAoECs were pretreated with the indicated concentrations of CCL5 plus CXCL4 fixed at 4 nM (CCL5 + CXCL4f), indicated
concentrations of CXCL4 plus CCL5 fixed at 4 nM (CXCL4 + CCL5f), or indicated concentrations of OPRAH or nOPRAH (N-terminally tethered OPRAH) (n = 3 to 6). (K) HAoECs
were pretreated with CCL5 plus CXCL4 or OPRAH (all 4 nM) with or without CKEY (40 nM; n = 5). Data represent means ± SEM from the indicated numbers of independent
experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 versus chemokine combinations (cyan), as analyzed by one-way analysis of variance (ANOVA) (C, E, and F) or Kruskal-Wallis test
(D, G, H, and K).












CXCL4 may improve presentation of CCL5 to its arrest-triggering re-
ceptors (Fig. 4F). CXCL4 but not CXCL4R>Q increased surface binding
of CCL5 to monocytes, indicating that this was mediated by GAG
binding via CXCL4 (Fig. 4G). As a consequence, CXCL4 but not
CXCL4R>Q prevented CCR1 internalization by CCL5 (Fig. 4H), with-
out altering the affinity of CCL5 for CCR1 or CCR5 (fig. S18, D and E).
This effect was also observed using primary mouse monocytes adherent
in carotid arteries perfused ex vivo (fig. S18F). CXCL1 and CXCL4L1,
which neither specifically interact with CCL5 nor activate CCR1, but
bind to GAGs, did not recapitulate the effect on CCR1 internalizationvon Hundelshausen et al., Sci. Transl. Med. 9, eaah6650 (2017) 5 April 2017  
55observed with CXCL4, indicating that this is dependent on hetero-
dimer formation with CCL5 (Fig. 4H). SPR on a low–molecular weight
heparin-conjugated chip revealed binding of CXCL4L1 but not of
CXCL4R>Q, and combination with wild-type CXCL4 but not with
CXCL4L1 or CXCL4R>Q supported strong binding of CCL5E66S on im-
mobilized heparin (fig. S19A). Such GAG-mediated binding of CCL5-
containing heterodimers was confirmed by binding of OPRAH to
heparin with similar affinity as CCL5E66S (fig. S19, B and C). Thus, the
GAG-binding capacity of CCL5-CXCL4 heterodimers limits receptor


































































































































































































































Fig. 4. Mechanisms for the synergistic effects of chemokine heterodimers. (A to C) Interactions between murine CCL5, CCL17, CCR4, and CCR5 were detected on
the surface of adherent DCs using a proximity ligation assay after the cells were incubated with CCL5, CCL17, or both (6 nM each) in the presence/absence of CAN (60 nM) or
transmembrane (TM) 1/4 CCR5 peptides (50 mg/ml) known to inhibit CCR5 dimerization. Representative images depict the presence of CCL5-CCL17 and CCR4-CCR5 hetero-
mers (red dots) on the DC surface (A). Proximity ligation signals generated by interactions of CCL5-CCL17 (n = 8) (B) and CCR5-CCR4 (n = 5) (C) were quantified relative to CCL5
alone (control). (D) Transwell filter chemotaxis assays were performed using CD3/CD28-activated primary mouse T cells (n = 8). Chemotactic index was determined as the ratio
of chemokine-induced versus unstimulated migration by counting the cells in the bottom chamber. Migration toward CCL5 and/or CCL17 (6 nM each) in the bottom chamber
was analyzed in the presence/absence of CAN (60 nM) or TM1/4 peptides (50 mg/ml). (E) Binding competition assay; CCL17–Alexa Fluor 647 (2.5 nM) bound to CCR4-expressing
human embryonic kidney (HEK) 293 transfectants was displaced by unlabeled CCL17 in the presence or absence of CCL5 (1 nM; n = 6). (F) Isolated human monocytes were
perfused over IL-1b–activated HAoECs pretreated with CCL5 and CXCL4 or the GAG binding–deficient mutant CXCL4R>Q (all 4 nM), and numbers of adherent cells per HPF
were counted (n = 4). (G) Deposition of exogenous CCL5, alone or in combination with CXCL4 or CXCL4R>Q (all 100 nM) on the surface of primary human monocytes, was
detected by flow cytometry and reported as specific mean fluorescence intensity (MFI) (n = 3). ns, not significant. (H) CCR1 surface expression on monocytes was detected by
flow cytometry after treatment with CCL5 (4 nM), alone or in combination with CXCL4, CXCL4R>Q, or CXCL1 (all 40 nM; n = 4). Data represent means ± SEM from the indicated
numbers of independent experiments. *P < 0.05, **P < 0.01 versus chemokine combinations (cyan), as analyzed by one-way ANOVA (B and D), Kruskal-Wallis test (C), or Mann-
Whitney test (F and G).












G protein signaling, as seen for GPCR families lacking b-arrestin re-
cruitment for endosomal targeting (29). Experiments using HEK293
transfectants coexpressing C-terminally tagged CCR5-RlucII and
enhanced yellow fluorescent protein–tagged arrestin 1/2 to analyze bio-
luminescence resonance energy transfer events confirmed that the
presence of CXCL4 inhibited the CCL5-induced association of arrestin
with CCR5 (fig. S19D), reflecting a prolonged signaling cycle.
Specific targeting of heterodimers in inflammatory
disease models
To confirm a role of heterodimer formation in vivo, we used a short-
term model of lipopolysaccharide (LPS)–induced acute lung injury,
which relies on platelet chemokines mediating neutrophil recruitment
and subsequent extravasation (11). Treatment with CKEY (but not with
CKEYRE) dose-dependently reduced infiltration in the lung, as evi-
denced by lower intravascular, interstitial, bronchoalveolar, and total
neutrophil counts (Fig. 5A and fig. S20, A to C). Conversely, reconstitu-
tion of mice carrying Ccl5−/−Cxcl4−/− bone marrow (deficient in the het-
erodimer pair) with OPRAH but not with CCL5 exacerbated lung
infiltration, as reflected in higher intravascular neutrophil numbers
and a trend toward higher total counts (Fig. 5B and fig. S20D).
To demonstrate the biological relevance of heterodimer interac-
tions, we generated Cxcl4L1/L1mice with a CXCL4 knockout and knock-
in of the CXCL4L1 variant (which neither exists in mice nor forms
heterodimers with CCL5) to study diet-induced atherosclerosis on an
Apoe−/− background (fig. S21). Notably, Cxcl4L1/L1 mice showed a
marked reduction of atherosclerotic lesion size in the aorta and the aor-
tic arch, comparable to that in CXCL4-deficient mice (Fig. 5, C and D,
and fig. S22, A and B). Heterozygous Cxcl4L1/+ mice displayed an
intermediate gene-dosing effect. Lesion size in the aortic root was atte-
nuated in Cxcl4−/− mice but not in Cxcl4L1/L1 mice (fig. S22, C and D),
implying regional differences unrelated to heterodimerization. Except
for lower macrophage content in Cxcl4L1/L1 mice, plaque composition
(that is, phenotype classification, smooth muscle cells, necrotic core, and
T cell content), lipid profiles, body weight, and blood cell counts did not
differ among all groups (Fig. 5E, fig. S23, and table S6). Platelet-specific
expression of a CXCL4L1 transgene in Apoe−/−mice did not alter lesion
size, indicating that its effects are not dominant negative but are due to a
lack of interaction (Fig. 5F). Treatment with mouse OPRAH restored
lesion formation in the aorta including the arch and increased macro-
phage content in aortic root plaques but did not change other param-
eters in Ccl5−/−Cxcl4−/−Apoe−/−mice and heterozygous Cxcl4L1/wtApoe−/−
mice expressing noninteracting CXCL4L1 (Fig. 5, G and H, fig. S24,
and table S7).
The atheroprotective homeostasis of regulatory T cells (Tregs) is
suppressed by DC-derived CCL17, a phenotype not replicated in
Ccr4-deficient mice (3, 30, 31), possibly implicating other chemokine
receptors or heterodimers. We detected CCL5-CCL17 heteromers in
aortic root lesions of Apoe−/− mice (Fig. 6A), in the intima and ad-
ventitia of human coronary arteries with advanced atherosclerosis
but not in undiseased vessels or segments (Fig. 6B). Notably, com-
bined interference with CCR4-CCR5 using the CCR5 antagonist
DAPTA in CCR4-deficient Apoe−/− mice increased Treg numbers
in the paraaortic lymph nodes and, marginally, in peripheral blood
(Fig. 6, C and D). Similar results were obtained by treatment with
CAN (for 6 weeks), which also reduced lesion size in the aortic root
(Fig. 6, C to F), phenocopying the effects of CCL17 deficiency (30).
These findings may be due to limiting CCL17-mediated recruitment
of naïve CD3+ T cells, in which Treg conversion or maintenance isvon Hundelshausen et al., Sci. Transl. Med. 9, eaah6650 (2017) 5 April 2017  
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other receptors.
To exploit inhibitory interactions exemplified by the CXC-type
heterodimer CCL5-CXCL12, we tested whether [VREY]4 inhibits
CXCL12-depedent platelet aggregation, as relevant to atherothrombo-
sis. Notably, CXCL12 facilitated platelet aggregation as deletion of
Cxcl12 in blood of CreERT2Cxcl12fl/flApoe−/− mice showed reduced
multiparameter platelet activity and thrombus scores ex vivo (Fig. 6,
G and H). Treating Apoe−/− mice with [VREY]4 afforded a similar
inhibition of platelet activity (Fig. 6, G and H). Likewise, [VREY]4
inhibited CXCL12-induced human platelet aggregation and CXCR4
activation in HEK293 cells, likely due to conformational effects on
CXCL12 (Fig. 6, I and J).DISCUSSION
The comprehensive map of all heteromeric chemokine interactions
obtained by immunoligand blotting and SPR contributes to the com-
pletion of the binary human protein interactome network (32). We
found that inflammatory and nonhomeostatic chemokines, for ex-
ample, platelet-derived atherogenic CCL5 and CXCL4, favor interac-
tions, whereas homeostatic chemokines are generally less interactive.
This may correspond to the need to amplify, fine-tune, and resolve
chemokine activity at inflammatory sites through heteromeric inter-
actions, whereas the stand-alone functions of noninteracting chemo-
kines appear sufficient for organogenesis, immune architecture, and
surveillance or antimicrobial activity. For example, CXCL4-deficient
mice have no overt phenotype and show unaltered immune re-
sponses in the absence of challenge, whereas CXCL12 deficiency en-
tails embryonic lethality, and CXCL13 deficiency shows its essential
role for lymph node development and natural immunity (33, 34).
Structure-function analysis revealed an interesting dichotomous
pattern wherein CC-type heterodimers promote synergy and CXC-
type heterodimers cause inhibition. The use of obligate heterodimers
such as OPRAH provided conclusive proof that CC-type heterodimers
mediate functional synergy. Functional inhibition with a CCL5-
derived N-terminal peptide supports a more general role of the N ter-
minus in CC-type heterodimer formation and synergy. The spacing
and shapes adopted by CC-type homodimers can vary with minimal
changes in N-terminal sequence (16). Functional synergy indeed
involved flexible N termini, as illustrated by a tethered version of
the obligate heterodimer OPRAH, and could be ascribed to addressing
receptor heteromers (increasing potency of CCL5-CCL17) or to aux-
iliary GAG binding and impaired receptor internalization (increasing
efficacy of CCL5-CXCL4).
Chemokine-receptor activation follows a two-site binding mecha-
nism involving interactions of the chemokine N-loop/core with the
receptor N terminus (site I) and of the chemokine N terminus with
extracellular/transmembrane residues (site II). The modeled structure
for binding of the atypical CC chemokine vMIP-II to CXCR4 appears
to support findings that CC chemokine homodimers cannot bind or
activate receptors because the dimerization interface largely coincides
with an intermediate recognition site (35–37); however, this may not
extend to all chemokine-receptor interactions because N-terminal
and core structures in a CC-type heterodimer, for example, OPRAH,
may be differently presented to receptors. Instead, binding may in-
volve receptor complexes enabling synergy. Concomitant peptide-
based disruption of CCL5-CCL17 and CCR4-CCR5 formation/
function supported the concept that CC-type heterodimers can












prompt the formation of corresponding receptor complexes, requir-
ing CCR5 transmembrane regions. Furthermore, because chemokine
N-terminal residues play an important role in receptor activation,
they may also affect the mechanisms of action for heterodimers.
For instance, N-terminal sequence variations may cause differences
in N-terminal orientation and/or accessibility between CCL17-CCL5
heterodimers and CCL5 homodimers to affect receptor binding and
activation. As evidenced from a disulfide-trapped CCL4 variant, disso-
ciation of CCL4 homodimers may be required to accomplish receptor
binding and activation by a monomer (37). This may also hold truevon Hundelshausen et al., Sci. Transl. Med. 9, eaah6650 (2017) 5 April 2017  
57for chemokine heterodimers, namely, CCL5-CCL17, when addressing
respective heterodimers.
The conserved GP motif in CXCL8 can couple sites I and II, dic-
tating both substrates and cross-talk between sites to control recep-
tor activity (38). Conformational coupling was corroborated by a
CC mutant of CXCL8 that retained binding via N-loop–site I interac-
tions for CXCR1 activation (39). Moreover, a disulfide-trapped CXCL8
dimer had reduced affinity for CXCR1 due to perturbed binding at N-
loop residues, giving rise to a model where binding of a CXC-type di-
mer triggers conformational changes, leading to release and high-affinityFig. 5. Inflammatory effects of CCL5-CXCL4 in vivo require heterodimer formation. (A and B) Acute lung injury in C57/BL6 mice was induced by LPS inhalation.
Intravascular neutrophil accumulation was detected by intravenous injection of a fluorescein isothiocyanate–GR1 antibody before lung explantation. (A) Mice were
injected intraperitoneally with CKEY at a low dose (LD; 1 mg/kg) or high dose (HD; 10 mg/kg) or with CKEYRE at high dose before LPS challenge (n = 5 to 6). PMN,
polymorphonuclear neutrophil. (B) Bone marrow of Ccl5−/−Cxcl4−/− chimeric mice were intravenously injected with CCL5 (150 mg/kg) or OPRAH (300 mg/kg) or vehicle
(ctrl) before LPS challenge. (C to E) Atherosclerosis was analyzed in wild-type (wt) Cxcl4wt/wt mice, homozygous Cxcl4L1/L1 mice with a Cxcl4 knockout and knockin of a
mouse variant of human CXCL4L1, heterozygous Cxcl4wt/L1 mice, and CXCL4-deficient Cxcl4−/− mice on an Apoe−/− background after 12 weeks of high-fat diet (HFD).
Representative images of the aorta stained with Oil Red O are shown (C). The area of the aorta showing Oil Red O–positive lesions (D) and the area of Mac2-positive
cells in the aortic arch (E) were quantified and expressed as percentage of the total area (n = 4 to 11). (F) The lesion area in the aorta of Apoe−/− mice expressing a
human CXCL4L1 transgene (tg-L1) in addition to CXCL4 was analyzed after 12 weeks of HFD. (G and H) Cxcl4wt/L1Apoe−/− and Ccl5−/−Cxcl4−/−Apoe−/− mice were treated
(intraperitoneally) with OPRAH (10 mg, twice a week) while on HFD for 6 weeks. The Oil Red O–positive lesion area (G) and Mac2-positive area in the aortic arch (H) were
quantified and expressed as percentage of the total area (n = 6 to 13). Data represent means ± SEM from the indicated numbers of mice. *P < 0.05, **P < 0.01, as
analyzed by Kruskal-Wallis test (B, D, and E) or Mann-Whitney test (A, G, and H).












receptor binding of a monomer (40). Whether this applies to CC-type
heterodimers is unclear; however, findings with OPRAH indicate that
dissociation may not be essential for function. Conversely, some recep-
tors, for example, CXCR2, are permissive for dimer binding (41). Mac-
rophage migration inhibitory factor (resembling a CXCL8 dimer)
features sites I and II binding to CXCR2 without typical N termini
(42, 43). Thus, N termini may not need to fit fully into the site II pocket.
The increased efficacy of CCL5-bearing heterodimers may be ex-
plained by several aspects. CCR5 antagonists inhibited both CCL5-von Hundelshausen et al., Sci. Transl. Med. 9, eaah6650 (2017) 5 April 2017  
58CXCL4– and CCL5-CCL17–induced arrest. Thus, CC-type heterodi-
mers can modulate CCR5 functionality, converting it into an arrest
receptor such as CCR1 (requiring CCL5 oligomers and extracellular
loop 3 for sensing) (44–46). As revealed by GAG binding–impaired
CXCL4, synergy with CCL5 relies on elevated cell surface presenta-
tion, impeding CCR1 internalization to sustain its signaling activity.
Formation of chemokine homo- and heterodimers can be affected
by GAGs, which may foster or prevent an association of chemokines
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Fig. 6. Specific peptides inhibit atherogenic CCL5-CCL17 and CXCL12-driven platelet activity. (A and B) Interactions of CCL5-CCL17 (left; red dots indicated by
arrows in the representative image) were detected in the adventitia (adv) and intima/media (I/M) of human coronary arteries with (diseased) or without (healthy)
atherosclerotic lesions [representative image with inset (left) and quantification (right); n = 9 to 14] (A) or in aortic root sections from Apoe−/− mice fed an HFD for
12 weeks (B) using a proximity ligation assay. PL, proximity ligation. (C and D) Wild-type or bone marrow from Ccr4−/− chimeric Apoe−/− mice were injected intra-
peritoneally with the CCR5 inhibitor DAPTA or CAN (each at 1 mg/kg, three times a week) for 2 weeks, and the number of Foxp3+CD4+ Tregs in peripheral blood (relative
to CD4+ T cells; n = 6 to 8) (C) and paraaortic lymph nodes [per lymph node (ln); n = 8 to 9] (D) was determined by flow cytometry. (E and F) Apoe−/− mice were injected
(intraperitoneally) with CAN (1 mg/kg, three times per week) while on HFD for 2 weeks. Oil Red O–positive lesion areas in the aortic root were quantified and expressed
as percentage of the total area (n = 9 to 10) (E). Representative images of aortic roots stained with Oil Red O are shown (F). (G and H) Blood from CreERT2−Cxcl12fl/fl (ctrl)
or CreERT2+Cxcl12fl/flApoe−/− mice (Cxcl12−/−) after tamoxifen treatment for Cxcl12 deletion (top) and from Apoe−/− mice treated with or without the CCL5 peptide [VREY]4
or vehicle (ctrl; bottom) was perfused over collagen for 4 min at 1000 s−1 (n = 5 to 10). (G) Multiparameter assessment of thrombus formation using distinct surfaces (a,
vWF-BP + laminin; b, vWF-BP + laminin + rhodocytin; c, collagen I) was performed and depicted in a heat map. Parameters were assessed by bright-field and sub-
sequent tricolor fluorescence microscopy as follows: 1, morphological score; 2, platelet deposition [surface area coverage (SAC)]; 3, thrombus contraction score; 4, multilayer
thrombus score; 5, multilayered thrombus (% SAC); 6/7, phosphatidylserine exposure (% SAC or platelet count/field); 8, CD62P expression (% SAC); and 9, aIIbb3 activation
(% SAC). Heat maps for all microspots (normalized per parameter) and genotype/perturbation were colored as increased (red) or decreased (green) based on statistical
significance versus controls. The multilayered thrombus score is exemplified in (H). (I) Platelet aggregation in human blood treated with combinations of CXCL12 (100 nM),
[VREY]4 (500 nM), and CCL5 (1 mM) was measured by impedance using a Multiplate analyzer (n = 12; CCL5 alone, n = 3). (J) cAMP signaling, expressed as decrease of the
specific Rluc signal, was analyzed in GloSensor and CXCR4-transfected HEK293 cells 15 min after stimulation with CXCL12 (40 nM) in the presence or absence of [VREY]4
(100 nM) (n = 8). Data represent means ± SEM from the indicated numbers of mice or independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, as analyzed by Mann-Whitney
test (A to C), unpaired t test (D, E, and J), or Kruskal-Wallis test (H and I).












interactions but rather that the interactome may vary depending on
the presence of soluble or membrane-bound GAGs. Binding of
CXCL4 to surface-bound heparin allowed for an additive, likely het-
eromeric, association of CCL5. The structural basis for CCL5 oligo-
merization and GAG binding has been elaborated (47). Polymerization
creates distinctive grooves that increase GAG avidity; besides the BBXB
motif, CCL5 uses another positively charged motif, KKWVR, which
supports CCR5 function (44). Models further predict that CXCL4 can
assemble heterooligomers with CCL5 featuring an altered surface charge
distribution that facilitates GAG binding (47).
Regarding the inhibitory effects of CXC-type heterodimers, it is re-
markable that a constitutively homodimeric CXCL12 variant bridged
by N-terminal CXCR4 peptides induces calcium signals but inhibits
chemotaxis, whereas a monomeric variant remains chemotactic, indi-
cating that dimerization limits monomer-induced chemotaxis (48).
Related mechanisms may apply to CXC-type heterodimers, whereby
functional activity is impeded by more stable b-sheet interactions at-
tenuating monomer release. Alternatively, CXC-type heterodimeric
interactions may cause conformational alterations, for example, by
aligning the a-helices (12). Consistent with spectral changes, a-helical
peptide [VREY]4 inhibited CXCL12 function, mimicking the effects of
full-length CCL5.
When assessing the stoichiometry of chemokines, it is reasonable
to also consider the role of receptor stoichiometry. Although we de-
tected chemokine receptor heteromers (CCR4-CCR5), the stoichi-
ometry of this association currently remains unknown. Chemokine
receptors can cluster in arrays, thereby influencing their surface ex-
pression, ligand levels, and function (49). The functional effects ob-
served herein are mediated by distinct mechanisms, depending on
which chemokine heterodimer is actually formed, and can involve
one agonist receptor or receptor heterodimers. Similar principles
may apply to the heterodimerization of chemokines, as for their
homooligomerization. In particular, inhibition by CXC-type chemo-
kine heterodimers may favor a 2:1 receptor/chemokine model as a
feasible explanation for negative binding cooperativity and transin-
hibition between chemokine receptor heterodimers (50).
We should point out that the models proposed herein, for instance,
with regard to underlying mechanisms by which chemokine heterodi-
mers address their respective receptors, are elaborated to best explain
our data but still await direct structural evidence. In addition, we could
functionally test and validate only a selected number of chemokine
heterodimers but not all possible combinations. Hence, we cannot ex-
clude that some heterodimer pairs may not comply with the functional
dichotomy observed for CC- and CXC-type heterodimers.
Several lines of evidence support a functional relevance of hetero-
mer formation in disease models. First, obligate CC-type heterodimers
show high efficacy and potency in recruitment assays, namely, OPRAH-
exacerbated LPS-induced acute lung injury and chronic macrophage-
laden atherosclerosis. Second, knocking in of CXCL4L1 (not interacting
with CCL5) was similarly effective in protecting from atherosclerosis as
CXCL4 deficiency, indicating that heterodimer formation with CCL5
was essential for atherogenic activity of CXCL4. Finally, the inhibition
of Treg-dependent atherosclerosis by CAN extends findings that CKEY
limits atherosclerosis and acute lung injury (7, 11) by interfering with
residues crucial for heterodimerization.
Notably, structural information regarding the type of interaction
and precise location of the interface can be exploited to design peptide
inhibitors selectively blocking CC-type heterodimers (as exemplified by
CKEY targeting CCL5-CXCL4 and CAN targeting CCL5-CCL17). Byvon Hundelshausen et al., Sci. Transl. Med. 9, eaah6650 (2017) 5 April 2017  
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between CCL5 and CXCL12 and attenuates CXCL12-mediated platelet
aggregation. Therefore, such CXCL12-targeting peptides could serve as
alternative antiplatelet therapeutics. Our paradigms illustrate strategies
for specific targeting of heterodimer-mediated functions in the chemo-
kine interactome and may allow for multivalent interference with a di-
versity of responses in disease-related chemokine microenvironments
(fig. S25). The TASP scaffolding used for [VREY]4 may also be ap-
plicable to bundle different peptides in a polyantagonist approach.
Alternatively, sequence hybridization could be used to generate mono-
molecular polyantagonists, as described for peptide triagonists (51). Our
data enable the development of peptide therapeutics based on endoge-
nous sequences that are selective in modulating heteromeric but not
primary receptor interactions of chemokines and could thus lack many
adverse effects associated with direct receptor-ligand antagonism.MATERIALS AND METHODS
Study design
The overall objective of this study was to establish a comprehensive
map of the chemokine interactome and to identify the structure-
function relationship of different chemokine heterodimer types. Sub-
sequent objectives were the design of specific peptides to disrupt func-
tional synergy or to mimic the inhibitory effects of heterodimers and
their validation in models of inflammation and atherosclerosis. For
mouse studies, a power analysis was performed using BiAS software
(version 11.02). We assumed a detectable biological difference of at
least 50% among up to four groups with an SD of <15%, an a of
0.05, and a resultant power of 0.8. On the basis of these assumptions,
at least four mice were included in each group. The number of
biological replicates for each data point is included in the figure le-
gends. All data were included (no outliers were excluded).
Ligand blots
Chemokines (1 mg) were spotted on a nitrocellulose membrane, which
was immersed overnightwith the soluble chemokine (1 to 5 mg/ml), and
reactedwithbiotinylatedantibodiesandstreptavidin-conjugatedhorseradish
peroxidase andenhanced chemiluminescence substrate (ThermoFisher Sci-
entific) essentially as described (52). The chemiluminescence signal was dig-
itally recorded and analyzed by the luminescence image analyzer LAS-3000
and Multi Gauge software (Fuji Photo Film).
Surface plasmon resonance
SPR was performed using a Biacore X100 instrument (GE Healthcare
Europe GmbH) and neutravidin-modified C1 sensor chips (52). Bio-
tinylated chemokines were immobilized on flow cells to 0.3 × 103 to
1.3 × 103 RU. Screening of chemokine binding was performed at 100 nM
in HBS-EP+ buffer at 90 ml/min after 20 s. Apparent affinities were
calculated from on and off rates after fitting of the curves obtained from
increasing analyte concentrations using a 1:1 Langmuir interaction model
(BIAevaluation software). To assess the inhibitory capacity of peptides,
we recorded the binding of chemokines (20 nM) incubated with increas-
ing peptide concentrations and calculated the percentage inhibition. Half-
maximal inhibitoryconcentrations(IC50)weredeterminedbyfour-parameter
logistic nonlinear regression (GraphPad version 5.0).
NMR spectroscopy
NMR samples were prepared in Wilmad 3-mm NMR tubes (160 ml).
Typically, chemokine samples were buffer-exchanged and concentrated











into 25 mM sodium acetate-d3 (pH 4.5) containing 0.1 mM EDTA
and 0.2 mM sodium azide, through five ultracentrifugation steps over
Amicon Ultra-4 3-kDa filter devices (Merck Millipore). Concentra-
tions of final stock solutions were determined using a NanoDrop
2000 spectrophotometer (Thermo Fisher Scientific). Mixtures of che-
mokines at defined molar ratios were prepared from these stock solu-
tions, and 5% (v/v) D2O was added for field locking, together with a
trace of DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) as internal
chemical shift standard. NMR spectra [1H-15N HSQC with flip-back
pulse, DIPSI (decoupling in the presence of scalar interactions), and
NOESY (nuclear Overhauser effect spectroscopy)] were recorded at 37°C
on Bruker Avance III HD 700- and 850-MHz spectrometers equipped
with cryogenically cooled TCI probes. Spectra were processed and analyzed
using Bruker TopSpin 3.2 and Sparky 3.114 software (T. D. Goddard,
D. G. Kneller, SPARKY 3, and the University of California, San Francisco).
Resonance assignments of CCL5E66S and CXCL12 were performed
by two-dimensional (2D) NOESY and 3D-edited NOESY spectra. Be-
cause CCL5E66S show homodimers and monomers that are in slow
exchange on the NMR chemical shift time scale, resonances for both
dimers and monomers are observed and well resolved in HSQC
spectra, allowing assessment of effects on both states (22). Chemical
shift differences (Dd) induced upon binding were calculated as follows:
[(D1H)2]1/2 + [(0.25D15N)2]1/2 (in 1H ppm). DIntensity was calculated
as follows: 1 − Inti/Into, where Inti is the resonance intensity of
CCL5E66S or CXCL12 resonances in the presence of the other chemo-
kine, and Into is the intensity of CCL5
E66S or CXCL12 resonances in
its absence.
Statistical analysis
Data are expressed as means ± SEM unless otherwise specified. If
D’Agostino-Pearson omnibus and/or Shapiro-Wilk normality test
indicated Gaussian distribution, an unpaired t test for side-by-side
comparisons or one-way ANOVA with Newman-Keuls posttest for
multiple comparisons was performed. Otherwise, Mann-Whitney tests
for side-by-side comparisons and Kruskal-Wallis test with Dunn’s
posttest for multiple comparisons were performed using GraphPad
Prism version 5.04 for Windows (GraphPad Software).
For all other Materials and Methods, please see Supplementary
Materials.arch 5, 2020SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/9/384/eaah6650/DC1
Materials and Methods
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Fig. S3. CXCL4K50E- and CCL17-induced changes in the HSQC spectrum of CCL5E66S.
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Fig. S11. Targeting of CCL5-CCL17 heterodimer by CAN.
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Fig. S13. Dose dependency of T cell chemotaxis elicited by single chemokines.
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Fig. S21. Generation of mice deficient in Cxcl4 or Cxcl12 or carrying Cxcl4 variants.
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Materials and Methods 
Cells and cell culture 
Human CD4 T cells were isolated from whole blood of healthy volunteers after separating pe-
ripheral blood mononuclear cells (PBMCs) with Biocoll (Biochrom, Merck Millipore using the 
Dynabeads Untouched Human CD4 T Cells kit, stimulated with Dynabeads Human T-Activator 
CD3/CD28 (both Thermo Fisher Scientific) for 3 days and expanded in the presence of Dyna-
beads with hIL-2 (30 U/mL) for another 3 days. Human monocytes were isolated from PBMCs, 
and purified by negative selection using the “Monocyte Isolation Kit II” (Miltenyi Biotec). 
Mouse CD4 T cells were isolated from spleens of mice with indicated genotypes using Dyna-
beads Untouched mouse CD4 Cells Kit and activated using Dynabeads Mouse T-Activator, 
Thermo Fisher Scientific), as described for human cells. Mouse dendritic cells were isolated 
from spleens by positive and negative selection using magnetic beads (Pan DC MicroBeads, 
mouse, Miltenyi Biotec). Human aortic endothelial cells (HAoECs) were from PromoCell. Oli-
gonucleotides were synthesized at MWG-Biotech. 
The Flp-In system and Flp-In™ TREx-293 (HEK293) cells were from Invitrogen. Plasmids har-
boring sequences for CCR1, CCR4, CCR5 and CXCR4 were from Missouri S&T cDNA Re-
source Center (www.cdna.org). The pGloSensor™-20F-vector and luciferin-EF were from 
Promega. The sequence of the luciferase-cAMP binding site fusion protein from the pGloSen-
sor™-20F-vector was amplified and ligated into a bicistronic pIRESneo vector (Clontech) to 
obtain the reporter gene plasmid. The pcDNA5/FRT/TO vector (Invitrogen) was used to express 
receptor constructs carrying an N-terminal hemagglutinin-tag or enhanced yellow fluorescent 
protein (eYFP) (53). HEK293 cells were transfected with the reporter gene vector using Eco-
Transfect (OZBioscience), stable clones were selected as host cell lines for expressing receptor 
constructs using the Flp-In system (53), and re-selected with G418 and hygromycin B. 
Chemokines and peptides 
CCL5, CXCL4 and CXCL12 were recombinantly expressed using codon-optimized genes 
(Genscript, NJ, USA), and pET-24a(+), -32a(+) or -43.1a(+) vectors, respectively, in E.coli 
BL21(DE3) cells and purified, essentially as described (54). To generate 15N-labeled chemo-
kines, we used Spectra M9 medium (Cambridge Isotope Laboratories). Mass and disulfide bond 
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integrity were examined by UPLC-QTOF mass spectroscopy. Biotinylation of chemokines was 
performed while bound to heparin columns. Purified CCL5E26A and the synthesized CCL5MT7 
variant were kindly provided by Dr. A. Proudfoot (55). Other chemokines were purchased from 
Peprotech or R&D Systems. CCL5 and CCL17 C-terminally-conjugated with AF647 were from 
ALMAC science. 
The peptides CAN and CKEY were synthetized by Bachem AG. All other peptides (Table S4) 
were synthesized manually by SPPS on PAM resin or thioester (COSR) generating resin using in 
situ neutralization/HCTU activation for tBoc chemistry (56). Semi-preparative HPLC was per-
formed using Vydac C18 or C4 HPLC columns using a Waters Deltaprep system. Peptide analy-
sis was performed on a Waters UPLC XEVO-G2QTOF system. The peptide monomer VREY 
was extended at the N-terminus by introducing a glycine spacer to which (Boc-aminooxy) acetic 
acid (AO) was coupled (AO-G-EKKWVREYINSLEMS-COOH). A modified cyclic backbone 
TASP template was used to obtain a parallel 4-helix bundle (H2N-CPKGKGPGKGKG-COSR) 
(25). TASP-lysines were modified to present a ketone group using 4-acetylbutyric acid (56). 
TASP was cyclized by native chemical ligation (NCL) (25) and the free cysteine was alkylated 
to prevent dimer formation. Ketone-derivatized TASP and a 2.5-fold excess of aminooxy-VREY 
were reacted to obtain [VREY]4 through oxime linkage. 
The total chemical synthesis of OPRAH (obligate PF4-RANTES heterodimer), nOPRAH (n-
terminally tethered OPRAH), mOPRAH (mouseOPRAH using the murine orthologs) and 
ORATH (obligate RANTES-TARC heterodimer) comprised the individual synthesis of CCL5, 
CXCL4 or CCL17, which were subsequently folded and coupled by oxime chemistry. The indi-
vidual chemokines were synthesized in three parts that were joined by NCL and folded by oxida-
tion (57). CCL5 N-termini were modified to introduce aminooxy moieties for oxime ligation. For 
both human and mouse CCL51-10, Lys(-amino-Alloc) was introduced at position T7 to allow for 
on-resin aminooxy modification. As counterparts in the oxime ligation reactions, ketones (4-
acetylbutyric acid) were added in the chemokine N-termini by introducing Lys(-amino-Alloc) at 
position L8 of human CXCL4, at position L13 of mouse CXCL4, and at position G7 of human 
CCL17 (58). The folded N-terminally ketone-derivatized chemokines were reacted with a 2-fold 
excess of aminooxy-CCL5. The mixture was placed at -20°C for 1 h to complete the reaction. 
The covalent heterodimer product was purified using HPLC. Detailed information about the syn-






Molecular dynamics (MD) simulation and binding free energy calculations  
Chemokine structures were downloaded from the Protein Data Bank (PDB): codes 1DOK 
(CCL2), 2L9H (CCL5), 1NR4 (CCL17), 1F9Q (CXCL4), 4UAI (CXCL12). Dimer complexes 
(CC or CXC type) were manually assembled by superimposition onto the CC-conformation of 
CCL5 or the CXC-conformation of CXCL4. The different chemokine complexes were subjected 
to MD simulations as described (60, 61), except applying Amber12SB force field and TIP4P-Ew 
water model. Free MD simulations were performed for 100 ns and accelerated molecular dynam-
ics were employed for another 30 ns. Snapshots between 100-130 ns were extracted for binding 
free energy calculation using molecular mechanics/generalized Born surface area (MM/GBSA) 
approach and the binding free energies were approximated from enthalpy values (61). Default 
parameters were applied for binding free energy calculation, except using generalized Born 
model 8 to compute the free energy of solvation. 
Transmigration assays 
Transmigration assays were performed using Transwell-96 Permeable Support (Corning) with 
5.0 µm (human T cells) or 3.0 µm (mouse T cells) pore size (45). Chemokines were added to the 
bottom chambers and 104 activated T cells were allowed to migrate for 2 h from the top cham-
ber. Receptor antagonists were added to top chambers, while compounds modulating chemokine 
interactions were added to bottom chambers at 10x molar excess relative to chemokine. The 
number of cells migrated was analyzed by flow cytometry (FACSCanto II, BD Biosciences) and 
FlowJo v.10 software (Tree Star Inc.). The chemotactic index was calculated as the ratio of 
chemokine-stimulated to unstimulated migration.  
Arrest assays 
Confluent HAoEC monolayers were activated with IL-1β for 4 h before incubation with chemo-
kines, synthetic obligate chemokine heterodimers and/or peptides for 30 min. Monocytes or T 
cells (0.7×106/ml) pretreated with receptor antagonists (C021, DAPTA, Met-RANTES) were 
perfused over activated HAoECs in a laminar flow chamber at a shear stress of 1.5 dyn/cm2 for 2 
min. Cells were visualized and recorded by video microscopy (Olympus IX 50, Shinjuku, Japan, 
20x objective). Firmly adherent leukocytes were counted in 10 high-power fields (HPF) per plate. 
Proximity Ligation Assay  
Proximity ligation was performed using the Duolink In Situ Red Kit Goat/Rabbit on PFA-fixed 
cryo-sections of aortic roots or lymph nodes of Apoe-/- mice, using primary polyclonal antibodies 
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to mouse CCL17 (R&D, AF529), mouse CCL5 (Acris, AP20618PU-N) according to the manu-
facturer’s instructions. Mouse dendritic cells and SV40-transformed endothelial cells (SVECs) 
cultured on collagen-coated cover slips were pre-incubated with mouse CCL5, CXCL4 and 
CCL17 (Biolegend) alone or in combination with CAN or CCR5-derived transmembrane pep-
tides TM1 and TM4 known to inhibit CCR5 dimerization (27). The same kit was used on paraf-
fin sections of human coronary arteries using polyclonal antibodies to human CCL5 (AF278-NA, 
R&D Systems) and CCL17 (ab182793, Abcam). Imaging was performed using fluorescence 
microscopy (Leica DM4000) after which deconvolution algorithms for wide field microscopy 
were applied to improve overall image quality (Huygens professional 16.10; SVI). The number 
of Duolink-detected interactions was determined in the processed images using the Leica LAS 
4.2 analyses software. In order to more accurately resolve the interactions detected with Duolink, 
representative dendritic cell samples of each condition were also visualized with a Leica SP8 3X 
microscope using a combination of 3D confocal microscopy (DAPI) and 3D STED nanoscopy 
(Duolink Red). Image processing and deconvolution of the resultant 3D datasets was performed 
using the Leica LAS X and Huygens professional software packages. The study was approved by 
the Ethics Committee of the Academic Medical Centre at the University of Amsterdam. Anony-
mous post-mortem coronary artery specimen did not require informed consent. 
Flow cytometry 
Whole blood obtained from the retro-orbital plexus of mice was EDTA-buffered and subjected to 
red blood-cell lysis. Lymph nodes and spleens were mechanically disrupted and passed through a 
cell strainer. Leukocytes were counted and analyzed by the following antibody cocktail: anti-
CD45, anti-CD115, anti-Gr1, anti-CD11b, anti-CD19 (eBioscience, clone MB19-1) and anti-
CD3 (eBioscience, clone 145-2C11). Leukocyte subsets were defined using FlowJo software: 
neutrophils (CD45+CD115-Gr1high), monocytes (CD45+CD115+), classical monocytes (CD45+
CD115+Gr1high), non-classical monocytes (CD45+CD115+Gr1low) and lymphocytes (CD45+CD3+ 
and CD45+CD19+). Chemokine receptors were analyzed using FITC-anti-Ccr1 (R&D, 
FAB5986F), AF647-anti-Ccr3 (BioLegend, clone TG14/Ccr3), PE-anti-Ccr5 (eBioscience, clone 
HM-CCR5) and PE-anti-Ccr2 (R&D Systems). 
Mice 
All animal experimental procedures were designed and conducted in agreement with the German 
Animal Welfare Legislation, and were reviewed and approved by the local authorities (Regier-
ung von Oberbayern, Munich, Germany). All mice were housed in IVC units and maintained on 
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a 12-h dark/12-h light cycle. B6.129P2-Apoe/J (Apoe-/-) and B6.129P2-Ccl5tm1Hso/J (Ccl5-/-) mice 
were obtained from The Jackson Laboratory, C57BL/6J mice were from Janvier and tamoxifen-
inducible general Cre-deleter C57BL/6-Gt(ROSA)26Sortm9(Cre/ESR1)Arte (CreERT2) mice were 
from Taconic (TaconicArtemis GmbH). 
Cxcl4L1/L1, Cxcl4tg-L1and Cxcl12-/- mice were generated by laser-assisted (XY-Clone Hamilton 
Thorne) injection of R1/E(129/Sv) cells into 8-cell stage C57Bl/6NCrl embryos. Embryo recipi-
ents were Crl:CD1(ICR) mice (Charles River). All manipulations were carried out in the Trans-
genic Core Facility (TCF) of the MPI-CBG, Dresden. Chimeras were crossed to C57Bl/6NCrl 
mice and their offspring were screened for germline transmission. Details of the targeting con-
structs used to induce homologous recombination and knock-in into the Rosa locus are depicted 
in Fig. S21.  
Bone marrow transplantation 
Apoe-/- mice underwent lethally whole body irradiation (2x5Gy) and were reconstituted with do-
nor bone marrow cells from Apoe-/-Ccr4-/- or Apoe-/-Ccl5-/-Cxcl4-/- mice, essentially as described 
(7). After 4 weeks, animals were injected i.p. with the CCR5 antagonist DAPTA (TOCRIS) or 
CAN peptide every second day for 2 weeks.  
Atherosclerotic lesion formation, quantification and histological analysis 
To induce lesions, 8 week old Apoe-/- mice fed a high-fat diet (HFD, 21% fat, 19.5 % casein, 
0.15% cholesterol, ssniff) for 2 weeks (bone-marrow chimeras) for 6 weeks (OPRAH injection) 
or 12 weeks (analysis of Cxcl4-deficient and knock-in strains). Mice were anesthetized with ket-
amine (80 mg/kg) and xylazine (10 mg/kg) and EDTA-anticoagulated blood was retroorbitally 
collected. Cell counts were determined using an automated hematology analyzer (scil Animal 
Care). Plasma was used to detect cholesterol and triglyceride levels (CHOD-PAP or GPO-PAP 
kit, Roche). After complete bleeding, in situ perfusion fixation was performed using 4% buffered 
formaldehyde (Carl Roth) and the heart and entire aorta were excised. The aorta was longitudi-
nally opened and stained en face with Oil-Red-O to visualize lipid deposition. The lesion area 
was calculated as percentage of the Oil-Red-O+ stained area normalized to the respective aortic 
area (arch, thoracoabdominal, inner curvature, outer curvature). After paraffin-embedding and 
cutting into 4 µm transverse sections for aortic roots or 6 µm longitudinal sections for aortic 
arches, atherosclerotic lesion size was measured after Elastica-van Gieson (EVG) staining 
(Baacklab). In aortic roots, the percentage of lesion area of the aortic valves normalized to the 
area of the internal lumen was determined. In aortic arches, total lesion size was quantified in the 
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inner curvature and the three branches. Cellular content was analyzed by immunofluorescence 
staining for macrophages, CD3+ T cells and smooth muscle cells (SMCs) using anti-Mac-2 (Ce-
darlane Labs), anti-CD3 and anti-αSMA antibodies (Dako). Nuclei were counterstained with 
DAPI (Vector Laboratories). Primary antibodies were visualized using DyLight-488, -550 and -
650–conjugated secondary antibodies (Abcam). Images were recorded with a DM 6000B fluo-
rescence microscope (Leica, Solms), connected to a monochrome digital camera (DFC 365FX) 
for fluorescent imaging or a DFC425C camera for bright-field microscopy. Mac-2-, CD3- and 
αSMA cells were manually quantified as positive cells per plaque area. Stages of atherosclerotic 
lesions were determined in EVG-stained aortic root sections according to the Virmani classifica-
tion. Necrotic cores were quantified as anuclear crystal-laden areas of lesions and normalized to 
the lesion area. 
Acute lung injury 
The acute lung injury (ALI) model was performed as described (11). ALI was induced in 8 
weeks-old male C57BL/6 mice (Janvier) or Ccl5-/-CXCL4-/- bone marrow chimeric mice by ex-
posure to aerosolized LPS (500 µg/ml) from Salmonella enteritidis (Sigma) for 30 min. Peptides, 
chemokines or mOPRAH were injected i.v. at indicated doses. Alveolar, interstitial, and intra-
vascular neutrophils were analyzed after 4 h. To label intravascular neutrophils, FITC-Ly-6G 
(Gr1) (clone RB6-8L5, eBioscience) was applied by tail vein injection 30 min before sacrifice. 
Broncho-alveolar lavage (BAL) fluid was obtained by repeated injection and withdrawal of PBS. 
The pulmonary vasculature was rinsed with PBS 0.5 mM EDTA. Lungs were removed, minced 
and digested with liberase (Roche), passed through a cell strainer and neutrophils were analyzed 
by labeling with anti-mouse PerCP-Cy5.5-Ly-6G, PE-CD115, APC-Cy7-CD45 antibodies (eBi-
oscience).  
Competitive chemokine receptor-ligand binding 
HEK293 transfectants expressing CCR1, CCR4 or CCR5 were incubated with AF647-labeled 
CCL5 or CCL17 (2.5 nM) in presence or absence of unlabeled CCL5 or CCL17 (at increasing 
concentrations) for 1 h at 4°C. After washing, fluorescence intensity was measured by flow cy-
tometry (FACSCantoII) and analyzed using FlowJo v.10 software (Tree Star Inc.). 
Chemokine binding to monocytes 
Monocytes were incubated with CCL5 in combination with CXCL4 or CXCL4R>Q (each 100 
nM) for 1 h at 4°C. CCL5-binding was reacted with a CCL5-antibody (5 µg/ml, Abcam AB9679) 
and detected with an AF488-conjugated secondary antibody (2 µg/ml, Thermo Fisher Scientific). 
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Chemokine receptor internalization 
CCR1-, CCR4- or CCR5-expressing HEK293 transfectants were incubated for 1 h at 4°C with 
AF647- labeled CCL5 or CCL17 (2.5 nM) in presence of increasing concentrations of unlabeled 
chemokines. Cells were then washed with cold PBS and fluorescence intensity was analyzed by 
flow cytometry.  
CCR1 surface expression on adherent arterial leukocytes 
Carotid arteries of wild-type mice (C57BL/6) were carefully mounted in custom-made perfusion 
chambers and set at a physiological pressure of 80 mmHg. A syringe pump (Harvard apparatus 
PHD ULTRA) was connected to the common carotid side of the artery while a water column 
was attached to the bifurcation side, in order to maintain physiological pressure under flow. The 
artery was placed on the microscope stage in a climate chamber (37°C). Bone marrow-derived 
leukocytes from these mice were fluorescently labeled with cell tracker red CMTPX (Thermo 
Scientific) and stimulated with or without CCL5 (30 ng/ml) alone or combined with CXCL4 or 
CXCL4R>Q (300 ng/ml each) in Hanks Balanced Salt Solution (HBSS) containing Ca++ and Mg++ 
for 45 min at 37°C. After staining with a FITC-conjugated antibody to CCR1 (Biorbyt), leuko-
cytes (106/ml) were perfused in the mounted carotid artery at an arterial flow rate of 0.54 ml/min, 
the endothelium was stained with an Alexa Fluor 450®-conjugated antibody against CD31 (eBio-
science), and after 10 min, the artery was flushed with 2 ml HBSS. Subsequently, two-photon 
laser scanning microscopy was performed to visualize the luminal area within the artery using a 
Leica SP5MPII system with a pulsed Ti:Sapphire laser (Spectra Physics MaiTai DeepSee) tuned 
at 800 nm and a 20×NA1.00 water immersion objective. Adherent leukocytes were imaged at 
1024*1024 pixels and three-fold line and frame average, in Z-stacks of 2.5 μm intervals. To 
quantify cell surface CCR1, images were processed using LAS AF 3.0 software (Leica), and 3D 
cropping of single cells adhering to the endothelium was performed. Standard background noise 
reduction and thresholding of CCR1 signal was equally applied to every image. Mean Intensity 
Fluorescence (MFI) of single cells was quantified. 
Cyclic AMP signaling 
Levels of cyclic adenosine monophosphate (cAMP) were measured in confluent HEK293 chem-
okine receptor transfectants after stimulation with chemokines using Glosensor technology over 
up to 30 min. After incubation with luciferin-EF (2.5 mM) at RT for 2 h, cells were stimulated 
with CXCL12 in the presence or absence of [VREY]4 and luminescence indicating the reduction 
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of cAMP was recorded. Likewise, HEK293 cells were transfected with CCR4 or with CCR4 and 
CCR5 and stimulated with CCL5, CCL17 or both. CCR1 transfectants were stimulated by con-
centrations of OPRAH as indicated. 
Bioluminescence resonance energy transfer (BRET) 
Transfection of HEK293 cells with 0.05 µg of a plasmid harboring the CCR5-RlucII construct 
and 0.2 µg of a plasmid containing the eYFP-arrestin-1/2 constructs or a mock plasmid was per-
formed in 24-wells using 0.5 µl of EcoTransfect. After 24 h, cells were transferred into black 96-
well plates with clear bottom, and 72 h after transfection cells were washed and further incubated 
in HBSS (30 µl) at 21°C. Fluorescence was measured in a plate reader (excitation 480, emission 
530). HBSS (10 µl) containing coelenterazine H (5 µM) was added to each well, a white sticker 
attached to the bottom and total luminescence measured for 5 min. Then, HBSS (10 µl) with and 
without stimulus (CCL5, CXCL4 or both) was added and the BRET signal (ratio 530/480 nm) 
determined for 1 s intervals over 20 min. Net-BRET was calculated as the BRET ratio in the 
presence of the respective eYFP-construct minus BRET ratio obtained with the mock plasmid. 
Platelet aggregometry and ex vivo thrombus formation 
Human venous blood was collected in hirudin-precoated tubes (Sarstedt, ). Informed consent was 
obtained as approved by the Ethics Committee of the Faculty of Medicine, LMU Munich. Plate-
let aggregation in blood was determined by multiple electrode aggregometry (MEA) using the 
Multiplate® device (Roche Diagnostics). Whole blood was diluted with NaCl 1:1 and CXCL12, 
CCL5 or [VREY]4 were added, stirring was started and the increase in electrical impedance was 
recorded continuously for 5 min. The mean value of two independent determinations is ex-
pressed as area under the curve in arbitrary units (U).  
The multi-parameter assessment of thrombus formation has been described in detail for human 
blood (62, 63). Mouse blood was collected into 0.1 volume of saline with a final concentration of 
4 µM PPACK, 4 U/ml fragmin and 5 U/ml heparin. Microspot-coated coverslips, coated as de-
scribed with three distinct surfaces (a: VWF + laminin. b: VWF + laminin + CLEC-2 ligand. c: 
collagen type I, Horm), were mounted onto a parallel-plate flow chamber and a shear rate of 
1000 s-1 was applied. In thrombi, platelets were stained with monoclonal antibodies against 
CD62P (FITC), activated integrin αIIbβ3 (PE-JON/A)t, and AF647-annexin-A5. Parameters were 
assessed by bright-field and sub-sequent tri-color fluorescence microscopy. 
74
Supplementary Figures 
Fig. S1. Representative ligand blot and densitometric values. 
(A) Chemokines were spotted on a nitrocellulose membrane (1 µl, 1 ng) as indicated. In this 
example, CCL5 served as the positive control (orange). (B and C) The membrane was left un-
treated to test for antibody specificity (B) or incubated overnight at 4°C with 100 nM CCL5 (C). 
CCL5 partners were detected using a biotinylated antibody to CCL5 and a HRP-conjugated 
secondary antibody (C). (D) The absolute luminescence signal (area and density) was digitally 
recorded, background was subtracted and expressed relative to the signal of the positive control 
(CCL5). 
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Fig. S2. Interaction of CCL5 and CCL5E66S with CCL17 analyzed by SPR. 
To validate chemokine interactions of interest, we performed kinetics analyses of their binding 
curves using surface plasmon resonance (SPR). Apparent affinities were calculated from on-
rates (ka) and off-rates (kd) obtained by fitting the curves using BIAevaluation with the 1:1 inter-
action model (Langmuir). In this example, CCL17 was biotinylated and immobilized onto a neu-
travidin-coated sensor chip C1 (BIAcore). (A) CCL5E66S was perfused at 2, 4, 8, 16, 32, 64, 128, 
256, and 512 nM, and (B) CCL5 was perfused at 1.6, 3.1, 6.3, 12.5, 25, 50, 100, 20, 400 and 
800 nM, at 5 µl/min in running buffer (HBS-EP+, pH 7.4) and regenerated with 100 mM NaOH, 
0.05% SDS and 30% acetonitrile. KD was calculated to be 93 nM for CCL5E66S and 65 nM for 
native CCL5.  
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Fig. S3. CXCL4K50E- and CCL17-induced changes in the HSQC spectrum of CCL5E66S. 
(A and B) 15N-1H heteronuclear single quantum coherence (HSQC) spectra (1H frequency of 700 MHz) obtained by nuclear magnetic resonance 
(NMR) are shown for 30 µM 15N-labeled CCL5E66S in the presence of 600 µM CXCL4K50E (A) and 20 µM 15N-labeled CCL5E66S in the presence of 
650 µM CCL17 (B). In both spectra, free CCL5E66S cross-peaks are in red, and CCL5E66S cross-peaks in presence of CXCL4K50E or CCL17 are in 
blue. We denote CCL5E66S dimers with “d” and CCL5E66S monomers with the prefix “m”, Arginine NE sidechain peaks are folded in the 15N dimen-
sion. Solution conditions were 25 mM Na-acetate-d3 buffer (95% H2O; 5% D2O), pH 4.5, 37°C. Expanded regions taken from these two HSQC 
spectral overlays are displayed in Fig. 2A and B. 
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Fig. S4. Chemical shift and resonance intensity changes of CCL5E66S residues. 
Chemical shift (δΔ) and resonance intensity (ΔIntensity) changes for 15N-labeled CCL5E66S (30 
µM) in the presence of CXCL4K50E or CXCL4 (600 µM) or for 15N-labeled CCL5E66S (20 µM) in 
the presence of CCL17 (650 µM) were quantified and plotted vs the CCL5 amino acid se-
quence. We denote CCL5E66S dimers with “d” and CCL5E66S monomers with the prefix “m”. (A) 
ΔIntensity values for dCCL5E66S plus CXCL4K50E; (B) δΔ values for dCCL5E66S plus CXCL4K50E; 
(C) ΔIntensity values for dCCL5E66S plus CCL17; (D) δΔ values for dCCL5E66S plus CCL17; (E) 
ΔIntensity values for mCCL5E66S plus CXCL4; (F) δΔ values for mCCL5E66S plus CXCL4; (G) 
ΔIntensity values for dCCL5E66S plus CXCL4; (H) δΔ values for dCCL5E66S plus CXCL4. Solution 
conditions were 25 mM Na-acetate-d3 buffer (95% H2O; 5% D2O), pH 4.5, 37°C. 
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Fig. S5. CXCL4K50E-induced changes in the HSQC spectrum of CCL5. 
15N-1H heteronuclear single quantum coherence (HSQC) spectra were acquired with 128 scans 
per transient and sweep widths of 16 ppm in the 1H (2k points) dimension and 22 ppm in the 
15N (200 points) dimension. Shown are full spectra (A) and expansions (B) of wildtype 15N-
CCL5 (5 µM) either alone (red) or in the presence of unlabeled 400 µM CXCL4K50E (blue). Val-
ues for δΔ (C) and ΔIntensity (D) (calculated as described in the legend to Fig. S4) are plotted 
versus the amino acid sequence of CCL5. 
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Fig. S6. Concentration-dependent formation of CC- versus CXC-type heterodimers. 
Changes in resonance intensity (ΔIntensity) for 15N-labeled CCL5E66S monomer resonances in 
the presence of increasing concentrations of CCL17 are plotted vs the amino acid sequence of 
CCL5. The final CCL17:CCL5E66S molar ratios were 8:1 (A), 33:1 (B) and 265:1 (C), as indicat-
ed. The total concentration of CCL5E66S was 20 µM at the two lowest ratios and 10 µM at the 
265:1 ratio. ΔIntensity was calculated as in Fig. S4. Solution conditions were 25 mM Na-
acetate-d3 buffer (95% H2O; 5% D2O), pH 4.5, 37°C. (D) ΔIntensity values increasing the most 
by the highest CCL17 concentration are highlighted in red on the X-ray crystal structure of 
CCL5 (PDB code 1U4L). (E) ΔIntensity values averaged over residues at the CC-type (residues 
3-16; 30-35, 46-50) or CXC-type (residues 24-30, 53-68) heterodimer interfaces are plotted vs 
the CCL17:CCL5E66S molar ratio. 
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Fig. S7. CCL5-induced changes in HSQC spectra of CXCL12. 
(A) 15N-1H heteronuclear single quantum coherence (HSQC) spectra (1H frequency of 700 MHz) 
for 15N-labeled CXCL12 (30 µM) in the absence (red contours) and presence (blue contours) of 
CCL5E66S (315 µM) are overlaid. (B) From the HSQC spectra shown in A, δΔ and ΔIntensity 
values (calculated as in Fig. S4) are plotted vs the amino acid sequence of CXCL12. (C) 15N-1H 
HSQC spectra (1H frequency of 700 MHz) for 15N-labeled CCL5E66S (20 µM) in the absence (red 
contours) and presence (blue contours) of CXCL12 (770 µM) are overlaid. (D) From the HSQC 
spectra shown in C, δΔ and ΔIntensity values (calculated as described in the legend to Fig. S4) 
are plotted versus the amino acid sequence of CCL5. (E) From 15N-1H HSQC spectra of 15N-
CCL5E66S (20 µM) in the absence and presence of CXCL10 (1.0 mM), ΔIntensity values (calcu-
lated as in Fig. S4) are plotted vs the amino acid sequence of CCL5. Solution conditions were 
25 mM Na-acetate-d3 buffer (95% H2O; 5% D2O), pH 4.5, 37°C. 
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Fig. S8. Structural models of CC-type and CXC-type heterodimers. 
Structures of CCL5-CCL17 (CC-type, A) and CCL5-CXCL12 (CXC-type, B) modelled following 
molecular dynamics simulation plus minimization (CCL5 in green, CCL17 and CXCL12 in red, 
respectively) are illustrated. 
83
Fig. S9. Targeting of CCL5-CXCL4 heterodimer by CKEY. 
15N-1H heteronuclear single quantum coherence (HSQC) spectra (A) and spectral expansions 
for mCCL5E66S residues C10 and Y14 (B) at the heterodimer interface are shown to exemplify 
the inhibitory effect that increasing concentrations of CKEY peptide has on the formation of 15N-
CCL5E66S-CXCL4K50E heterodimers. Red contour lines show relatively sharp resonances of free 
CCL5E66S monomer peaks, blue contours indicate the corresponding broadened peak caused by 
heterodimer formation with CXCL4K50E, while green contours show reverse trends in linewidth 
and chemical shift on CCL5E66S heterodimer peaks caused by the competitive binding of CKEY. 
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Fig. S10. Interaction of CAN with CCL17. 
The amide region of DIPSI spectra of unlabeled CCL17 (20 µM) in the absence (red peaks) and 
presence of CAN peptide (200 µM, green peaks) recorded at 37°C and pH 4.5 are overlaid. 
Resonances arising from CCL17 are dispersed and defined, indicating a well-folded protein. On 
the other hand, resonances from the CAN peptide are generally broad and less disper-sed, 
most likely reflecting highly interconverting conformations and random coil states expected for a 
short linear peptide. Although many CCL17 and CAN resonances overlap, a number of CCL17 
resonances are chemically shifted and broadened by the 10-fold molar excess of CAN.
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Fig. S11. Targeting of CCL5-CCL17 heterodimer by CAN. 
(A) 15N-1H heteronuclear single quantum coherence (HSQC) spectra of 15N-labeled CCL5E66S 
(20 µM) in the absence (red peaks) and presence of CCL17 (320 µM, orange peaks) and upon 
addition of CAN peptide (640 µM, blue peaks) are overlaid. (B) 15N-1H HSQC spectral expan-
sions for residues at the heterodimer interface are shown to exemplify inhibitory effects of CAN 
on the formation of 15N-CCL5E66S-CCL17 heterodimers. Residues T7 and T8 are centrally posi-
tioned at the CC-type dimer interface in CCL5E66S homodimers and CCL17-CCL5E66S heterodi-
mers. Note that presence of CCL17 (orange peaks) substantially shifts T7 and T8 resonances, 
and addition of CAN (blue peaks) partially shifts those resonances back towards the CCL5E66S 
monomer state, whereas resonances of C10, F12, Y14 and V49 do not show such a reversal. 
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Fig. S12. Efficient targeting of CCL5-CXCL12 heterodimer by [VREY]4. 
(A) Chemical structure of 4 VREY molecules on a TASP scaffold resulting in [VREY]4. (B) Over-
lays of 15N-1H heteronuclear single quantum coherence (HSQC) spectral expansions of 10 µM 
monomeric 15N-CXCL12 in the absence (red contours) and presence (blue contours) of 40 µM 
[VREY]4 peptide. (C) Using these HSQC data, δΔ values (calculated as in Fig. S4) are plotted 
versus the amino acid sequence of CXCL12. (D) Structural perturbation plot of CXCL12 (mon-
omeric) induced by [VREY]4, as taken from the experimentally derived delta ppm values. (E) 
15N-1H HSQC spectral expansions for five residues at the heterodimer interface are shown to 
exemplify the inhibitory effect that [VREY]4 has on the formation of 15N-CXCL12-CCL5 hetero-
dimers. Solution conditions were 25 mM potassium phosphate buffer (95% H2O; 5% D2O), pH 
7.1, 25°C. Poor solubility of [VREY]4 at pH values lower than 7 prevents the study of heterodi-
mer formation at standard pH 4.5 buffer conditions. 
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Fig. S13. Dose dependency of T cell chemotaxis elicited by single chemokines. 
Membrane expression of chemokine receptors was detected by antibodies directly conjugated 
to a fluorophores and expressed as percentage of positively stained human T cells (A). (B–G) 
Chemotaxis assays were performed using IL-2- and CD3/C28-activated human T cells in 3 µm 
Transwell-filter plates. Chemokines were added to the bottom chamber at indicated concentra-
tions: CCL5 (B), CCL17 (C), CXCL12 (D), CXCL4 (E), CXCL4L1 (F), CXCL10 (G). The chemo-
tactic index was calculated as the ratio of chemokine-induced versus unstimulated migration, as 
determined by counting cells in the bottom chamber. Data represent mean±SEM of n=5-20 in-
dependent experiments. 
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Fig. S14. Differential effects of chemokine combinations on T cell chemotaxis. 
(A-H) Chemotaxis assays were performed using IL-2- and CD3/C28-activated human T cells in 
Transwell-filter plates. Combinations of CCL5 (1 nM) with CCL17 (0.1 nM) (A, n=14), of CXCL4 
(n=5) or CXCL4L1 (n=6) with CCL5 (all at 4 nM) (B,C), of CXCL12 with CCL5 (n=14), CXCL4 
(n=9), or CXCL4L1 (n=9) (all at 40 nM) (D–F) and of CCL5 (1 nM) with CCL3 (n=3) or CXCL10 
(n=4) (both at 100 nM), (G,H) were added to the bottom chamber. The chemotactic index was 
calculated as the ratio of chemokine-induced versus unstimulated migration. Dashed lines indi-
cate virtually calculated additive effects (A-C, G,H). Data represent mean±SEM from the indi-
cated number of independent experiments. *p<0.05, as analyzed by Kruskal-Wallis-test.
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Fig. S15. Differential effects of chemokine heterodimerization on leukocyte recruitment. 
(A–I) The firm arrest of IL-2- and CD3/C28-activated human T cells (A, F, I, J) or isolated monocytes (B, C, G) perfused over IL-1β-stimulated hu-
man aortic endothelial cells (HAoECs) at 1.5 dyne/cm2 was analyzed by counting high-power fields (HPF) and chemotaxis assays were performed 
using IL-2- and CD3/C28-activated human T cells in Transwell-filter plates (D, E). For T-cell arrest, CCL5 (1 nM) and CCL17 (0.1 nM) were immo-
bilized on HAoECs in combination with CAN or CKEY (both 10 nM) (A, n=5; F, n=3). For monocyte arrest, HAoECs were pre-incubated with 
CXCL8 and/or CXCL4 (B, n=4) and with CCL5 and/or CXCL12 (all at 40 nM) in combination with a 10-fold excess of [VREY]4 (C, n=6). The effect 
of CCL5 (1 nM) plus CCL17 (0.1 nM) on T-cell chemotaxis was inhibited by blocking CCR4 (C021) or CCL5 receptors with Met-RANTES (Met-R) 
(D, n=5). The effect of CCL5 plus CXCL4 (both 4 nM) on T-cell chemotaxis was inhibited by blocking CCL5 receptors with Met-R (E, n=8). Isolated 
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human blood monocytes were perfused on IL-1β-activated HAoECs pre-incubated with CCL5 (4 nM) plus CXCL4 (40 nM) and CKEY or CKEYRE 
with the substitutions R44A and E26A (both 400 nM), and arrest was quantified (G, n=5). A combination of CXCL12 with or without CCL5 (both 40 
nM) and a 10-fold excess of [VREY]4 were added to the bottom chamber to assess T-cell chemotaxis (H, n=5). Combinations of CCL5, CXCL4 (4 
nM) plus CAN (40 nM) or obligate platelet factor 4-RANTES heterodimer (OPRAH, 4 nM) were added to the bottom chamber and T-cell chemotax-
is was evaluated (I, n=3). Arrest of activated T cells on IL-1β -stimulated HAoECs pre-incubated with CCL5 (1 nM) plus CCL17 (0.1 nM) or with 
covalently bound CCL5-CCL17 heterodimer ORATH (Obligate RAntes Tarc Heterodimer) at indicated concentrations (J, n=3). Dashed lines indi-
cate virtually calculated additive effects (A, C). Data represent mean±SEM from the indicated number of independent experiments. *p<0.05, 
**p<0.01, ***p<0.001, as analyzed by Kruskal-Wallis-test (A–D, F–I) or one-way ANOVA (E, I), or Mann-Whitney-test (J). 
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Fig. S16. Microscopy of chemokine interactions at the cell surface. 
(A–D) Interactions of murine CCL5 with CCL17 or CXCL4 were analyzed using an antibody-
based proximity-ligation assay. (A, B) Signals indicative of interaction (green, as indicated by 
arrows) were detected on the surface of mouse Simian-virus 40-transformed endothelial cells 
(SVECs) without (ctrl) or after incubation with CCL5 or Met-RANTES in combination with CCL17 
(A) or CXCL4 (B) (6 nM each) by fluorescence microscopy. The endogenous presence of 
CCL5-CCL17 (red signals, as indicated by arrows) was detected by proximity ligation in frozen 
sections of murine para-aortic lymph nodes (C) but not in controls (ctrl) (D). 
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Fig. S17. Mechanisms for synergy of chemokine heterodimers. 
(A–D) Interactions between CCL5, CCL17, CCR4, and CCR5 were detected on the surface of 
adherent dendritic cells (DCs) using a proximity-ligation assay after the cells were incubated 
with CCL5, CCL17, or both (all at 6 nM). The proximity ligation signals generated by the direct 
or indirect interactions between CCL17-CCR4 (A, n=3), CCL5-CCR5 (B, n=3), CCL5-CCR4 (C, 
n=3), and CCL17-CCR5 (D, n=4) were measured. (E, n=4) Migration of activated primary 
mouse T cells was elicited by CCL5, CCL17, or both (all at 6 nM) and compared between cells 
from wild-type (WT) or CCR5-deficient (Ccr5-/-) mice, wild-type (WT) mice or cells pretreated 
with the CCR4-inhibitor C021. (F) Binding competition assay; CCL17-Alexa647 (2.5 nM) bound 
to CCR4-expressing HEK293 transfectants was displaced by unlabeled human CCL17 in pres-
ence or absence of CXCL1 (1 nM) (n=6). (G) Gi signaling was investigated by determining 
cAMP levels using Glosensor-HEK293 cells transfected with CCR4 or a mix of CCR4 and CCR5 
after stimulation with CCL5 (12.5 nM), CCL17 (125 nM) or a combination of both (shown is one 
representative experiment at 20 min). Data represent mean±SEM from a number of independ-
ent experiments, as indicated. *p<0.05, **p<0.01, compared to CCL5 and CCL17 combined in 
the absence of CAN,as analyzed by Mann-Whitney-test (A–D) or two-way ANOVA (E). 
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Fig. S18. Effect of heterodimers on signaling pathways, receptor affinity, and internaliza-
tion. 
(A) Glosensor HEK293 cells transfected with CCR1 were challenged by indicated concentra-
tions of OPRAH and the reduction of cAMP was recorded after 20 min. (B, C) Human 
CD3/CD28-activated T cells of three donors were stimulated with CCL5 (1 nM) and/or CCL17 
(0.1 nM) for the indicated time periods and subsequently lysed. Protein (30 µg) was separated 
by SDS-PAGE and the phosphorylation of tyrosine 458 in the regulatory subunit p85 of  phos-
phoinositide-3-kinase was detected by specific antibodies relative to  GAPDH control. Shown is 
a representative western blot (B) and ratios obtained by densitometry quantification (C). (D, E) 
For binding competition assays, CCL5-Alexa647 (2.5 nM) bound to CCR1-expressing (D) or 
CCR5-expressing (E) HEK293 transfectants was displaced by unlabeled CCL5 at indicated 
concentrations in presence or absence of CXCL4 (40 nM) (n=5 and n=3, respectively). (F) Ca-
rotid arteries were explanted, mounted and perfused with bone marrow-derived leukocytes upon 
stimulation with either buffer (controls), human CCL5 alone (4 nM), in the presence of human 
CXCL4 or CXCL4R>Q (both 40 nM). Intensity of CCR1 on adherent cells was quantified with two-
photon laser scanning microscopy. Mean fluorescence intensities were standardized to control, 
Data represent mean±SEM, n>67 cells from two carotid arteries. ***p<0.001, calculated by 
ANOVA. 
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Fig. S19. CCL5-CXCL4 heterodimers bind to heparin and prevent arrestin recruitment. 
(A–C) The binding of soluble CCL5 with CXCL4 or OPRAH to immobilized enoxaparin, a low 
molecular weight heparin, was analyzed by SPR. To prevent higher order aggregation and 
complex binding behavior CCL5E66S was used instead of CCL5. (A) The response of CCL5E66S 
at 50 nM, combined with CXCL4, CXCL4L1 or CXCL4R>Q (all at 100 nM), was assessed at the 
end of the association (1000 s) and the binding of CXCL4 (white bar) or CCL5E66S (black bars) 
alone was subtracted, respectively (n=2). (B) CCL5E66S or OPRAH (C) were perfused over the 
heparin-conjugated chip at increasing concentrations (at 6.2, 12.5, 25, 50, 100, 200 nM), and 
association and dissociation were recorded (left panels). Apparent affinities were derived from 
steady-state analysis (right panel). (D) The association of arrestin-1 or arrestin-2 with CCR5 
after chemokine stimulation was determined by bioluminescence-initiated resonance energy 
transfer (BRET) using HEK293 transfectants expressing stably the reporter construct eYFP-
fused arrestin-1 or arrestin-2 and transiently transfected with the donor construct CCR5-RlucII 
or mock. The BRET signal (acceptor/donor ratio 530/480 nm, 1 s acquisition) was recorded by a 
BRET reader (Tecan Infinity) after addition of the substrate coelenterazine and stimulation with 
CCL5 (10 nM) and/or CXCL4 (30 nM) for 20 min. Net BRET was calculated by subtracting the 
BRET signals from mock-transfected cells. 
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Fig. S20. Relevance of chemokine heterodimer formation in acute lung injury. 
(A–D) Acute lung injury was induced by LPS inhalation of 10 week old female C57/BL6 mice 
and 30 minutes before sacrifice a FITC conjugated Ly6G antibody was injected i.v., to discrimi-
nate intravascular from interstitial neutrophils. (A–C, n=4-10, ctrl=10) CKEY was injected i.v. at 
low dose (1 mg/kg, LD) or high dose (10 mg/kg, HD), as well as the variant CKEYRE with the 
substitutions R44A and E26A. Neutrophils were counted by FACS from total lungs (A), the in-
terstitial space (B) or bronchoalveolar lavage (BAL) fluid (C). (D) Lethally irradiated female 
C57/BL6 mice were transplanted at 10 weeks of age with bone marrow from Ccl5-/-Cxcl4-/- mice. 
Acute lung injury was induced by LPS inhalation and CCL5 (150 µg/kg) or the obligate PF4-
RANTES heterodimer (OPRAH, 300 µg/kg) were injected i.v. (n= 3-4). Neutrophils from total 
lungs were counted. Data represent mean±SEM from the indicated number of mice. *p<0.05, as 
analyzed by Kruskal-Wallis-test. 
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Fig. S21. Generation of mice deficient in Cxcl4 or Cxcl12 or carrying Cxcl4 variants. 
(A–C) Targeting strategy to generate Cxcl4l1 knock-in, Cxcl4 knock-out and Cxcl12 knock-out 
mice. The exon-intron structures of the gene loci and the targeting vector (right) and correct 
targeting as evidenced by southern blotting (left) are shown. Green bars indicate the position of 
the probe, grey bars indicate flippase recognition target (frt) sites, black triangles indicate loxP 
sites. (A) Cxcl4L1/L1 mice were generated by homologous recombination with a targeting vector 
of mutated murine Cxcl4 (Pf4), which included a 2.3 kb 5′ homology arm harboring exon 1, in-
tron 1-2 and a frt-flanked neomycin selection cassette (Neo). The 3′ recombination arm spanned 
3.6 kb, loxP sites flanked exons 2-3 (the coding part of Cxcl4 gene) substituting proline P64 by 
leucine (L), lysine K72 by glutamate (E) and isoleucine I73 by histidine (H) to obtain the murine 
orthologue of human CXCL4L1. Cxcl4-/- mice resulted from off-springs of CreERT2-Cxcl4L1/L1 
parents after ubiquitous deletion of Cxcl4 by tamoxifen. Southern blots demonstrated wild-type 
Cxcl4wt/wt and correct targeting of heterozygous Cxcl4wt/L1 and homozygous Cxcl4wt/L1. (B) 
Transgenic Cxcl4tg-L1 mice were generated by inserting the human CXCL4L1 gene into the Ro-
sa26 locus. The targeting vector contained a 1.1 kb 5′ arm harboring intron 1-2, a Neo selection 
and Stop cassette flanked by loxP sites, IRES and eGFP were flanked by frt sites. The 3′ re-
combination arm spanned 4.3 kb containing intron 1-2. Southern blots demonstrated correctly 
targeted ES clones (4 and 5). (C) Shown is the mouse Cxcl12 locus and the targeting vector 
consisting of a 1.9 kb 5′ homology arm including exon 1 and intron 1-2, frt-flanked Neo, loxP-
flanked exon 2 and the 3′ recombination arm spanning 6.7 kb. Southern blots show wild-type (1, 
2) and correctly targeted heterozygous (3) ES clones. Cxcl12-/- mice were generated by condi-
tional inactivation of Cxcl12 by intercrossing CreERT2 and injecting tamoxifen i.p. 
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Fig. S22. Analysis of atherosclerotic lesion in mice expressing Cxcl4 or its variant. 
(A) Overview and zoom-in insets of a longitudinal section through the aortic arch presenting 
typical sites of plaque development (1: brachiocephalic trunk; 2: left common carotid artery; 3: 
left subclavian artery; 4: arch; 5: lesser curvature). (B-D) Apoe-/- mice homozygous for wild-type 
Cxcl4 (wt/wt), heterozygous for Cxcl4 and Cxcl4l1 (wt/L1), homozygous for Cxcl4l1 (L1/L1), or 
deficient for Cxcl4 and Cxcl4l1 (-/-) were fed a HFD for 12 weeks. (C) Shown are representative 
aortic root cross-sections after Elastica-van Gieson (EVG) staining. (D) Quantification of (C). 
Data represent mean±SEM from the indicated number of mice. *p<0.05, **p<0.01 versus wt/wt, 
as analyzed by one-way ANOVA (B,D). 
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Fig. S23. Composition of aortic root lesions in mice expressing Cxcl4 or its variant. 
Apoe-/- mice homozygous for wild-type Cxcl4 (wt/wt), heterozygous for Cxcl4 and Cxcl4l1 
(wt/L1), homozygous for Cxcl4l1 (L1/L1), or deficient for Cxcl4 and Cxcl4l1 (-/-) were fed a HFD 
for 12 weeks. Cross-sections of paraffin-embedded roots were analyzed for the content (per-
centage) of smooth muscle cells by staining smooth muscle-actin (SMA) (A), of T cells by stain-
ing CD3 (B), for necrotic core (C) or for staging the plaque phenotype according to the Virmani 
classification into advanced i.e. fibrous cap atheroma (FCA) or early lesions i.e. pathological 
intimal thickening (PIT) (D). Data represent mean±SEM from the indicated number of mice, as 
analyzed by Kruksal-Wallis-test (A–C, n=6-11). 
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Fig. S24. Obligate chemokine heterodimers mimic natural heterodimers. 
Apoe-/- mice, homozygous for wild-type Cxcl4 (wt/wt), heterozygous for Cxcl4 and Cxcl4l1 
(wt/L1), or deficient for Cxcl4 and Ccl5 (Ccl5-/-Cxcl4-/-) were fed a HFD for 6 weeks. Atherogene-
sis was exacerbated by injecting i.p. the obligate RANTES-PF4 heterodimer (OPRAH) or saline 
(control) 3 times a week for 6 weeks (A, B, n=5-6 mice). Shown are the lesion size of the aortic 
arch (A), content of SMA+ smooth muscle cells (B) and CD3+ T cells (C) in aortic root plaques. 
Data represent mean±SEM. *p<0.05, as analyzed by the Mann-Whitney-test). 
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Fig. S25. Summary scheme. 
Based on the map derived for the chemokine interactome, paradigmatic chemokine heterodimers were selected. CCL5 interacts with CXCL4 and 
CCL17 in CC-type but favors a CXC-type interaction with CXCL12. CC-type interactions show synergistic effects, whereas CXC-type interactions 
are inhibitory. Disrupting heterodimers by specific peptides CKEY (CCL5-CXCL4) or CAN (CCL5-CCl17) blocks inflammatory monocyte/neutrophil 
recruitment or promotes Treg homeostasis by preventing CCR1 retention (via GAG binding) or CCR5-CCR4 heteromerization at the cell surface, 
respectively. In contrast, [VREY]4 interacts with CXCL12 to mimic inhibitory effects of CCL5 on CXCR4 activation, and inhibits platelet aggregation. 
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Supplementary Tables 
Table S1. Densitometry analysis of bidirectional immunoligand blotting. 
Chemokines immobilized on nitrocellulose membranes are arranged in rows, chemokines added in solution are arranged in columns. 
Following detection by specific antibodies, the density and area of positive reactions were determined by densitometry, and the ratio 
relative to the respective positive control is given. Reactions exceeding 5% of the value of the positive control were regarded as posi-
tive and are highlighted in green. Means were calculated from 2-4 independent immuno-ligand blots. 
CCL1 CCL2 CCL3 CCL3L1 CCL4 CCL5 CCL7 CCL8 CCL11 CCL13 CCL14 CCL15 CCL16 CCL17 CCL18 CCL19 CCL20 CCL21 CCL22 CCL23 CCL24 CCL25 CCL26 CCL27 CCL28 XCL1 XCL2 CXCL1 CXCL2 CXCL3 CXCL4 CXCL4L1 CXCL5 CXCL6 CXCL7 CXCL8 CXCL9 CXCL10 CXCL11 CXCL12 CXCL13 CXCL14 CXCL16 CXCL17 CX3CL1
CCL1 x 0.000 0.000 0.000 0.000 0.013 0.000 0.022 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.015 0.000 0.000 0.001 0.046 0.000 0.000 0.000 0.211 0.000 0.000 0.000 0.000 0.000 0.000 CCL1
CCL2 0.033 x 0.000 0.000 0.000 0.053 0.017 0.056 0.114 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.015 0.000 0.000 0.000 0.220 0.000 0.000 0.000 0.051 0.000 0.000 0.040 0.019 0.070 0.077 0.000 0.000 0.017 0.000 0.000 0.000 0.158 0.000 CCL2
CCL3 0.000 0.024 x 0.000 0.049 0.007 0.019 0.006 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.012 0.000 0.000 0.016 0.019 0.000 0.000 0.000 0.000 0.017 0.000 0.000 0.000 0.000 0.000 CCL3
CCL3L1 0.000 0.029 0.000 x 0.036 0.000 0.012 0.028 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.004 0.000 0.000 0.004 0.046 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 CCL3L1
CCL4 0.000 0.000 0.000 0.000 x 0.000 0.014 0.020 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.007 0.000 0.000 0.022 0.012 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 CCL4
CCL4L1 0.003 0.073 0.000 0.000 x 0.000 0.022 0.027 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.026 0.191 0.000 0.046 0.044 0.000 0.000 0.000 0.000 0.030 0.053 0.000 0.000 0.000 0.000 CCL4L1
CCL5 0.000 0.014 0.000 0.000 0.000 x 0.042 0.004 0.326 0.123 0.000 0.000 0.000 0.287 0.000 0.000 0.000 0.000 0.000 0.000 0.211 0.319 0.268 0.054 0.330 0.111 0.077 0.000 0.000 0.000 0.292 0.000 0.000 0.063 0.038 0.000 0.000 0.000 0.000 0.056 0.000 0.000 0.000 0.132 0.000 CCL5
CCL7 0.000 0.048 0.000 0.000 0.000 0.000 x 0.004 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.343 0.000 0.000 0.000 0.007 0.000 0.000 0.054 0.007 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 CCL7
CCL8 0.000 0.057 0.000 0.000 0.000 0.019 0.031 x 0.008 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.099 0.000 0.000 0.000 0.008 0.000 0.000 0.029 0.067 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.159 0.000 CCL8
CCL11 0.000 0.012 0.000 0.014 0.008 0.020 0.041 0.636 x 0.000 0.000 0.002 0.000 0.000 0.699 0.000 0.000 0.013 0.000 0.000 0.000 0.000 0.051 0.065 0.137 0.000 0.047 0.000 0.000 0.009 0.009 0.233 0.027 0.022 0.013 0.017 0.000 0.134 0.000 0.076 0.000 0.000 0.000 0.000 0.000 CCL11
CCL13 0.000 0.056 0.000 0.000 0.000 0.267 0.018 0.078 0.435 x 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.127 0.000 0.000 0.209 0.000 0.090 0.000 0.223 0.072 0.000 0.000 0.032 0.000 0.037 0.014 0.000 0.033 0.001 0.000 0.033 0.313 0.188 0.057 0.000 0.000 0.000 0.317 0.000 CCL13
CCL14 0.000 0.015 0.000 0.000 0.000 0.000 0.014 0.000 0.192 0.000 x 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.290 0.000 0.000 0.000 0.010 0.000 0.000 0.000 0.003 0.000 0.000 0.000 0.004 0.000 0.000 0.008 0.019 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 CCL14
CCL15 0.002 0.062 0.000 0.000 0.000 0.000 0.023 0.000 0.000 0.000 0.000 x 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.006 0.000 0.000 0.000 0.007 0.000 0.000 0.009 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 CCL15
CCL16 0.000 0.000 0.000 0.000 0.000 0.094 0.007 0.005 0.000 0.000 0.000 0.000 x 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.017 0.021 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 CCL16
CCL17 0.000 0.000 0.000 0.000 0.000 0.086 0.012 0.006 0.000 0.000 0.000 0.000 0.000 x 0.000 0.000 0.000 0.187 0.000 0.000 0.000 0.000 0.088 0.000 0.089 0.000 0.041 0.000 0.000 0.000 0.001 0.000 0.000 0.002 0.008 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 CCL17
CCL18 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.003 0.000 0.000 0.000 0.000 0.000 0.000 x 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.025 0.000 0.000 0.000 0.005 0.000 0.000 0.028 0.021 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 CCL18
CCL19 0.000 0.000 0.000 0.000 0.000 0.017 0.006 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 x 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.021 0.000 0.000 0.003 0.000 0.000 0.043 0.014 0.000 0.000 0.000 0.000 0.000 0.034 0.000 0.000 0.000 0.000 CCL19
CCL20 0.000 0.000 0.000 0.000 0.000 0.056 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 x 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.344 0.021 0.021 0.000 0.094 0.000 0.063 0.024 0.002 0.000 0.000 0.013 0.228 0.053 0.015 0.000 0.000 0.109 0.000 CCL20
CCL21 0.000 0.000 0.000 0.000 0.000 0.192 0.004 0.010 0.000 0.299 0.000 0.000 0.000 0.000 0.000 0.000 0.000 x 0.000 0.000 0.245 0.000 0.072 0.000 0.211 0.029 0.278 0.018 0.051 0.000 0.016 0.085 0.000 0.017 0.003 0.000 0.116 0.150 0.058 0.053 0.019 0.138 0.000 0.203 0.000 CCL21
CCL22 0.000 0.000 0.000 0.000 0.000 0.002 0.001 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 x 0.000 0.000 0.000 0.000 0.000 0.000 0.032 0.021 0.000 0.000 0.000 0.006 0.000 0.000 0.015 0.024 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 CCL22
CCL23 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.263 0.000 x 0.000 0.000 0.000 0.000 0.000 0.046 0.015 0.000 0.000 0.000 0.010 0.000 0.000 0.036 0.049 0.000 0.000 0.000 0.000 0.003 0.000 0.000 0.000 0.000 0.000 CCL23
CCL24 0.000 0.000 0.000 0.000 0.000 0.063 0.000 0.003 0.022 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.004 0.000 0.000 x 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.009 0.000 0.000 0.038 0.033 0.000 0.000 0.000 0.283 0.000 0.000 0.000 0.000 0.000 0.000 CCL24
CCL25 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.003 0.000 0.000 0.000 0.000 0.000 0.215 0.000 0.000 0.000 0.000 0.000 0.000 0.000 x 0.000 0.000 0.000 0.022 0.000 0.019 0.006 0.000 0.154 0.449 0.003 0.041 0.027 0.000 0.021 0.000 0.253 0.012 0.000 0.000 0.000 0.085 0.000 CCL25
CCL26 0.000 0.110 0.000 0.000 0.000 0.263 0.002 0.407 0.030 0.324 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.256 0.000 0.000 0.000 0.000 x 0.000 0.192 0.079 0.211 0.000 0.017 0.000 0.282 0.000 0.019 0.011 0.005 0.000 0.112 0.194 0.069 0.248 0.000 0.115 0.000 0.146 0.000 CCL26
CCL27 0.001 0.000 0.000 0.000 0.000 0.060 0.007 0.019 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 x 0.000 0.000 0.005 0.000 0.000 0.000 0.011 0.000 0.001 0.002 0.047 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 CCL27
CCL28 0.012 0.025 0.005 0.016 0.017 0.190 0.020 0.031 0.354 0.379 0.000 0.004 0.011 0.162 0.000 0.000 0.000 0.163 0.000 0.000 0.000 0.000 0.113 0.000 x 0.000 0.192 0.000 0.051 0.000 0.391 0.000 0.030 0.000 0.000 0.000 0.021 0.074 0.037 0.070 0.187 0.009 0.000 0.202 0.000 CCL28
XCL1 0.000 0.000 0.000 0.000 0.000 0.062 0.013 0.000 0.098 0.325 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.167 0.000 0.000 0.341 0.000 0.097 0.000 0.181 x x 0.000 0.050 0.000 0.052 0.053 0.000 0.036 0.000 0.000 0.016 0.205 0.030 0.014 0.000 0.000 0.000 0.272 0.000 XCL1
CXCL1 0.000 0.000 0.000 0.000 0.000 0.000 0.006 0.002 0.063 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.019 x 0.000 0.000 0.048 0.000 0.345 0.330 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 CXCL1
CXCL2 0.000 0.000 0.000 0.000 0.000 0.053 0.007 0.094 0.167 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.000 0.000 0.000 0.029 0.041 0.000 0.000 0.000 0.087 0.000 x 0.010 0.098 0.000 0.347 0.059 0.017 0.000 0.000 0.000 0.308 0.089 0.000 0.105 0.000 0.000 0.000 CXCL2
CXCL3 0.001 0.000 0.000 0.000 0.000 0.019 0.006 0.004 0.112 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.137 0.000 0.000 x 0.009 0.000 0.296 0.116 0.011 0.000 0.000 0.000 0.000 0.047 0.000 0.003 0.000 0.000 0.000 CXCL3
CXCL4 0.006 0.029 0.000 0.000 0.000 0.192 0.000 0.034 1.015 0.586 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.167 0.000 0.000 0.000 0.240 0.175 0.000 0.200 0.013 0.118 0.000 0.001 0.000 x 0.000 0.000 0.254 0.011 0.248 0.186 0.161 0.082 0.140 0.000 0.276 0.000 0.512 0.000 CXCL4
CXCL4L1 0.031 0.035 0.000 0.000 0.046 0.004 0.007 0.000 0.032 0.000 0.000 0.009 0.003 0.000 0.000 0.593 0.029 0.076 0.473 0.000 0.000 0.146 0.239 0.134 0.225 0.315 0.186 0.000 0.000 0.000 x x 0.025 0.000 0.024 0.016 0.000 0.341 0.534 0.345 0.419 0.000 0.000 0.000 0.000 CXCL4L1
CXCL5 0.005 0.000 0.000 0.000 0.000 0.000 0.011 0.023 0.068 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.287 0.027 0.002 0.005 0.002 0.000 x 0.000 0.021 0.000 0.000 0.000 0.000 0.013 0.000 0.000 0.000 0.000 0.000 CXCL5
CXCL6 0.004 0.000 0.000 0.000 0.000 0.000 0.005 0.223 0.402 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.040 0.000 0.000 0.016 0.012 0.000 0.028 x 0.796 0.000 0.000 0.000 0.000 0.005 0.000 0.000 0.000 0.000 0.000 CXCL6
CXCL7 0.004 0.000 0.000 0.000 0.000 0.098 0.005 0.046 0.013 0.302 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.196 0.000 0.000 0.000 0.000 0.071 0.000 0.211 0.000 0.000 0.000 0.000 0.000 0.008 0.000 0.000 0.005 x 0.000 0.123 0.173 0.079 0.246 0.000 0.162 0.000 0.016 0.000 CXCL7
CXCL8 0.006 0.000 0.000 0.000 0.000 0.000 0.003 0.053 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.009 0.000 0.000 0.000 0.000 x 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 CXCL8
CXCL9 0.002 0.000 0.000 0.000 0.000 0.178 0.003 0.032 0.062 0.293 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.197 0.000 0.000 0.000 0.000 0.115 0.000 0.175 0.079 0.000 0.000 0.050 0.000 0.221 0.000 0.000 0.009 0.055 0.000 x 0.253 0.070 0.062 0.000 0.102 0.000 0.157 0.000 CXCL9
CXCL10 0.003 0.010 0.000 0.000 0.000 0.101 0.000 0.184 0.551 0.343 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.182 0.000 0.000 0.000 0.000 0.096 0.000 0.221 0.043 0.000 0.000 0.042 0.000 0.013 0.000 0.001 0.083 0.015 0.000 0.131 x 0.168 0.114 0.000 0.007 0.000 0.174 0.000 CXCL10
CXCL11 0.000 0.000 0.000 0.000 0.000 0.070 0.006 0.122 0.206 0.104 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.008 0.000 0.000 0.300 0.000 0.058 0.000 0.000 0.091 0.000 0.000 0.000 0.000 0.002 0.148 0.000 0.021 0.017 0.000 0.000 0.000 x 0.164 0.000 0.088 0.000 0.000 0.000 CXCL11
CXCL12 0.003 0.000 0.000 0.000 0.000 0.100 0.016 0.019 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.057 0.000 0.000 0.000 0.119 0.255 0.024 0.005 0.000 0.052 0.445 0.000 0.057 0.008 0.000 0.000 0.000 0.169 x 0.000 0.017 0.000 0.000 0.000 CXCL12
CXCL13 0.001 0.000 0.000 0.000 0.000 0.000 0.005 0.016 0.031 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.024 0.000 0.000 0.000 0.000 0.005 0.011 0.000 0.019 0.000 0.000 0.021 0.011 0.000 0.000 0.000 0.000 0.000 x 0.000 0.000 0.000 0.000 CXCL13
CXCL14 0.002 0.007 0.000 0.000 0.000 0.238 0.001 0.039 0.565 0.581 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.119 0.000 0.000 0.000 0.000 0.066 0.000 0.232 0.185 0.000 0.000 0.047 0.000 0.267 0.000 0.144 0.010 0.011 0.000 0.106 0.269 0.052 0.065 0.000 x 0.000 0.213 0.000 CXCL14
CXCL16 0.004 0.000 0.000 0.000 0.000 0.000 0.000 0.020 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.012 0.000 0.000 0.017 0.007 0.000 0.000 0.000 0.000 0.000 0.000 0.000 x 0.000 0.000 CXCL16
CXCL17 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.054 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.051 0.000 0.000 0.000 x 0.000 CXCL17
CX3CL1 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.035 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.015 0.000 0.000 0.000 0.002 0.000 0.000 0.009 0.005 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 x CX3CL1
CCL1 CCL2 CCL3 CCL3L1 CCL4 CCL5 CCL7 CCL8 CCL11 CCL13 CCL14 CCL15 CCL16 CCL17 CCL18 CCL19 CCL20 CCL21 CCL22 CCL23 CCL24 CCL25 CCL26 CCL27 CCL28 XCL1 XCL2 CXCL1 CXCL2 CXCL3 CXCL4 CXCL4L1 CXCL5 CXCL6 CXCL7 CXCL8 CXCL9 CXCL10 CXCL11 CXCL12 CXCL13 CXCL14 CXCL16 CXCL17 CX3CL1
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Table S2. Kinetic analysis of chemokine binding by SPR. 
Biotinylated CCL5, CXCL4, CXCL12 and CCL17 were immobilized on neutravidin-coated C1 
sensor chips. Analytes were injected over the 2 flow cells at flow rates and concentrations de-
scribed in Online Methods. All kinetic rate analyses were performed in running buffer, pH 7.4 at 
25°C (n=3). Responses from analyte injections were overlaid with the fit of a 1:1 interaction 
model to determine on-rates (ka), off-rates (kd), and dissociation constants (KD). 
chemokine ka (M-1s-1) × 104 kd (s-1)× 10 -4 KD (nM) 
CCL5 chip 
CCL2 1.5 ± 0.6   15 ± 6.1  95 ± 40 
CCL11 286 ± 115 1450 ± 667  51 ± 11 
CCL17      169 ± 25 161 ± 35  9.6 ± 1.5 
CXCL4 45 ± 19    18 ± 6.4  4.1 ± 1.8 
CXCL4R>Q 30 ± 17  11 ± 0.1  4.5 ± 2.6 
CXCL4K50E 12 ± 0.5  150 ± 4.3  127 ± 3.0 
CXCL4L1 0 - - 
CXCL7 11 ± 2.2 30 ± 18  27 ± 16 
CXCL10 24 ± 1.5 21 ± 3.2  8.8 ± 1.9 
CXCL12 1.6 ± 0.1 94 ± 5.8 578 ± 61 
CXCL4 chip 
CCL5 20 ± 14  7.7 ± 2.7  5.2 ± 2.8 
CCL5E66S 3.2 ± 0.1  2.2 ± 0.1  6.7 ± 0.5 
CCL5MT7 0 - - 
CCL5E26A 9.2 ± 5.2  499 ± 110  678 ± 365 
CCL544AANA47 0 - - 
CXCL7 0 - - 
CXCL8 0.3 ± 0.1  2.9 ± 0.4     105 ± 11 
CXCL12  33 ± 9.1 113 ± 28   35 ± 8.6 
CXCL12 chip 
CXCL4 2.2 ± 0.7  4.6 ± 2.9   20 ± 7.4 
CXCL4L1  10 ± 6.1   12 ± 5.7   13 ± 6.1 
CXCL4K50E        23 ± 0.9     279 ± 10 121 ± 3.0 
CCL5 4.9 ± 1.2     159 ± 80  298 ± 119 
CCL5E66S 42 ± 29  1415 ± 1217     319 ± 60 
CCL17 chip 
CCL5  16 ± 3.3  14 ± 2.1   8.6 ± 1.8 
CCL5E66S  69 ± 4.8  27 ± 4.5   3.9 ± 0.4 
CCL5MT7 0.8 ± 0.2  11 ± 2.2 145 ± 64 
CCL5E26A  49 ± 0.8  20 ± 3.9   4.1 ± 0.8 
CCL544AANA47 8.5 ± 1.4  25 ± 2.9    30 ± 5.5 
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Table S3. Weighted averaging of Δintensity changes and MDS-based in silico modeling. 
The changes in resonance intensity (ΔIntensity) of 1H-15N resonances in heteronuclear single 
quantum coherence spectra of 15N-CCL5E66S in the presence of indicated CXC and CC chemo-
kines were recorded and calculated as 1 minus the ratio presence/absence of any given chem-
okine. Average ΔIntensity values are shown; “top 10” indicates the average of the 10 resonanc-
es showing the greatest reduction in intensity; “all” means the average over all resonances. 
Free energies (ΔG) for various pairs of chemokines were calculated from molecular dynamics 
simulations (MDS) of pre-constructed CC-type or CXC-type heterodimers, as indicated. Values 













CCL5E66S/CCL17 0.85 0.37 2.3 CC 
CCL5/CCL17 CC -61.3 -45.7 
CCL5E66S/CXCL4 0.25 0.11 2.3 CC -53.2 -40.3 
CCL5/CXCL4 CC -62.6 -44.9 
CCL5E66S/CCL2 0.48 0.37 1.3 CC/CXC 
CCL5/CCL2 CC -56.8 -34.6 
CCL5E66S/CXCL12 0.15 0.11 1.4 CXC/CC -7.9 -44.5 
CCL5/CXCL12 CXC -7.5 -31.5 
CXCL4/CXCL12 CXC -3.0 -67.7 
CCL5E66S/CCL3 0.7 0.61 1.1 none 
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Table S4. Sequence and origin of peptide inhibitors. 
*The synthetic unprotected pro-helical VREY αCOSH peptide was reacted with a template-
assembled synthetic protein (TASP) molecule resulting in a 4-helix TASP. 
peptide sequence configuration CCL5 origin 
CCL51-33 SPYSSDTTPCCFAYIARPLPRAHIKEYFYTSGK linear 1-33 
CKEY CKEYFYTSGKCSNPAVVFITRC cyclic 25-45 
CKEYRE CKAYFYTSGKCSNPAVVFITAC cyclic 25-45 
CAN CKSSNPAVVFVTRKNRQVSANC cyclic 33-53 
[VREY]4 [TASP]* + 4x [EKKWVREYINSLEMS] branched 54-68 
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Table S5. CCL5-derived peptides specifically inhibit heterodimer formation. 
Chemokines were biotinylated and immobilized on neutravidin-coated C1 sensor chips. The RU 
signal of the soluble chemokine was obtained at 50 nM. The inhibition of chemokine heterodi-
merization by the peptides CCL51-33, CKEY, CKEYRE, CAN, and [VREY]4 was tested at increas-
ing concentrations and is indicated by IC50 values (n=3). Owing to aggregation of peptides, 
IC50 values > 5.0 µM could not be determined (ND).  
peptide 
inhibitor 







CCL5 CXCL4 1.7 
CCL17 CCL5 0.24 
CXCL12 CCL5 2.4 
CKEY 
CCL5 CXCL4 1.9 
CCL17 CCL5 ND 
CXCL12 CCL5 ND 
CKEYRE CCL5 CXCL4 ND 
CAN 
CCL5 CXCL4 ND 
CCL17 CCL5 0.27 
CXCL12 CCL5 ND 
[VREY]4 
CCL5 CXCL4 ND 
CCL17 CCL5 ND 
CXCL12 CCL5 2.7 
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Table S6. Lipid parameters and peripheral blood counts of different CXCL4 genotypes. 
Wild-type mice (wt/wt), homozygous Cxcl4L1/L1mice with a CXCL4 knock-out and knock-in of the 
human variant CXCL4L1, heterozygous Cxcl4L1/+ mice and Cxcl4-deficient Cxcl4-/- mice on an 
Apoe-/- genetic background were fed a high-fat diet for 12 weeks. Lipid parameters, body weight 
and differential peripheral blood counts were determined using standard methodology. Data 
represent mean±SEM from 8-15 mice, as analyzed by Kruskal-Wallis-test (ns; not significant). 
CXCL4wt/wt CXCL4wt/L1 CXCL4L1/L1 CXCL4-/- P-value 
cholesterol (mg/dl) 1048 ± 202 1088 ± 146 1152 ± 177 1017 ± 88 ns 
triglycerides (mg/dl)   394 ± 179   426 ± 144   256 ± 120     379 ± 159 ns 
body weight (g)  22.9 ± 1.7  26.1 ± 4.4   25.9 ± 3.1   25.3 ± 2.5 ns 
RBC (106/µl)    9.1 ± 0.4    8.9 ± 0.6     8.9 ± 0.5  9.5 ± 0.4 ns 
WBC (103/µl)    4.5 ± 1.4    4.5 ± 1.3     5.3 ± 1.8  4.5 ± 1.5 ns 
lymphocytes (103/µl)    3.1 ± 1.1    3.2 ± 1.0     4.0 ± 1.3  3.2 ± 1.2 ns 
neutrophils (103/µl)    1.3 ± 0.7    1.2 ± 0.4     1.1 ± 0.6  1.2 ± 0.4 ns 
platelets (103/µl) 1019 ± 204   844 ± 242    868 ± 280  937 ± 229 ns 
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Table S7. Effect of OPRAH on lipid parameters and peripheral blood counts. 
Wild-type mice (wt/wt), heterozygous Cxcl4L1/wt mice and Ccl5-/-Cxcl4-/- mice on an Apoe-/- genet-
ic background were fed a high-fat diet for 6 weeks and were treated (i.p.) with vehicle (ctrl) or 
OPRAH (10 µg, twice a week). Lipid parameters, body weight and differential peripheral blood 
counts were determined using standard methodology. Data represent mean±SEM from 5-6 
mice, as analyzed by Kruskal-Wallis-test (ns; not significant). Dunn's multiple comparison test 
revealed no significant differences in body weight and platelet counts between relevant treat-
ment groups or when comparing the other groups to wt/wt controls, respectively. 




treatment ctrl ctrl OPRAH ctrl OPRAH 
cholesterol (mg/dl) 1019 ± 182   905 ± 103 969 ± 169  968 ± 124 
  754 ± 
239 
ns 
triglycerides (mg/dl) 140 ± 50 121 ± 28 105 ± 20 152 ± 56   93 ± 66 ns 
body weight (g) 25.2 ± 2.6 23.0 ± 1.9 23.6 ± 2.6 31.7 ± 2.2  31.8 ± 4.6 0.0012 
RBC (106/µl)   9.1 ± 0.2 8.6 ± 1.2 9.1 ± 0.3    9.1 ± 0.5    8.2 ± 1.1 ns 
WBC (103/µl)   4.2 ± 0.8 3.7 ± 0.9 3.8 ± 0.8    4.0 ± 0.9    3.6 ± 0.4 ns 
lymphocytes (103/µl)   3.0 ± 0.6 2.5 ± 0.7 2.7 ± 0.6    2.8 ± 0.9    2.4 ± 0.4 ns 
neutrophils (103/µl)   1.1 ± 0.2 1.1 ± 0.3 1.0 ± 0.2    1.2 ± 0.3    1.1 ± 0.2 ns 
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Abstract
Chemokines and galectins are simultaneously upregulated and
mediate leukocyte recruitment during inflammation. Until now,
these effector molecules have been considered to function inde-
pendently. Here, we tested the hypothesis that they form molecu-
lar hybrids. By systematically screening chemokines for their
ability to bind galectin-1 and galectin-3, we identified several
interacting pairs, such as CXCL12 and galectin-3. Based on NMR
and MD studies of the CXCL12/galectin-3 heterodimer, we identi-
fied contact sites between CXCL12 b-strand 1 and Gal-3 F-face resi-
dues. Mutagenesis of galectin-3 residues involved in heterodimer
formation resulted in reduced binding to CXCL12, enabling testing
of functional activity comparatively. Galectin-3, but not its
mutants, inhibited CXCL12-induced chemotaxis of leukocytes and
their recruitment into the mouse peritoneum. Moreover, galectin-3
attenuated CXCL12-stimulated signaling via its receptor CXCR4 in
a ternary complex with the chemokine and receptor, consistent
with our structural model. This first report of heterodimerization
between chemokines and galectins reveals a new type of interac-
tion between inflammatory mediators that can underlie a novel
immunoregulatory mechanism in inflammation. Thus, further
exploration of the chemokine/galectin interactome is warranted.
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Introduction
Coordinated trafficking of leukocytes is central to host defense and
inflammation. In order to regulate its timing and strategic course of
action, various mediators (such as chemokines and adhesion/
growth-regulatory galectins) are involved to orchestrate leukocyte
recruitment [1–3]. The prototypic CXC chemokine CXCL12 plays a
major role in many inflammatory and homeostatic situations.
CXCL12 activates the Gi protein-coupled receptor CXCR4 that is
expressed by hematopoietic cell types, including T cells, monocytes,
and neutrophils, thus promoting their recruitment [4–6]. The
CXCL12/CXCR4 axis plays a crucial role in the trafficking of these
types of cells in immune homeostasis and in various acute and
chronic inflammatory diseases, such as atherosclerosis and rheuma-
toid arthritis [7–11].
Structurally, chemokines consist of a three-stranded b-sheet and
a C-terminal a-helix [12]. In solution, most chemokines form
homodimers (CXCL12) or higher-order oligomers. Because of their
structural homology, certain CXC and CC chemokines can form
heterodimers with altered functionality compared to their homod-
imer counterparts [13,14]. For example, CXCL12 binds to CCL5 and
inhibits its function, whereas CXCL4 enhances CCL5-mediated
monocyte recruitment in atherosclerosis [15,16].
In addition to proteins, cell surface glycans convey signals rele-
vant to pathophysiological processes. Their relatively complex and
heterogeneous structures are read and translated by various tissue
lectins to effect biological functions [17–19]. (b-)Ga(lactoside-
binding) lectins (=galectins) are a class of potent cis/trans-acting
modulators that function as bridging factors between their carbohy-
drate recognition domain (CRD) and cell surface glycoconjugates
[20,21]. In particular, proto-type galectin-1 (Gal-1) and chimera-type
galectin-3 (Gal-3) are involved in inflammatory cell recruitment
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[22,23]. Both galectins are upregulated in inflammatory diseases
such as atherosclerosis and osteoarthritis that also involve chemoki-
nes [24–27].
Structurally, all galectins share a highly conserved b-sandwich
fold consisting of a six-stranded b-sheet on one face (S-face or
sugar-binding face) and a five-stranded b-sheet on the opposing face
(F-face) [28–30]. Gal-3 is unique among galectins, because it has a
relatively long N-terminal tail (NT) extending out from its CRD. The
NT is relevant to Gal-3 function, self-association, and serine phos-
phorylation, and it can be proteolytically truncated and fully cleaved
from the CRD, thus explaining the term chimera type. Analogous to
chemokines, galectins can also form homodimers and oligomers
[31,32], as well as galectin/galectin heterodimers [33].
Until now, chemokines and galectins have been investigated as
physically separate and functionally independent entities. Here, we
test the hypothesis that they can associate as heterodimers with
functional consequences, a hitherto unappreciated concept. We
first demonstrate by screening that several CC and CXC chemoki-
nes can interact with Gal-3 and Gal-1, and then, we focus work
on the specific case of CXCL12/Gal-3. Nuclear magnetic resonance
(NMR) studies reveal that CXCL12 and Gal-3 form heterodimers
and allow for a molecular dynamics (MD) simulation-based struc-
tural model to be made. This model is validated by investigating
several Gal-3 CRD mutants (engineered by replacing key residues
at the interface with CXCL12) that reveal reduced binding to
CXCL12. Functionally, wild-type (WT) Gal-3 CRD, but not the
mutants, blocks CXCL12-mediated leukocyte migration, indicating
relevance of the structurally defined association. Impairing CXCR4
signaling by the CRD is presumably due to its capacity to build a
ternary complex with the chemokine and its receptor on the cell
surface.
Results
Physical interaction of Gal-3, Gal-3 CRD, and Gal-1 with CC and
CXC chemokines
Our initial evidence supporting the new concept for interactions
between chemokines and galectins was obtained by using a solid-
phase immunoassay with membrane-adsorbed chemokines and
biotinylated Gal-3 and Gal-1 in solution. Chemokine-dependent
association in the mix was detected with horseradish peroxidase
(HRP)-conjugated streptavidin (SA) and chemiluminescence.
Figure 1A–D shows an exemplary image and qualitative analysis of
a chemokine blot incubated with biotinylated Gal-3. Examination of
a comprehensive panel of CC and CXC chemokines with these galec-
tins revealed multiple cases of interaction with a similar binding
pattern (Fig 1E). Figure EV1A–D shows an image with qualitative
analysis of a chemokine blot incubated with biotinylated Gal-1.
Surface plasmon resonance (SPR) experiments were also
performed with these chip-conjugated galectins and soluble chemo-
kines. Excluding artifactual effects from surface adsorption, we
found that results from both assays were consistent (Fig EV1E–G).
A negative result from the solid-phase assay (e.g., CXCL9 and
CXCL11 show no interaction with Gal-3) may be attributed to inacti-
vation and/or inaccessibility of the binding site due to surface
adsorption. SPR binding kinetics of CXCL12 with chip-immobilized
Gal-3 allowed us to derive a CXCL12/Gal-3 KD of 80 nM when Gal-3
was coupled via its sole cysteine (Fig 1F). Immobilized Gal-3 CRD
bound CXCL12 with a slightly higher affinity of 34 nM (Fig 1G),
suggesting that the NT of Gal-3 is not the site of interaction with
CXCL12 and may even interfere with CXCL12 binding due to its
transient interactions with the CRD [34]. The affinity of Gal-3 was
about 10-fold higher than that of the proto-type (homodimeric) Gal-1,
supporting the idea of a galectin-specific interaction (Fig 1H).
Lactose, the canonical ligand for the galectin CRD, did not inhibit
the interaction between CXCL12 and Gal-3 (Appendix Fig S1A and
B). This result indicates that the contact region for the chemokine
does not involve the canonical glycan-binding site on the S-face of
the CRD, as is the case for pairing of Gal-3 CRD via the NWGR motif
(W is central for lactose binding due to C-H/p-interaction) with Bcl-2
family proteins [35]. Besides, unfractionated heparin blocked the
binding of Gal-3 CRD to CXCL12 (Appendix Fig S1C), indicating that
CXCL12 residues relevant to glycosaminoglycan (GAG) binding
contribute to the heterodimer interface.
We then compared the affinity of Gal-3 for CXCL12 with that for
a panel of chemokines that showed a robust response to the Gal-3
chip (Figs EV1E and EV2A–F). Whereas CCL17 gave uninterpretable
weak responses (Fig EV2C), the other chemokines examined (CCL1,
CCL5 E66S, CCL22, CCL26, and CXCL11) gave well-detectable
signals with KD values falling into the range from 7.9 to 99 nM
(Fig EV2G). In this experiment, we used the E66S mutant of CCL5
that cannot form higher-order homooligomers, because WT CCL5
did not permit accurate determination of KD values. For subsequent
structural and functional studies, we selected the Gal-3/CXCL12 pair
due to its broad tissue distribution, co-expression in diverse organs,
and biological relevance (Appendix Fig S2) [36].
In conclusion, Gal-3 interacts with CC and CXC chemokines
primarily via its CRD, and without direct involvement of the canoni-
cal glycan-binding S-face of the CRD.
Formation of CXCL12/Gal-3 heterodimers
To identify the interacting contact surfaces between CXCL12 and
Gal-3, we performed 1H–15N HSQC experiments with 15N-labeled
CXCL12 and unlabeled Gal-3 CRD, as well as with 15N-labeled Gal-3
CRD and unlabeled CXCL12. Since CXCL12 itself forms relatively
weak homodimers in fast exchange on the chemical shift timescale,
the equilibrium between CXCL12 monomers and dimers can be
shifted to mostly monomer by lowering the pH [37,38]. Addition of
unlabeled Gal-3 CRD to 15N-labeled CXCL12 (and vice versa)
resulted in some significant chemical shift changes as shown in the
HSQC spectral expansions and chemical shift maps provided in
Fig 2A and B. The entire HSQC spectra from which these expansions
were made are provided in Appendix Fig S3A and B with some key
interacting residues boxed in. Changes in resonance line widths and
chemical shifts indicate that binding interactions occur in the inter-
mediate exchange regime on the NMR chemical shift timescale,
which in turn suggests that the heterodimer dissociation constant,
KD, falls in the 10
6 M range [39], slightly higher than from our SPR
measurements. In addition, our HSQC data showed that lactose did
not disturb the interaction, consistent with our SPR data
(Appendix Fig S1A and B). Chemical shift changes identify regions
of inter-protein contacts, as highlighted in orange and red on the
structures of CXCL12 (Fig 2C) and Gal-3 CRD (Fig 2D). In support
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of these NMR data, silver staining of SDS–PAGE gels loaded with
CXCL12, the cross-linker BS(PEG)5, and increasing concentrations
of Gal-3 CRD exhibited bands at the position expected for the
CXCL12/Gal-3 CRD heterodimer (Appendix Fig S4).
Whereas Gal-3 CRD exists as a compact monomer in solution,
full-length Gal-3 is characterized by intramolecular dynamics via
transient backfolding of the NT onto the CRD F-face and a very
weak tendency for self-association, both of which complicate struc-
tural interaction analyses [34]. Nevertheless, we assessed CXCL12-
induced chemical shift changes in 15N-labeled full-length Gal-3 and
found that chemical shifts were overall reduced (Appendix Fig S5).
In addition to the residues within the CRD, residues 5-15 near the N-
terminus were also chemically shifted (Appendix Fig S5). This may
reflect competition of chemokine/galectin heterodimer formation
with intramolecular interactions between the NT and CRD [34]. In
any event, our ligand blotting, SPR, and cross-linking results show
that the NT of Gal-3 is not required for formation of Gal-3/CXCL12
heterodimers (Figs 1E and G, and EV1F, and Appendix Fig S4). Of
A
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Figure 1. Physical interaction of Gal-3 and Gal-1 with CC and CXC chemokines.
A–E Chemokine–galectin interactions were detected by using a solid-phase immunoassay. For this, 46 human CC and CXC chemokines were adsorbed on nitrocellulose
membranes and the stripes incubated in parallel with (A) TBS or (B) TBS containing biotinylated galectins (the representative image shows a processed membrane
tested with labeled Gal-3). Signals had been generated by using SA-HRP and chemiluminescence reagents. (C, D) The blots were subjected to densitometric
analysis, and (E) all independent experiments were combined (binding chemokines in light blue, Gal-3: n = 5, Gal-3 CRD: n = 5, Gal-1: n = 4).
F–H For SPR-based experiments, (F) Gal-3 (density 650 RU), (G) Gal-3 CRD (density 1180 RU), and (H) Gal-1 (density 130 RU) were immobilized and increasing
concentrations of CXCL12 were passed over the flow cells. The red curve represents a single-site fit to the data. Insets are representative sensorgrams of CXCL12
testing on immobilized galectin. Data represent the mean  SD from six (F) or three (G and H) independent experiments.
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note, analyses of interactions between Gal-1 and CXCL12 are likely
hampered by homodimerization of Gal-1 that is favored over
heterodimerization (data not shown), thus likely explaining its
weaker affinity for CXCL12 compared to Gal-3 (Fig 1F and H).
Having identified mutual sites of interaction on CXCL12 and Gal-3
CRD (Fig 2A–D), we performed MD simulations started after manu-
ally docking the Gal-3 CRD to CXCL12 in 10 different rotational
orientations that were all consistent with our HSQC data.
Appendix Fig S6A shows the resulting heterodimer structures follow-
ing energy minimization, with complex 6 being the energetically
most favorable (50 kcal/mol). Decomposition analyses of the free
binding energies (DG) for each residue in the Gal-3 CRD
(Appendix Fig S6B) and CXCL12 (Appendix Fig S6C) in complex 6
identify the residue pairing sites (Fig 2). Regions of contact in
complex 6 (Fig 2E) correspond best to those identified by NMR
(Fig 2A and B). A few specific residue pairings are depicted in
Fig 2F. Several amino acids contribute to two major contact sites
within the Gal-3 CRD at the strands b6 and b8-9 (CRD F-face), and
the loop between b4 and b5. Gal-3 strands b6, b8, and b9 (in particu-
lar, residues E185 (b6), H217, Q220, and N222 (b9)) interact with a
dominant binding region in the strands b1 and b2 of CXCL12 (in
particular, R41 (b2), K27 (b1), and K24 (b1); please see Fig 2F, left
panel). In addition, Gal-3 S188 (b6) and residues of the loop between
b4 and b5 (i.e., R168 and R169) interact with the CXCL12 helix resi-
dues Y61, E63, A65, and N67 to establish a neighboring contact site
(Fig 2F, right panel). These HSQC experiments thus revealed that
CXCL12 engages in heterodimer formation with the Gal-3 CRD. Since
the CRD F-face is located on the opposite side of the lactose-binding
b-sheet S-face (Fig 2D), this explains why lactose does not reduce
the binding of Gal-3 to CXCL12 and vice versa.
Using complex 6 (Fig 2E and F, Appendix Fig S6A) and decom-
position analysis (Appendix Fig S6B and C), we selected several
residues at the CXCL12/Gal-3 binding interface, mutated those resi-
dues in silico, and performed MD simulations to calculate BFE
(Appendix Table S1). Whereas some Gal-3 mutants showed rela-
tively small energetically favorable changes (e.g., K210D, Q220D,
Q220E) in binding CXCL12, others showed highly unfavorable ener-
getics (R168A, E185A, H217A, Q220A, Q220K, Q220R, N222A).
Several positively charged residues in CXCL12 are located at the
interface with Gal-3 (Fig 2F, left panel); Q220 of Gal-3 is one of
them, such that introducing a negatively charged residue (i.e., gluta-
mate) at that position (i.e., Q220E) might promote favorable electro-
static interactions and a more negative ΔG value as obtained
in silico (Appendix Table S1). On the other hand, N160 lies on the
opposing, non-interacting S-face in Gal-3 and is known to contribute
to carbohydrate binding (Fig 2F, right panel).
For empirical validation of our model, we used site-directed
mutagenesis to produce several mutants and assess effects on
heterodimer formation. Q220E in NMR and N160A in ligand blots
and SPR were used as controls. Three Gal-3 CRD mutants (Q220E,
Q220K, and H217A) were selected to assess their effects on HSQC
spectra of 15N-labeled CXCL12 when examining mixtures. Even
though all HSQC spectra look highly similar, analysis of the data
could reveal distinct differences. Figure EV3 shows chemical shifts
of 15N-labeled CXCL12 with each of these Gal-3 CRD mutants.
These maps show the same trends as observed with WT Gal-3 CRD.
Although this indicates that WT Gal-3 CRD and its mutants interact
with CXCL12 in the same way, the magnitudes of Δd changes are
different. Compared to WT Gal-3, Q220E Δd values are slightly
increased (Fig EV3A), whereas those for Q220K and H217A are
decreased (Fig EV3B and C). CXCL12 sequence-averaged Δd values
are 0.0061 ppm for WT Gal-3 CRD, 0.0073 for Q220E, 0.0036 for
Q220K, and 0.0048 for H217A. Smaller chemical shift changes
usually indicate weaker intermolecular interactions [39]. Here,
average Δd values suggest slightly stronger binding between
CXCL12 and Q220E, and weaker binding between CXCL12 and
Q220K and H217A. These trends parallel those observed in our MD-
based free energy calculations, which yielded ΔG values of
50 kcal/mol for WT Gal-3 CRD, 58 kcal/mol for Q220E,
31 kcal/mol for Q220K, and 38 kcal/mol for H217A
(Appendix Table S1).
Densitometric analysis of CXCL12 binding to variants of Gal-3
(Appendix Fig S7A) and Gal-3 CRD (Appendix Fig S7B) demon-
strates that residues N222 and E185 are indeed involved in the inter-
action with CXCL12, whereas N160 is not. Similarly, the affinity of
CXCL12 injected over sensor chips with immobilized Gal-3 mutants
R168A, E185A, H217A, and Q220K was reduced, whereas the affin-
ity of N160A was not (Appendix Fig S8A–H). In addition, Gal-3
mutant binding to the N-glycans of a common galectin binder, i.e.,
the glycoprotein asialofetuin (ASF), was only impaired in the case
of N160A that showed no significant effect on heterodimer forma-
tion (Appendix Fig S8I–L), which supports our findings that
CXCL12/Gal-3 heterodimer formation is not significantly affected by
glycan binding (Appendix Fig S1A and B).
Gal-3-mediated inhibition of CXCL12-induced
leukocyte migration
We next investigated the functional consequences of CXCL12:Gal-3
heterodimerization. Initially, we examined whether Gal-3 affects
CXCL12-induced migration of Jurkat T cells, and discovered that
both Gal-3 and Gal-3 CRD inhibited chemotaxis in a dose-dependent
manner (Fig 3A and B). In contrast, Gal-1 only inhibited migration
at 1 lM (Fig 3C). These results with Jurkat cells were replicated
using primary cells, i.e., activated human CD4+ T cells (Fig 3D). A
bell-shaped chemotaxis curve was observed upon increasing the
◀ Figure 2. Formation of the CXCL12/Gal-3 CRD heterodimer.A, B Expansions of 1H–15N HSQC spectra are overlaid, and Dd values are plotted vs. the amino acid sequences, along with secondary structures: (A) 10 lM 15N-enriched
CXCL12 alone (black peaks) and in the presence of 330 lM Gal-3 CRD (red peaks; assignments reported by Murphy et al [74]) and (B) 30 lM 15N-enriched Gal-3
CRD alone (black peaks) and in the presence of 500 lM CXCL12 (red peaks; assignments for Gal-3 reported by Ippel et al [34]).
C–E X-ray crystal structures are depicted (C) for the CXCL12 homodimer (PDB access code 4UAI; monomer in magenta) and (D) for Gal-3 CRD bound with lactose (PDB
access code 1A3K; in light green). (E) The energy-minimized structure of the CXCL12/Gal-3 CRD heterodimer was calculated by MD simulations. Residues with the
largest Dd values in HSQC spectra are highlighted in red (2SD-1SD) and orange (1SD-mean).
F A model structure of the CXCL12/Gal-3 CRD heterodimer interface is shown with Gal-3 CRD in light green, the CXCL12 monomer in magenta, mutated residues in
red, and hydrogen bonds as dashed orange lines.
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concentration of CXCL12, with the height of the curve being signifi-
cantly reduced in the presence of 0.1 nM Gal-3 CRD (Fig 3 E and F).
Consistent with our concept, the CXCL12 chemotaxis curve with
Gal-1 remained unchanged even in the presence of 100 nM lectin
(Fig 3G). Because the affinity of CXCL12 for Gal-1 is lower than that
for Gal-3 and Gal-1 has no apparent effect on chemotaxis, we
assumed that chemotactic inhibition resulted from the physical
interaction between Gal-3 and CXCL12. Galectins alone at 1 lM had
no effect on Jurkat cell migration or viability (Fig 3H and I), consis-
tent with a previous report [40].
Extending the scope of our investigation to other CXCR4-expres-
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Figure 3. Gal-3-mediated inhibition of CXCL12-induced leukocyte migration in vitro.
A–C Jurkat T cells migrated in the presence of 10 nM CXCL12 with increasing concentrations of (A) Gal-3, (B) Gal-3 CRD, and (C) Gal-1 (A–C: n = 4).
D Human CD4+ T cells migrated in the presence of 10 nM CXCL12 alone and with 10 nM Gal-3 (dark green), Gal-3 CRD (light green), and Gal-1 (blue, n = 3).
E, F (E) Jurkat T cells migrated to increasing concentrations of CXCL12 alone (black) and CXCL12 in the presence of 0.1 nM of Gal-3 CRD (light green). (F) The inhibitory
effect of Gal-3 CRD is shown as percentage of the chemotactic effect of CXCL12 (E, F: n = 3).
G Jurkat T cells were allowed to migrate in the presence of CXCL12 at increasing concentrations alone and with 0.1 nM Gal-1 or 100 nM Gal-1 (n = 3).
H Jurkat T cells did not migrate in the sole presence of 1 nM to 1 lM Gal-3, Gal-3 CRD (both n = 5), or Gal-1 (n = 4).
I The viability of Jurkat T cells was assessed after incubation with 1 lM CXCL12 alone and in the presence of Gal-3, Gal-3 CRD, and Gal-1 (n = 2).
J, K (J) THP-1 cells and (K) neutrophils migrated in the presence of 10 nM CXCL12 alone and with 10 nM Gal-3, Gal-3 CRD, and Gal-1 (J, K: n = 3).
L Human eosinophils migrated in the presence of 10 nM CCL26 alone and with 10 nM Gal-3, Gal-3 CRD, and Gal-1 (n = 3).
M CD4+ T cells migrated in the presence of 1 nM CCL17 alone and with equimolar concentrations of Gal-3, Gal-3 CRD, and Gal-1 (n = 4).
Data information: Cell migration is shown as absolute cell counts. Data represent the mean  SD from the indicated number of independent experiments each
performed in three technical replicates, and these were statistically analyzed by using (A–C, F–G, J) a single sample t-test or (D, I, J–M) by an unpaired t-test against the
effect of the chemokine alone or as indicated (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
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CXCL12-induced migration of monocytic THP-1 cells and neutro-
phils (Fig 3J and K), whereas Gal-1 caused only subtle effects.
Supporting the idea of a functional impact from chemokine-Gal-3
interactions, we found that Gal-3 and Gal-3 CRD (both of which
interact with CCL26) also inhibit CCL26-mediated migration of
human eosinophils (Fig 3L). On the other hand, these galectins have
no effect on CCL17-mediated migration of CD4+ T cells (Fig 3M),
consistent with our observation that Gal-3 and Gal-3 CRD do not
interact with CCL17 (Figs 1E, and EV1E and F, and EV2C).
Under physiological conditions, co-injection of Gal-3 and CXCL12
into mice completely abrogated CXCL12-induced intraperitoneal (IP)
recruitment of neutrophils (Fig 4A) and classical monocytes
(Fig 4B) after 4 h. To find out whether genetic deletion of Gal-3 had
an enhancing effect on IP recruitment of classical monocytes post-
injection of thioglycolate (TG) broth into the peritoneum, responses
in WT and KO mice were analyzed 18 h after stimulation with TG.
As Fig 4C documents, (i) TG induces cell recruitment into the peri-
toneum, (ii) its extent is partially reduced by the CXCR4 antagonist
to signal involvement of CXCR4-independent mechanisms, and (iii)
Gal-3 absence increases recruitment, pointing to involvement of
other chemokines as targets or of CXCR4-independent CXCL12
blocking. TG increased the amount of CXCL12 in the peritoneal
lavage (Fig 4D) and reduced CXCR4 expression on classical mono-
cytes (Fig 4E). The TG response was partly dependent on the pres-
ence of CXCR4, because pre-injection of the CXCR4 antagonist
AMD3465 attenuated the effect (Fig 4C). Therefore, we surmise that
these effects are attributable to the absence of CXCL12/Gal-3 inter-
actions in these Gal-3/ mice.
In addition, we performed antibody-based proximity ligation
(PLA, Duolink), demonstrating that CXCL12 and Gal-3 are in close
proximity on cells recruited to the peritoneum after TG injection,
and thus allowing for functional interactions under inflammatory
conditions (Fig EV4A and B). To further substantiate the formation
of CXCL12/Gal-3 heterodimers in vivo, we stained Gal-3 and
CXCL12 simultaneously in frozen sections of lymph nodes from WT
and CXCL12/ mice (Fig EV4C and D). Here, we found partial co-
localization of Gal-3 and CXCL12 that was primarily detectable at
the lymph node capsule where CXCL12-expressing lymphatic
endothelial cells come into close proximity with subcapsular sinus
macrophages (SSM). Further evidence for close contacts between
CXCL12 and Gal-3 in situ was obtained by antibody-based PLA
staining of lymph nodes extracted from WT and CXCL12/ mice
(Fig EV4E), indicating the potential for CXCL12 and Gal-3 to directly
interact under physiological conditions.
To further make the case for this new type of pairing between
inflammatory mediators, we found that the weaker interacting Gal-3
mutants E185A and N222A and Gal-3 CRD mutants E185A and
N222A did not inhibit CXCL12-mediated chemotaxis up to 100 nM
(Fig 5A and B). Similarly, CXCL12-mediated Jurkat cell migration
was not inhibited by other weaker binding Gal-3 and Gal-3 CRD
mutants, namely R168A, H217A, and Q220K (Fig 5C and D). In
contrast, Gal-3 CRD mutant N160A, Gal-3 mutant Q220E, and Gal-3
CRD mutant Q220E (Fig EV3A) that did bind CXCL12 comparable to
WT (Appendix Figs S7B, S8B, and Fig EV3A) did have an inhibitory
effect (Fig 5C and D).
The observation that variants of Gal-3 at 1 lM inhibited chemo-
taxis independent of CXCL12, whereas Gal-3 CRD and its mutants
E185A and N222A did not completely block cell migration (Fig 5A
and B), may be explained by considering that the variants of full-
length Gal-3 induce cell aggregation at 1 lM, an effect that was
blocked by lactose (Fig 5E). We also performed transmigration
assays with lactose (as well as with the disaccharide cellobiose that
does not bind galectins) and with cells pre-treated with 1-deoxy-
mannojirimycin hydrochloride (DMJ) that reduces the level of
galectin-binding ligands on the cell surface by a shift to high-











































































































Figure 4. Peritoneal recruitment of leukocytes by CXCL12 in the presence of Gal-3.
A, B The peritoneal recruitment of (A) CD45+/CD115/Ly6G+ neutrophils and (B) CD45+/CD115+/Ly6Chi classical monocytes in C57BL/6J mice was assessed 4 h after
intraperitoneal (IP) injection of 500 nM CXCL12 alone (black) and in the presence of 50 nM Gal-3 (dark green; A, B: n = 7 mice).
C The peritoneal recruitment of classical monocytes after IP injection of PBS (n = 6) or TG in C57BL/6J WT (dark green, n = 10 mice) and Gal-3/ (black, n = 5 mice)
mice was assessed after 18 h. Where indicated, the mice received an IP injection of CXCR4 antagonist AMD 3465 12 h prior to the experiment.
D The concentration of CXCL12 concentration was determined by ELISA on the peritoneal lavage normalized with levels from the mesenterium (n = 4 mice).
E CXCR4 expression levels on Ly6Chi monocytes of the blood and the peritoneal lavage after 18 h of TG stimulation were determined by flow cytometry and indicated
as mean fluorescence intensity (MFI) (n = 4 mice).
Data information: Cell migration to the peritoneum is shown as cells/ml lavage. Data represent the mean  SD from the indicated number of mice and were statistically
analyzed by using the unpaired t-test, as indicated (*P ≤ 0.05, **P ≤ 0.01).
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at 1 lM was markedly reduced by the presence of lactose and DMJ
(Fig 5F and G), whereas the effect of Gal-3 CRD was unaffected
(Fig 5H). Because DMJ alone did not affect CXCL12-induced chemo-
taxis (Appendix Fig S9A), we assume that abrogation of chemotaxis
at 1 lM galectin concentration was caused by cell aggregation due
to galectin oligomerization and cell–cell cross-linking.
Lactose and DMJ have no effect on CXCL12-mediated chemotaxis
with Gal-1 (Appendix Fig S9B). However, they do reverse the
Gal-3 [nM]
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Figure 5. Inhibition of CXCL12-induced leukocyte migration by Gal-3 mutants and the role of galectin/glycan interactions in vitro.
A, B Jurkat T cells migrated in the presence of 10 nM CXCL12 with increasing concentrations of E185A (orange, n = 4) and N222A (red, n = 5) mutants of (A) Gal-3 and
(B) Gal-3 CRD.
C, D Jurkat T cells migrated in the presence of 10 nM CXCL12 with 10 nM (C) Gal-3 and (D) Gal-3 CRD mutants as indicated (C, D: n = 3).
E Aggregation of Jurkat T cells in the presence of 1 nM to 1 lM Gal-3 and Gal-1 alone and with 70 mM lactose, and Gal-3 CRD, was determined by flow cytometry
(n = 4).
F–J Jurkat T cells migrated with 10 nM CXCL12 alone and in the presence of (F) 1 lM Gal-3, (G) Gal-1, (H) Gal-3 CRD, and (I) 0.1 nM Gal-3 and (J) Gal-3 CRD in the
presence of 70 mM lactose or cellobiose or after treatment of cells with 150 lM DMJ.
Data information: Cell migration is shown as absolute cell counts. Data represent the mean  SD from the indicated number of independent experiments each
performed in three technical replicates, and these were statistically analyzed by using (A, B, E) a single sample t-test or (C, D, F–J) by an unpaired t-test against the effect
of the chemokine alone or as indicated (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
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inhibitory effect of WT Gal-3 on CXCL12-mediated chemotaxis
(Fig 5I). The reason they also do not have an effect with Gal-3 CRD
(Fig 5J) is likely due to the presence of the NT in WT Gal-3, which
complicates interpretation due to additional and unknown effects at
the cell surface. In solution, the Gal-3 NT interacts transiently with
the CRD F-face [34], a site of interaction that partially overlaps with
the CXCL12 binding site on the lectin. Based on increased line
broadening with WT Gal-3 in the presence of lactose, we know that
lactose enhances NT binding to the CRD F-face, which results in
attenuated CXCL12 binding to the lectin. Because DMJ treatment
attenuates binding of galectins to glycans on the cell surface, it may
be that some of them are necessary for optimal CXCL12/Gal-3
heterodimer formation and ensuing effects on the cell surface.
Furthermore, we found that the small molecule CXCR4 agonist
(NUCC-390) induces CXCL12-independent chemotaxis [41] that is
unaffected by the presence of Gal-3 or Gal-3 CRD (Appendix Fig
S9C).
For insight into the mechanism of Gal-3-mediated inhibition of
CXCL12 function, we investigated effects of the galectin on CXCR4-
mediated Gi signaling and b-arrestin 2 recruitment to CXCR4, a
process that is relevant to chemotaxis [42].
Inhibition of CXCL12-induced CXCR4 signaling by Gal-3 CRD
HEK 293 cells were transfected with CXCR4 and a luciferase-derived
intracellular cAMP sensor. As expected, CXCL12 alone reduced
cAMP levels reflecting Gi signaling, and Gal-3 CRD inhibited the
effect from the chemokine over time (Fig 6A) and in a concentra-
tion-dependent manner (Fig 6B). In addition, we transfected HEK
293 cells with Renilla sp. luciferase II (RlucII)-conjugated CXCR4
and eYFP–b-arrestin 2 constructs to assess b-arrestin recruitment to
the receptor by bioluminescence resonance energy transfer (BRET).
CXCL12 caused recruitment of b-arrestin 2 that was prevented by
Gal-3 CRD (Fig 6C). Unexpectedly, the effect of Gal-3 CRD was not
accompanied by reduced internalization of CXCR4 (Fig 6D), which
is mediated by b-arrestin recruitment [42]. However, it has been
reported that chemokine receptors may signal in a biased fashion,
with b-arrestin recruitment and internalization being uncoupled
[42–44].
To confirm that Gal-3 CRD exerts its effect on CXCL12 via
CXCR4, we performed cell-binding experiments with CXCL12 and
Gal-3 using Jurkat T cells. First, we incubated the cells with
CXCL12 and Gal-3, and demonstrated co-localization of the two
proteins by an antibody-based PLA (Fig 6E). Next, we incubated
the cells with fluorescently labeled Gal-3 CRD and unlabeled
CXCL12 in the presence of AMD 3100, a competitive CXCR4 antag-
onist, and recorded fluorescence intensity by flow cytometry [45].
We found that the signal from the galectin in the presence of the
chemokine was inhibited by AMD 3100 (Fig 6F). Furthermore,
when we blocked direct binding of Gal-3 CRD to the cell surface
with lactose, we observed an increase in the Gal-3 CRD signal
upon addition of CXCL12. Once again, this effect was inhibited by
AMD 3100 (Fig 6G). In contrast, unlabeled Gal-3 CRD did not
displace fluorescently labeled CXCL12 from the cell surface
(Fig 6H). Taken together, these findings suggest that Gal-3 CRD
interacts with CXCL12, either having an indirect effect on CXCR4
via CXCL12 or directly binding to CXCL12 and CXCR4. Since
glycan binding to the Gal-3 CRD is not required for the inhibition
of chemotaxis (Fig 5H and J), the involvement of an additional
Gal-3 co-receptor is unlikely.
To test these hypotheses, we performed MD simulations of the
CXCL12/Gal-3 CRD heterodimer interacting with CXCR4. Since the
structure of CXCL12 bound to CXCR4 has so far not been deter-
mined, we superimposed complex 6 of the heterodimer (Fig 2E and
F, Appendix Fig S6A) onto the structure of vMIP-II when associated
with CXCR4 and removed the docked vMIP-II from the complex.
The obtained model was then subjected to energy minimization in
the course of a MD run over a period of 50 ns with coordinates and
orientation from another monomer of CXCR4 (Fig EV5). The
obtained structure illustrates that CXCL12’s ligand property is not
impaired by the Gal-3 CRD; that is, binding of the CXCL12/Gal-3
CRD heterodimer to CXCR4 is sterically possible. It may even be
favored by direct interactions between Gal-3 CRD and CXCR4. This
model obtained by MD simulation clearly warrants further investi-
gation. Nonetheless, the experimental and computational lines of
evidence converge to exclude galectin-dependent blocking of
chemokine–receptor interaction for reducing CXCL12 activity as
probed.
Discussion
Chemokines and galectins regulate leukocyte recruitment and can
be simultaneously upregulated under inflammatory conditions. In
fact, in osteoarthritis, chemokines belong to a set of proteins that
are upregulated in a NF-jB-dependent manner by Gal-3 [46]. Build-
ing on our discovery that CXC and CC chemokines form heterodi-
mers with functional significance, we established a map of the
chemokine interactome that illustrates numerous interactions [15].
Moreover, we recently reported on galectin/galectin heterodimer
formation [33]. Due to the functional and structural similarities
between chemokines and galectins, we hypothesized that members
of both these effector molecule families may themselves interact to
form chemokine/galectin heterodimers with functional conse-
quences.
In the present study, we validated this hypothesis by demonstrat-
ing that Gal-1 and Gal-3 specifically interact with several chemoki-
nes in solid-phase immunoassays and SPR. When comparing the
function of interacting and non-interacting chemokines, it is worth-
while to note that some chemokines primarily involved in later
stages of inflammation, such as CCL22, CCL24, CCL26, and CXCL12,
interact with the galectins, whereas chemokines, such as CCL2,
CCL17, or CXCL8, that have been implicated in the initiation of
inflammation [11,47–49] do not bind. Therefore, we propose a new
concept that chemokine/galectin heterodimers may play a role in
later stages of inflammatory processes or chronic inflammation.
Focusing on Gal-3 and CXCL12 that are both often found to be
co-expressed and involved in inflammatory processes, we
performed HSQC studies that revealed formation of a CXCL12/Gal-3
heterodimer in which Gal-3 binds to CXCL12 via the F-face of its
CRD. The opposing glycan-binding S-face and the NT of Gal-3 are
not part of the primary interaction domain. NMR analysis of the
contact site between CXCL12 and Gal-1 or full-length Gal-3 was
impeded by either intramolecular conformational changes or
homodimerization. Viewed from the chemokine perspective, the
interaction site includes the first b-strand (residues 17–27) and the
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Figure 6. Inhibition of CXCL12-induced CXCR4 signaling by Gal-3 CRD.
A HEK cells transfected with a luminescent cAMP sensor were incubated with 10 nM CXCL12 alone and in the presence of 10 nM Gal-3 CRD followed by stimulation
with forskolin, an activator of adenylate cyclase. Results are shown as luminescence relative to baseline (RLU, example of n = 3).
B The effect of 10 nM Gal-3 CRD upon stimulation with 10 nM CXCL12 prior to forskolin stimulation was tested. Control experiments were performed as indicated
(n = 3, four technical replicates).
C HEK cells transfected with a RlucII-conjugated CXCR4 and an eYFP–b-arrestin 2 construct were stimulated with 10 nM CXCL12 alone and in the presence of 10 nM
Gal-3 CRD. Control experiments were performed as indicated. Results are given as the net BRET ratio (i.e., ratio of emissions at 535/485 nm minus the ratio of mock
cells, n = 5, three technical replicates).
D Internalization of CXCR4 with 10 nM CXCL12 alone and in the presence of 10 nM Gal-3 CRD was assessed by incubation with an APC-conjugated anti-CXCR4
antibody (baseline signal = 100%, n = 8, two technical replicates).
E 100 nM CXCL12 and Gal-3 were added to Jurkat T cells, and their co-localization was assessed on the cell surface by PLA. Control experiments were performed as
indicated (representative example of n = 3). White scale bar: 10 lm.
F, G Jurkat T cells were incubated with 100 nM of Gal-3 CRD Alexa Fluor 555 alone, with 10 lM AMD 3100, with 100 nM CXCL12, or with CXCL12 and AMD 3100.
Experiments were performed (F) without and (G) in the presence of 70 mM lactose (F, G: n = 3, two technical replicates).
H Jurkat T cells were incubated with 100 nM CXCL12 FITC alone and with increasing concentrations of Gal-3 CRD as indicated (n = 4, two technical replicates).
Data information: Data represent the mean  SD of the indicated number of independent experiments and were statistically analyzed by (F, G) unpaired t-test or (B–D,
H) single sample t-test against the effect of the chemokine alone or as indicated (*P ≤ 0.05, **P ≤ 0.01).
EMBO reports e47852 | 2020 ª 2020 The Authors
EMBO reports Veit Eckardt et al
 
120
C-terminal a-helix (residues 59–68), as well as the second b-strand
and 40s loop. Of note, these residues comprise the CXCL12 homo-
dimer interface in the first b-strand and the C-terminal a-helix [50].
Although acidic conditions shift the monomer–dimer equilibrium
toward monomer, Gal-3 may interfere with CXCL12 homodimeriza-
tion and thus affect CXCR4 signaling under more physiological
conditions [38,51,52]. Of particular note, the CXCL12/Gal-3 inter-
face contains the GAG-binding motif of CXCL12, which primarily
involves the first b-strand and 40s residues. Implying physiological
significance, this region is reported as being required for chemokine
presentation by endothelial cell GAGs [52,53]. Leading to an anti-
chemokine effect, Gal-3 may specifically block this binding, a
scenario that may impact on chemokine activity, as an antibody
does [54]. The finding that heparin prevents CXCL12 from binding
to Gal-3 CRD points into this direction so that interactions of
CXCL12 with cognate GAGs and Gal-3 CRD are mutually exclusive.
Studying the effect of Gal-3 on CXCL12 activity in a GAG-deficient
cell line will be an approach to contribute to answer the arising
question on the role of GAGs in situ for reducing CXCL12 activity by
the galectin.
Here, we have provided initial support for our hypothesis that
heterodimer formation affects chemokine function by performing
transmigration assays and using a murine model of peritonitis.
Whereas Gal-3 inhibited CXCL12-induced chemotaxis, Gal-1 (that
exhibited markedly reduced affinity in SPR), the non-interacting
chemokine CCL17 and the interaction-deficient mutants Gal-3
R168A, Gal-3 E185A, Gal-3 H217A, Gal-3 Q220K, and Gal-3 N222A
had a reduced effect, if any. At this moment, it is puzzling that the
effective concentrations of Gal-3 seem unexpectedly low and let it
appear that a substantial portion of CXCL12 may not be active.
Concerning the first point, should the chemokine be arranged in
clusters at high density (presenting multivalency to the lectin), then
a gradient of fractional affinity constants could arise with very high
affinity for the first step, as documented for Gal-3 CRD association
with a nonavalent glycoprotein [55]. Galectins bind to the multiva-
lent glycoprotein asialofetuin with enhanced affinities and a gradi-
ent of decreasing binding constants [55]. With respect to low
effective chemokine concentrations, although not yet mechanisti-
cally fully understood, it appears reasonable to postulate the follow-
ing: that competition between galectins and GAGs (these glycan
chains are discussed as direct or indirect factors for affecting chemo-
kine availability [56]) for the chemokine may have a tangible bear-
ing on CXCL12 activity, as also noted above.
On the cellular level, we showed that Gal-3 CRD affects CXCR4
signaling without interfering with receptor internalization. These
results, together with the computational modeling of the ternary
complex, suggest that the CXCL12/Gal-3 heterodimer binds CXCR4
rather than preventing the chemokine from interacting with its
receptor. The possibility that CXCL12, when associated with the
Gal-3 CRD, “may not be as potent as CXCL12 (alone) in triggering
intracellular signals” (as suggested by a reviewer) can establish a
mechanism toward galectin-mediated reduction of chemokine activ-
ity.
The biological functions of extracellular Gal-3 that have so far
been described mostly depend on the glycan-binding capacity of its
CRD and the formation of aggregates (lattice) with counterreceptors
involving the CRD and possibly its NT [57,58]. To give an example
from immune regulation, Gal-3 impedes diffusion of the
glycosylated cytokine interferon-c by cross-linking the cytokine with
components of the extracellular matrix in a glycan-dependent
manner [59]. Thus, Gal-3 can inhibit chemokine effects through
both direct and indirect mechanisms. Moreover, Gal-3 induces
neutrophil expression of CXCL8 in a glycan-dependent manner.
Cleavage of its NT by neutrophil elastase renders the resulting Gal-3
CRD non-functional [60]. Our study has broadened this functional
profile by demonstrating that regions of extracellular Gal-3 that are
not involved in carbohydrate binding may in fact modulate
inflammation. Our observations suggest that the Gal-3 CRD may
have an anti-inflammatory role that could be exploited therapeuti-
cally. These findings do not exclude S-face-dependent effects of the
galectin CRD in a physiological setting. Whether both sites operate
simultaneously should prompt further studies. Since homodimeric
Gal-3 variants have recently become available [61], this protein and
also Gal-1/3 heterodimers offer perspectives on how to resolve this
issue and may inspire biomedical efforts.
Since it was shown that CXCL12 and Gal-3 are simultaneously
upregulated under chronic inflammatory conditions, proinflamma-
tory Gal-3 may specifically block excessive or persistent inflamma-
tion by interfering with CXCL12 activity. Proteolytic Gal-3
truncation to its CRD by matrix metalloproteinases may be a control
mechanism that attenuates or resolves inflammation. This assump-
tion inspires the idea that a multimeric Gal-3 CRD construct (with
active CRD or a mutant) may efficiently block CXCL12 activity
in situ, while Gal-1 oligomerization appears to increase aspects of
its biomedical activity [62,63]. The interaction of a lectin with a
non-glycan counterreceptor, together with such engineering, can
thus have a biomedical potential [64]. As a promising target,
endothelial cell-derived CXCL12 drives atherosclerosis which under-
lies coronary heart disease [65,66]. Considering our discovery that
Gal-3 is a potential antagonist of CXCL12, the present evidence for
chemokine/galectin heterodimerization will prompt further investi-
gation into the inter-family interactome and its pathophysiological
relevance. Since Gal-3 fulfills criteria of an alarmin (or damage-asso-
ciated molecular pattern) and a mediator of autophagy [67,68], the
detection of CXCL12 binding will also warrant to explore its capacity
to engage in pairing in respective processes.
Materials and Methods
Galectins, chemokines, and asialofetuin
Galectins
Gal-1 and Gal-3 were produced using Escherichia coli BL21(DE3)
pLysS cells and the pGEMEX-1 expression vector (Promega). Cells
were cultured at 37°C until an optical density600 value of 0.6–0.8
was reached; then, protein production was induced by 100 lM of
IPTG (isopropyl-b-D-thiogalactoside) and cultivation continued at
37°C (Gal-1) or 22°C (Gal-3) for 16 h. Proteins were purified from
extracts by affinity chromatography on lactosylated Sepharose 4B as
crucial step, and lactose was removed by gel filtration [69]. Isotopic
labeling of full-length Gal-3 (residues 1–250) for NMR-spectrosco-
pical analysis was done by using [15N]NH4Cl as medium additive
for production at 30°C for 16 h in the presence of 100 lM IPTG
[34]. The Gal-3 CRD (residues 108–250) was generated by on-bead
collagenase treatment (1 mg/10 mg of protein) for 16 h at 4°C [70].
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One-site Gal-3 mutants (N160A, E185A, and N222A) were obtained
by mutagenesis of the pGEMEX-1-Gal-3 and pGEX-6P-2-Gal-3
vectors using the QuikChange Mutagenesis Kit (Agilent Technolo-
gies, Waldbronn, Germany). All proteins were routinely checked for
purity by one- and two-dimensional gel electrophoresis under dena-
turing conditions and for activity by solid-phase/cell-binding assays.
Chemokines
For the array of the solid-phase immunoassay, chemokines were
purchased from PeproTech (Rocky Hill, NJ, USA). WT human
CXCL12a was bacterially expressed using a codon-optimized cDNA
(Genscript, Piscataway, NJ, USA) as a thioredoxin-His-tagged fusion
protein from the pET-32(+) vector with an enterokinase cleavage
site at the N-terminus. The plasmid was transformed into E. coli
BL21(DE3) cells and grown at 37°C in either Luria–Bertani or 15N-
enriched Spectra 9 medium (Cambridge Isotope Laboratories, MA,
USA). CXCL12a was purified from inclusion bodies. After separation
using a HisTrap HP column (GE Healthcare, Chicago, IL, USA), the
sample was dialyzed against 50 mM Tris (tris(hydroxymethyl)
aminomethane) buffer (pH 8), filtered, and loaded on a Heparin HP
column. The bound protein was eluted in 50 mM Tris/2 M NaCl
(pH 8) and further dialyzed against 50 mM Tris/2 mM cysteine (pH
8) before cleavage using Enterokinase (Novagen, Merck, Darmstadt,
Germany). The cleaved protein was purified using a Mono S 5/50
GL column (GE Healthcare). The fractions containing the protein
were pooled, dialyzed against 1% acetic acid, lyophilized, and
stored at 20°C until further use. The correct mass of CXCL12a was
confirmed by mass spectrometry.
Conjugation of proteins with biotin and fluorescent labels
Fluorescent and biotinylated proteins were prepared with the
succinimidyl ester of Alexa Fluor 555 and the N-hydroxysuccinimide
ester derivatives of FITC and biotin (all from Thermo Fisher Scien-
tific, Waltham, MA, USA) according to the manufacturer’s protocol.
The conjugate was separated from the reagent using Sephadex G25
in PD-10 Desalting Columns (GE Healthcare). Preservation of activ-
ity was checked by cell signaling, hemagglutination, and binding
assays using (neo)glycoproteins as matrix.
Asialofetuin
Desialylation of fetuin from fetal calf serum (Sigma-Aldrich, Tauf-
kirchen, Germany) was performed by hydrolysis in 0.05 N sulfuric
acid at 80°C for 1 h, and the product (ASF) was purified by fast
protein liquid chromatography on a Superdex 75 column (GE
Healthcare).
Cells, cell culture, and cell transfection
Jurkat T cells (clone E6-1, ATCC) and human monocytic THP-1 cells
(no. ACC-16, DSMZ) were cultured as recommended by the
supplier.
Human CD4+ T cells
PBMCs were separated from whole blood by density gradient
centrifugation. CD4+ T cells were isolated from PBMCs with the
Dynabeads Untouched Human CD4+ T Cells Kit, stimulated with
the Dynabeads Human T-Activator CD3/CD28 Kit (both from Invit-
rogen, Thermo Fisher Scientific) for 3 days, and expanded in the
presence of the Dynabeads with 30 U/ml human IL-2 for another
3 days.
Human eosinophils
Whole-blood components were separated by density gradient
centrifugation. The erythrocyte pellet was lysed, and eosinophils
were isolated with the Eosinophil Isolation Kit in an unlabeled
manner (Miltenyi, Bergisch Gladbach, Germany).
Human neutrophils
Neutrophils were separated from whole blood by density gradient
centrifugation.
HEK 293 cell transfection for Gi signaling
The sequence of the luciferase-cAMP binding site fusion protein
from the pGloSensor-20F vector (Promega) was amplified and
ligated into a bicistronic pIRESneo vector (Clontech, Mountain
View, CA, USA) to obtain the reporter gene plasmid. The pcDNA5/
FRT/TO vector (Invitrogen) was used to express the CXCR4 receptor
constructs (cDNA Resource Center, Bloomsburg University, Blooms-
burg, PA, USA) [71]. Flp-In T-REx 293 cells (HEK 293, Invitrogen)
were first stably transfected with the reporter plasmid using the Flp-
In system (Invitrogen) and EcoTransfect (OZ Biosciences, Marseille,
France). Stable clones were selected with 1 mg/ml geneticin. A suit-
able clone was then chosen as host cell line for stable overexpres-
sion of the CXCR4 construct using the Flp-In system with 250 lg/ml
hygromycin B for selection.
HEK 293 cell transfection for b-arrestin 2 recruitment
HEK 293 cell monolayers at 90% confluency on a 24-well plate were
transiently transfected with 0.05 lg/well CXCR4-RlucII construct
(Promega) and 0.2 lg/well eYFP–b-arrestin 2 construct or mock
plasmid with 1 ll EcoTransfect. After 24 h, the cells were trans-
ferred to a black 96-well plate.
Solid-phase immunoassays
100 ng samples of human chemokines or galectins were blotted
onto a nitrocellulose membrane, and incubated with 200 nM
biotinylated galectins or 120 nM CXCL12 overnight, signals devel-
oped with SA-HRP for 1 h, and added enhanced chemiluminescence
substrate (Thermo Fisher Scientific). Densitometric analysis of digi-
tal records was performed using the program ImageJ.
Cross-linking protein interaction analysis
Galectins were incubated with 1 mM BS3 or BS(PEG)5 cross-linkers
(both from Thermo Fisher Scientific) in 20 mM HEPES (pH 8.3) at
room temperature. After 10 min, CXCL12 was added and the
mixture further incubated for 1 h. The reaction was then stopped by
addition of 1 M Tris (pH 8). Samples were analyzed by SDS–PAGE
followed by silver staining according to the manufacturer’s instruc-
tions (Alphalyse, Odense, Denmark).
Surface plasmon resonance measurements
SPR experiments were performed on a Biacore X100 system (GE
Healthcare).
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Biotinylated Gal-3 and Gal-1 were immobilized on SA sensor chips
at densities specified in the figure legends (Fig EV1E and G). Gal-3
CRD was immobilized using thiol-coupling chemistry on a NeutrA-
vidin (Thermo Fisher Scientific)-modified C1 sensor chip at the
specified density (Fig EV1F). 100 nM chemokines dissolved in
HEPES-buffered saline with EDTA and surfactant P20 (HBS-EP+)
were perfused at a flow rate of 30 ll/min for 3 min. The response
in resonance units (RU) was recorded 20 s after the end of the injec-
tion.
Kinetics experiments
Biotinylated (Gal-1 and Gal-3) and biotin-free (Gal-3, Gal-3 CRD,
and mutants) galectins and biotinylated asialofetuin were immobi-
lized on NeutrAvidin or using thiol- or amine-coupling chemistry
(Thermo Fisher Scientific) on C1 or SA sensor chips at surface densi-
ties specified in the figure legends (Figs 1F–H and EV2A–F, and
Appendix Figs S1A–C and S8A–L). CXCL12 and Gal-3 in HBS-EP+
were perfused for 1 min followed by a dissociation phase of 3 and
2 min for the chips with conjugated galectins and the chip present-
ing the glycoprotein ASF, respectively.
Nuclear magnetic resonance spectroscopy
NMR samples were prepared in 3-mm NMR tubes. Typically,
chemokine and galectin samples were buffer-exchanged and
concentrated into 20 mM sodium acetate buffer, pH 4.5, and
4.5 mM lactose through five ultracentrifugation steps over Amicon
Ultra-4 3-kDa filter devices (Merck, Darmstadt, Germany).
Mixtures of CXCL12 and Gal-3 CRD, Gal-3, or Gal-1 at defined
molar ratios were prepared from these stock solutions, and 5% (v/
v) D2O was added for field locking, together with a trace of DSS
as an internal chemical shift standard. 1H–15N HSQC experiments
with a flip-back pulse and decoupling in the presence of scalar
interactions, and nuclear Overhauser effect were recorded at 37°C
on Bruker Avance III HD 700- and 850-MHz spectrometers
equipped with cryogenically cooled triple resonance inverse
probes. Spectra were processed and analyzed using Bruker
TopSpin 3.2 and Sparky 3.114 software (T. D. Goddard, D. G.
Kneller, SPARKY 3, the University of California, San Francisco,
CA, USA). Resonance assignments of CXCL12 and Gal-3 CRD were
performed by 2D NOESY and 3D-edited NOESY spectra. Chemical
shift differences (Dd) induced upon binding were calculated as
follows: [(D1H)2]1/2 + [(0.25D15N)2]1/2 (in 1H ppm). DIntensity was
calculated as follows: 1  Inti/Int0, where Inti is the resonance
intensity of resonances of CXCL12 or Gal-3 CRD in the presence of
the other component, respectively, and Int0 is the intensity of
CXCL12 or Gal-3 CRD resonances in its absence. The same experi-
mental procedure was used for Gal-1 and Gal-3 proteins, as well
as for Gal-3 mutants.
Molecular dynamics simulations
The CXCL12/Gal-3 CRD heterodimer was subjected to MD simula-
tions for 50 ns as described except applying Amber 14SB force field
with TIP3P water models using Amber16 [72]. MD simulations were
performed for 50 ns. Snapshots between 40 and 50 ns were
extracted for binding free energy calculation using the MM/GBSA
approach, and the BFE values were approximated from enthalpy
values as described [72]. Default parameters were applied for BFE
calculation, except using the generalized Born model 8 to compute
the free energy of solvation. Ternary complex modeling between
CXCL12, Gal-3 CRD, and CXCR4 was performed as described above.
PDB access codes are as follows: CXCL12 homodimer (4UAI), Gal-3




Chemotaxis assays were performed in triplicate with the number of
independent experiments as stated in each respective figure legend.
Chemokines and galectins in 230 ll of RPMI 1640/0.5% BSA were
pipetted into the bottom well of a Transwell-96 permeable support
(Corning, NY, USA) with 3.0 lm pore size for human granulocytes
and 5.0 lm for all other cell types. 105 cells in 70 ll were pipetted
on top of the filter and allowed to migrate for 2 h for primary cells
and 4 h for Jurkat and THP-1 cells. 20 ll of a 0.05 M EDTA solution
was added to the bottom well, and the plates were incubated for
another 15 min. The number of cells at the bottom of a well was
measured by flow cytometry of the cell suspension for 30 s at
medium speed (FACSCanto II, BD Biosciences, Franklin Lakes, NJ,
USA).
Cell aggregation
Jurkat T cells were incubated with the indicated concentrations of
galectins for 4 h and subsequently analyzed by flow cytometry
(FACSCANTO II). The forward scatter area (FSC-A) was plotted
against the forward scatter width (FSC-W) to discriminate between
singlets (low FSC-A, low FSC-W) and doublets/multiplets (high
FSC-A, high FSC-W).
Apoptosis
Cell viability was determined by fluorescence-activated cell scan-
ning with the FITC Annexin V Apoptosis Detection Kit with 7-AAD
(7-amino-actinomycin D) (BioLegend, San Diego, CA, USA).
Mice
All animal experimental procedures were designed and conducted
in agreement with the German Animal Welfare Legislation, and
were reviewed and approved by local authorities (Regierung von
Oberbayern, Munich, Germany). All mice were housed in IVC units
and maintained on a 12-h dark/12-h light cycle. C57BL/6J mice
were from Janvier (Le Genest-Saint-Isle, France), and tamoxifen-
inducible general Cre-deleter C57BL/6-Gt(ROSA)26Sortm9(Cre/ESR1)Arte
(CreERT2) mice were from Taconic (TaconicArtemis GmbH,
Cologne, Germany) and crossed with CXCL12
flox/flox
mice (on the
Apoe/ background), which were generated as described [15].
CXCL12/ and WT mice were littermate offsprings from
CreERT2+, CXCL12flox/flox, or CreERT2+CXC12wt/wt mice after
application of tamoxifen. Mice deficient for Lgals3 (coding for Gal-
3) were from EUCOMM (C57BL/6N-Lgals3tm1a(EUCOMM)Wtsi/H,
Strain ID EM:06800) [73].
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Murine model of peritonitis
500 nM CXCL12 alone, or in combination with 50 nM Gal-3, in PBS
was injected into the peritoneal cavity of C57BL/6J mice (Janvier).
To ensure efficacy in this physiological system, the chemokine/
galectin molar ratio (10:1) was used. Mice were euthanized after
4 h. HBSS/0.3 mM EDTA/0.06% BSA was first injected into the
peritoneal cavity, and then collected.
Peritonitis was induced by IP injection of 0.5 ml of 4% sterile
thioglycolate broth. C57BL/6J mice were pre-treated IP with 125 lg
of the CXCR4 antagonist AMD3465 (Tocris Bioscience, Bristol, UK)
12 h earlier. The peritoneal lavage was obtained after 18 h.
Cells were stained with a mixture of fluorescent antibodies and
analyzed by flow cytometry. Only single cells (FSC-H/FSC-Wlow)
were gated. B cells (B220+) and macrophages (F4/80+) were
excluded, and classical monocytes (CD115+/Ly6Chi) and neutro-
phils (CD115/Ly6G+) were gated from CD45+ (Appendix Fig
S10A). Percentages of leukocyte subsets of untreated and TG-treated
mice are indicated (Appendix Fig S10B–H). All antibodies were
obtained from eBioscience (Thermo Fisher Scientific).
Proximity ligation assay
Lymph nodes for frozen sections were explanted from C57BL/6
mice. 106 Jurkat T cells were incubated with CXCL12 and Gal-3
at 4°C for 1 h, fixed, and mounted onto poly-L-lysine (Sigma-
Aldrich)-coated slides. On all samples, sites for non-specific
protein binding were blocked and the cells or sections were incu-
bated with 5 lg/ml of a polyclonal goat anti-mouse CXCL12 (Bio-
Rad Laboratories, Hercules, CA, USA) and 2.5 lg/ml of a rabbit
anti-human Gal-3 (affinity-purified IgG) antibody at 4°C overnight.
Samples were incubated with secondary antibodies conjugated to
complementary oligonucleotides that were ligated and amplified
according to the manufacturer’s instructions (all reagents from
the Duolink In Situ Red Goat/Rabbit Kit; Sigma-Aldrich).
Photomicrographs were taken using a confocal microscope (SP8;
Leica, Wetzlar, Germany; magnification × 100, numerical aperture




HEK 293 cells expressing the GloSensor (Promega, Madison, WI,
USA) and CXCR4 were cultured in a black 96-well plate (Perkin
Elmer, Waltham, MA, USA) for 2–3 days until the cells were conflu-
ent. Cells were then incubated with a HBSS/20 mM HEPES/2.5%
Luciferin-EF (Promega) solution for 2 h. Luminescence was deter-
mined using a plate reader (infinite F2000PRO; Tecan, Männedorf,
Switzerland) until steady state was achieved. Forskolin (1 lM) was
added 28 min after the stimulus, and the luminescence was
recorded.
b-Arrestin 2 recruitment
HEK 293 cells expressing eYFP-b-arrestin 2 and CXCR4 Renilla sp.
luciferase II (RlucII) were cultured to confluence in a black 96-well
plate with 0.5 lg/ml tetracycline used to induce expression. Total
fluorescence was determined at 535 nm. Coelenterazine (15 lM)
was added, and total luminescence was detected at 485 nm. The
stimulus was added, and the BRET ratio (emissions at 535 nm/
485 nm) was determined.
Internalization of CXCR4
105 Jurkat T cells were incubated with CXCL12 and Gal-3 CRD at
37°C, fixed in 4% PFA, and stained with a monoclonal (12G5) APC-
conjugated anti-human CXCR4 antibody (BD Biosciences).
Galectin and CXCL12 binding to T cells
105 Jurkat T cells were incubated as stated in the figure legend
(Fig 6F–H) for 1 h. Where indicated, cells were pre-incubated with
AMD 3100 (Sigma-Aldrich) for 15 min, and experiments were
performed in the presence of the compound. Fluorescence signals
were recorded by flow cytometry.
Expanded View for this article is available online.
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◀ Figure EV1. Physical interaction of Gal-3 and Gal-1 with CC and CXC chemokines.
A–D Chemokines were immobilized on a nitrocellulose membrane and incubated with (A) TBS or (B) TBS containing biotinylated Gal-1. The membranes were then
stepwise incubated in solutions with SA-HRP and chemiluminescence reagents. (C, D) The blots were subjected to densitometric analysis.
E–G Binding of galectins to chemokines was further assessed by immobilizing (E) Gal-3, (F) Gal-3 CRD, and (G) Gal-1 on sensor chips at a density of 700 RU and
detecting signals of human chemokines under flow. Signals of the solid-phase assays (Fig 1E) are depicted in light blue (n = 3). Data represent mean  SD from
three independent experiments.
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Figure EV2. Heterodimer formation between Gal-3 and chemokines.
A–F For kinetic SPR analyses, Gal-3 was immobilized on sensor chips to a density of 650 RU, and increasing concentrations of (A) CCL1, (B) CCL5E66S, (C) CCL17, (D)
CCL22, (E) CCL26, and (F) CXCL11 were passed over the flow cell. Insets show representative sensorgrams of chemokines on Gal-3. Data represent the mean  SD of
three independent experiments.
G KD values were calculated by fitting signals of steady-state phases vs. the concentration of the chemokine (A–F in red).
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Figure EV3. 1H–15N chemical shift maps for 15N-labeled CXCL12 with WT Gal-3 CRD and its mutants.
A–C Dd Values plotted vs. the amino acid sequence of CXCL12 are shown for 30 lM 15N-enriched CXCL12 in the presence of 500 lM label-free Gal-3 CRD mutants (A)
Q220E, (B) Q220K, and (C) H217A (black). The results of the experiment with WT Gal-3 CRD from Fig 2A are overlaid in gray.
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◀ Figure EV4. Co-localization of CXCL12 and Gal-3 on cells in vivo.
A, B Proximity of Gal-3 and CXCL12 on cells from peritoneal lavages after injection of (A) PBS or (B) TG was determined by PLA (representative example of n = 3). White
scale bar: 10 lm.
C, D Co-localization of Gal-3 and CXCL12 in frozen sections of lymph nodes from (C) WT and (D) CXCL12/ mice was determined by immunofluorescence staining
using antibodies against Gal-3 and CXCL12 (representative example of n = 3). Scale bar: 40 lm. Arrows indicate subcapsular sinus macrophages (SSM).
E Co-localization on the same sections was also detected by PLA (representative example of n = 3). Scale bar: 40 lm.
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◀ Figure EV5. MD simulation of a ternary complex between CXCL12, Gal-3 CRD, and CXCR4 in a lipid bilayer environment.
Complex 6 was superimposed onto the viral chemokine antagonist vMIP-II in complex with CXCR4 (PDB access code 4RWS). Subsequently, the viral chemokine antagonist
vMIP-II was deleted, and the complex between monomeric CXCR4 in complex with the CXCL12/Gal-3 CRD heterodimer was obtained. This model was refined by energy
minimization in the course of MD simulations (50 ns) with coordinates and orientation from another monomer of CXCR4 (CXCR4 as dimer (PDB access code 3ODU),
monomers in cyan and yellow, CXCL12 in magenta, and Gal-3 CRD in light green). The inset shows that N180 (Gal-3 CRD) forms H-bonds (dashed red lines) with N97 (CXCR4)
and R183 (Gal-3 CRD) can do so with E31 (CXCR4) and with R8 (CXCL12).
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Appendix Figure S1. CXCL12/Gal-3 heterodimer formation in the presence of lactose 
and heparin. 
A-B Gal-3 was immobilized using thiol-coupling on a C1-sensor chip to a density of 650 
RU and serial dilutions of CXCL12 were passed over the chip either in the (A) 
absence or (B) presence of 70 mM lactose (n=3). The KD values were obtained by 
fitting the signals of the steady-state phases against the concentration of the 
chemokine (red) using a single-site model. A representative sensorgram is provided 
in the inset to each panel.  
C For kinetic analysis CXCL12 at increasing concentrations alone or together with 
heparin (0.5 µg/mL) was passed over the Gal-3 CRD chip (CXCL12 alone in black, 
and with heparin in purple). 
Data information: Insets show exemplary sensorgrams of CXCL12 on immobilized galectin. 
Data represent the mean ± SD from three independent experiments. 
140
Appendix Figure S2. Co-expression of Gal-3 and chemokines in mouse tissue. 
Gene expression data from FACS-based full-length transcript analyses were obtained from 
Tabula Muris, a compendium of single cell transcriptome data derived from mouse organs 






Appendix Figure S3. 1H-15N HSQC spectra of CXCL12 and Gal-3 CRD. 
A-B Full 1H-15N HSQC spectra are overlaid depicting (A) 10 µM 15N-enriched CXCL12 
alone (black) and in the presence of 330 µM unlabeled Gal-3 CRD (red) and (B) 30 
µM 15N-enriched Gal-3 CRD alone (black) and in the presence of 500 µM unlabeled 
CXCL12 (red). The boxed regions in these spectra are shown in greater detail in 
Figure 2A and B. 
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Appendix Figure S4. Cross-linking of CXCL12 and Gal-3 CRD. 
CXCL12 and Gal-3 CRD were incubated with cross-linkers BS3 and BS(PEG)5. SDS PAGE 
and silver staining of the gel were performed. Using increasing concentrations of Gal-3 CRD 
and the longer BS(PEG)5 linker, bands appeared at the position expected for a molecular 
weight consistent with that of the CXCL12/Gal-3 CRD heterodimer (red rectangle). This is a 
representative image of three independent experiments. 
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Appendix Figure S5. CXCL12-induced chemical shifts of full-length 15N-labeled Gal-3. 
∆δ Values plotted vs. the amino acid sequence and secondary structure of Gal-3 are shown 





Appendix Figure S6. MD-based energy-minimized structure of the CXCL12/Gal-3 CRD 
heterodimer. 
A 10 Potential structures of the CXCL12/Gal-3 CRD heterodimer consistent with the 
NMR results (Figure 2A-D, Appendix Figure S3A and B) were modeled and the ΔG 
values of interaction were calculated. Complex 6 is the thermodynamically most 
favorable conformation, because its formation generates the largest ΔG value, thus 
the highest affinity (red). 
B-C Decomposition analyses of all residues of (B) Gal-3 CRD and (C) CXCL12 in a 
CXCL12/Gal-3 CRD heterodimer were performed. Secondary structures are shown 
below the graph. Sites of amino acid substitutions are highlighted in red. 
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Appendix Figure S7. Binding of CXCL12 to Gal-3, Gal-3 CRD and their mutants. 
A-B Membrane blot experiments were performed with (A) Gal-3 and (B) Gal-3 CRD and 
their mutants immobilized on the membrane and biotinylated CXCL12 in solution, as 
exemplified on the left in each panel. Chemokines served as negative and positive 
controls as described [15]. Membranes were subjected to densitometric analysis with 
values normalized to the galectin, as shown on the right (results of WT Gal-3 and Gal-
3 CRD in green and light green respectively, mutants in red). 
Data information: Data represent the mean ± SD from three independent experiments and 






Appendix Figure S8. Binding kinetics of Gal-3 mutants to CXCL12 and ASF. 
A-G For kinetic SPR analysis (A) Gal-3 (density 239 RU), (B) Gal-3 N160A (density 291 
RU), (C) Gal-3 R168A (density 160 RU), (D) Gal-3 E185A (density 264 RU), (E) Gal-3 
H217A (density 197 RU), (F) Gal-3 Q220K (density 216 RU) and (G) Gal-3 N222A 
(density 258 RU) were immobilized on sensor chips and increasing concentrations of 
CXCL12 were passed over the flow cell (A-G: n = 3). 
H KD values were determined by fitting the signals of steady-state phases vs. the 
concentration of CXCL12 (A-G in red). 
I-L The interaction of Gal-3 mutants with glycans was assessed by determining the 
binding capacity of increasing concentrations of galectin to ASF immobilized at a 
density of 460 RU on the sensor chip surface (representative example of n = 3). KD 
values were obtained by fitting the graphs according to a 1:1 Langmuir interaction 
model (in red). 
Data information: Data represent the mean ± SD from three independent experiments. 
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Appendix Figure S9. Effect of DMJ, galectin-mediated glycan binding and NUCC-390 
on the chemotaxis of Jurkat T cells. 
A Jurkat T cells migrated to 10 nM CXCL12 alone with and without pretreatment of cells 
with 150 µM DMJ, an inhibitor of N-linked glycosylation, for 24 hours (n = 3). 
B Jurkat T cells were allowed to migrate in the presence of 10 nM CXCL12 alone or in 
combination with 0.1 nM Gal-1, 70 mM lactose, DMJ and 70 mM cellobiose (n = 3). 
C Jurkat T cells migrated with 10 µM NUCC-390 (a CXCR4 agonist) and with 10 nM 
Gal-3 and Gal-3 CRD (n = 3). 
Data information: Cell migration is shown as absolute cell count. Data represent the mean ± 
SD from three independent experiments and were statistically analyzed by using an unpaired 
t-test as indicated (**=p≤0.01). 
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Appendix Figure S10. Analysis of leukocyte subsets from the peritoneal lavage of 
mice. 
A Sample data from a wild type mouse 18 h after injection of 4% thioglycolate are 
depicted. Leukocyte singlets were defined as FSC-H high and FSC-W low. 
Neutrophils, non-classical monocytes and classical monocytes were defined as B220-
/F4-80-/CD45+/CD115-/Ly6G+, B220-/F4-80-/CD45+/CD115+/Ly6Clo and B220-/F4-
80-/CD45+/CD115+/Ly6Chi respectively. 
B-H (B) All leukocytes in the peritoneal lavage and (C-H) percentages of leukocyte 
subsets of WT mice 18 h after injection with PBS and TG are shown (PBS: n = 6, TG: 
n = 10). 
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Appendix Table S1. ΔG of the heterodimer between CXCL12 and Gal-3 CRD and its 
mutants. 
Data from computational analyses of ΔG generated by CXCL12/Gal-3 CRD 
heterodimerization for WT and mutated Gal-3 CRD are provided. Mutants that were 
experimentally tested are labeled in color based on ΔG values compared to WT (see also 
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